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Preface
Despite signifi cant improvement in the treatment of cancer over the past decades, tumour 
response rates and survival in patients with advanced cancer are still poor. Therefore, it 
is important to fi nd anticancer agents with a novel mechanism of action and to further 
optimise existing treatment. Anticancer agents have a very narrow therapeutic window. 
In clinical practice, anticancer agents are administered at the maximum dose tolerated 
by the patient. Therapeutic drug monitoring (TDM) and, consequently, the assessment 
of pharmacokinetic parameters, allows the characterisation of relationships between 
pharmacokinetic parameters and therapeutic effi cacy and toxicity [1]. The determination 
of pharmacokinetic parameters of anticancer agents can help to facilitate optimal dosing of 
these agents in the clinic in order to improve therapeutic effi cacy and to decrease toxicity. 
The objective of this thesis is to study the pharmacokinetics of anticancer agents, with an 
emphasis on E7070, methotrexate and paclitaxel.
The thesis consists of four chapters. The aim of the fi rst chapter is to review the current 
insights into pharmacokinetically guided administration of anticancer agents. In cancer 
treatment, the dose calculation of most anticancer agents is based on body surface 
area (BSA). The interpatient pharmacokinetic variability of anticancer agents can be 
attributed to variable drug absorption, distribution and elimination processes [1]. TDM and 
pharmacokinetically guided dosing are not routinely used clinically, except for methotrexate 
and carboplatin. In current practice, TDM is routinely used in the clinic for treatment with 
moderate to high-dose methotrexate to guide supportive measures in patients at high risk 
for developing signifi cant toxicity. For carboplatin, the Calvert formula is clinically used to 
calculate the individualised dose [2]. In this chapter, clinical studies of pharmacokinetically 
guided administration of anticancer agents have been evaluated. 
The second chapter consists of pharmacokinetic studies of E7070, a novel sulphonamide 
agent that is currently in phase II of clinical development for the treatment of cancer. 
Sulphonamide agents are well known to have a variety of pharmacological activities 
including antibacterial, carbonic anhydrase-inhibitory, antidiabetic, diuretic, and antithyroid 
activity [3,4]. E7070 arrests the tumour cells at the transition of the G1- into the S-phase of 
the cell cycle by inhibiting the phosphorylation step of cyclin E and activation of cyclin 
dependent kinase 2. An excretion balance and pharmacokinetic study was performed 
following the intravenous infusion of E7070 radiolabelled with carbon-14, in patients with 
solid tumours (Chapter 2.1.1). Phase I trials of E7070 revealed non-linear pharmacokinetics 
(saturable distribution and elimination) after intravenous administration of the drug [5]. 
We studied the in vitro distribution of E7070 in human whole blood whether non-linear 
binding either to red blood cells or to plasma proteins (Chapter 2.1.2) can cause the non-
linear distribution of E7070. Moreover, an in vitro and in vivo pharmacokinetic study was 
performed to investigate whether there is a drug-drug interaction between E7070 and 
acenocoumarol. Since three patients in the phase I trials, treated with prophylactic daily oral 
Desirée van den Bongard 14-10   11 15-10-2002, 10:38:38
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maintenance therapy with acenocoumarol (Sintrom®), developed a haemorrhagic tendency 
and/or a prolonged prothrombin time following the intravenous administration of E7070. 
The infl uence of E7070 on the pharmacokinetics of acenocoumarol was studied in vivo, 
and the potential of E7070 to displace acenocoumarol from its plasma protein binding sites 
and/or to inhibit its hepatic metabolism was studied in vitro (Chapter 2.2).
The third chapter consists of pharmacokinetic studies of methotrexate after high-dose 
administration. The pharmacokinetics of methotrexate, an antimetabolite, vary considerably 
among patients mainly due to high interindividual variation in renal excretion of the drug 
and its major metabolite 7-hydroxy-methotrexate [6]. The successful rescue of a patient 
with severe methotrexate induced renal toxicity is presented (Chapter 3.1). An integrated 
population pharmacokinetic model for methotrexate and 7-hydroxy-methotrexate was 
developed to describe the pharmacokinetics of both compounds, and to study the infl uence 
of patient characteristics on the pharmacokinetic parameters (Chapter 3.2).
Chapter four describes the pharmacokinetics of paclitaxel and Cremophor EL. Cremophor 
EL is a polyethoxylated castor oil that is used for the formulation of vitamin preparations and 
a variety of poorly water-soluble drugs including teniposide and cyclosporin A. Cremophor 
EL can form micelles in blood in vitro, acting as a high-affi nity drug-transporting site for 
paclitaxel that results in a decreased unbound paclitaxel fraction in plasma. Cremophor 
EL can decrease the blood-plasma ratio of paclitaxel at higher dose-levels by reducing the 
uptake in red blood cells [7,8]. A population pharmacokinetic model of Cremophor EL, used 
as a formulation vehicle for paclitaxel, was developed (Chapter 4.1). Since the unbound 
paclitaxel concentration in blood is the pharmacologically active fraction, we developed a 
method for the quantifi cation of the unbound paclitaxel fraction in human plasma (Chapter 
4.3).
The relationships between plasma pharmacokinetics and pharmacodynamics of paclitaxel 
have been reported in patients with ovarian cancer and non-small cell lung cancer 
(NSCLC), whereby the drug’s effi cacy and toxicity were related to the time above a 
threshold concentration of paclitaxel in plasma [9-11]. A population model of paclitaxel was 
developed and used to evaluate the feasibility of Bayesian dose individualisation in patients 
with NSCLC (Chapters 4.2.1 and 4.2.2).
Desirée van den Bongard 14-10   12 15-10-2002, 10:38:38
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Chapter 1
Pharmacokinetically Guided Dosing of Chemotherapeutic Agents
HJG Desirée van den Bongard, Ron AA Mathôt, Jos H Beijnen and Jan HM Schellens 
Summary
The current practice for dose calculation of most anticancer agents is based on body 
surface area (BSA [in m2]), although lower interpatient variation in pharmacokinetic 
(PK) parameters has been reported with pharmacokinetically guided administration. As 
chemotherapeutic agents have a narrow therapeutic window, pharmacokinetically-guided 
dosing may lead to less toxicity and higher effi cacy than administration on the basis of BSA. 
Pharmacokinetically guided administration, using parameters such as area under the plasma 
concentration-time curve (AUC), steady state plasma drug concentration and drug exposure 
time above a certain plasma concentration, has been studied for many antineoplastic agents. 
Assessment of pharmacokinetic profi les allows the characterisation of relationships between 
pharmacokinetic parameters and effi cacy and toxicity. AUC appears to be more closely 
correlated with the pharmacodynamics than does the dose per unit of BSA. In particular, 
the AUC-guided administration of carboplatin has been extensively studied, based on the 
close relationship between the renal clearance and glomerular fi ltration rate (GFR). Several 
formulae and limited sampling models have been derived to predict the AUC of carboplatin. 
The relationship between AUC and pharmacodynamics has also been studied for other 
anticancer agents, for example fl uourouracil, topotecan, etoposide, cisplatin, and busulfan 
but all less extensively than for carboplatin. The pharmacokinetically guided administration 
of these agents needs to be investigated further before the use of alternative administration 
formulae can become standard clinical practice. 
Prospective studies of pharmacokinetically guided dosing versus surface area-based 
administration should be performed to validate pharmacokinetic-pharmacodynamic 
relationships and to facilitate optimal dosage of anticancer agents in the clinic.
Desirée van den Bongard 14-10   17 15-10-2002, 10:38:41
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Chapter 1
1. Rationale for individualised dosing of anticancer agents
In clinical practice, anticancer agents are almost invariably dosed per unit of body surface 
area (BSA [in m2]) and administered at the maximum dose tolerated (MTD) by the patient. 
Compared with many other drugs, anticancer agents have a very narrow therapeutic window, 
with delayed therapeutic effects and toxicity. Moreover, interpatient pharmacokinetic variability 
is generally high because of variable drug absorption, distribution and elimination processes.[1-
8] Table 1 lists the major aetiological factors of pharmacokinetic alterations in patients with 
cancer. In addition, metabolism may vary by genetically determined variation in expression and 
activity of drug metabolising enzyme systems. These enzymes can be cytochrome P450 (CYP) 
in cyclophosphamide, ifosfamide, paclitaxel and docetaxel metabolism; dihydropyrimidine 
dehydrogenase (DPD) in 5-fl uorouracil metabolism; and thiopurine methyltransferase (TPMT) 
activity in the elimination of 6-mercaptopurine (6-MP).[1,2,9] 
In patients with signifi cant renal or hepatic dysfunction dosage, reduction of the dosage 
of drugs eliminated through these organs is recommended to prevent severe toxicity. In 
general, no dosage reduction is recommended when the contribution of renal clearance 
to the excretion of the drug is below 33% and/or renal function is 70% or more of normal 
function.[4,7] It is more complicated to correlate liver enzyme levels with modifi cation of hepatic 
elimination activity, since there is no reliable biochemical test that adequately quantifi es 
the modifi ed hepatic drug clearance. This has resulted in confl icting recommendations for 
dosage reduction in patients with a modifi cation of these biochemical tests.[6.7] 
For several anticancer drugs, plasma concentration parameters (area under the plasma 
concentration-time curve (AUC), steady-state plasma concentration (Css) and peak plasma 
concentration (Cmax)) and drug exposure time above a certain threshold concentration 
have been reported to correlate with toxicity and therapeutic effect.[1,3,5,9-13] Consequently, 
individualised dosing may result in less undertreatment or severe toxicity compared with 
administration based on the BSA. To understand and predict normal tissue toxicity and 
tumour response, it is necessary to explore dose- or concentration-effect relationships. In 
several randomised prospective studies, AUC-guided administration has been compared 
with conventional dosing based on BSA. Adaptive administration of methotrexate, etoposide 
and fl uourouracil using pharmacokinetic parameters to reach a predefi ned effi cacy target 
AUC has been shown to result in a narrower and more accurate exposure range compared 
with administration based on unit of BSA alone.[14-18] 
In this review, we focus on the methods for pharmacokinetically guided dosing (emphasising 
AUC-guided administration) of anticancer agents that have been developed to decrease 
pharmacokinetic and pharmacodynamic variability. Clinical studies of pharmacokinetically 
guided administration correlated with therapeutic effi cacy and toxicity will be presented 
and discussed. Futhermore, we discuss the requirements for, and feasibility of, the wider 
applications of individualised administration in clinical practice.
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Chapter 1
2. Area under the plasma concentration-time curve (AUC)-guided dosing 
The systemic exposure of a drug is most often defi ned as the AUC. The AUC is the relevant 
pharmacokinetic parameter when toxicity and therapeutic effect of anticancer drugs are 
studied. An increased AUC in patients with a low elimination rate may result in more 
severe toxicity whereas a decreased AUC may  result in a lower effi cacy. Therapeutic drug 
monitoring (TDM) can be used to determine the AUC during the fi rst course of chemotherapy 
and to adjust the dose to achieve the target AUC in subsequent courses.[3,11]
2.1 Carboplatin
AUC-guided administration has been investigated extensively for carboplatin. This method 
has resulted in more precise prediction of the effect of carboplatin in terms of dose-limiting 
toxicity (mainly thrombocytopenia). The drug differs from many antineoplastic drugs in 
that its total body clearance (CL) is predominantly determined by glomerular fi ltration.[19-21] 
Consequently, the AUC of carboplatin is better correlated with the creatinine clearance (CL
cr
) 
than with the dose per unit of BSA. 
Determination of the AUC requires frequent blood sampling and is inconvenient for the 
patient. This has resulted in the development of more simple methods to calculate the AUC 
of carboplatin. A priori prediction of the desired AUC results in dose calculation based 
on the target AUC and glomerular fi ltration rate (GFR).[22-24] This method is based on the 
correlation of the AUC with pharmacodynamics during prior cycles. As frequent blood 
sampling may be inconvenient for the patient, limited sampling models (LSMs) have been 
developed. The equation is derived to predict one single variable, usually the AUC, based 
on plasma concentrations measured at several time-points. The doses for the following 
courses can be adapted to achieve an exposure at the target AUC.[12,25-27] 
2.1.1 A priori prediction of AUC
Egorin and co-workers demonstrated a signifi cant correlation between CL
cr
 and platelets 
nadir (PN).[22] They developed a formula in which the calculated dose was based on CL
cr
 
determined by 24-hour urine collection (CL
CR-24h
) and the target platelet nadir in pretreated 
and in non-pretreated patients (males and females).
For non-pretreated patients:
( ) ( ) 86100
PCntpretreatme
PNdesired-PCntpretreatme
BSA
CL
091.0Dose
CR
+»
¼
º
«
¬
ª
⋅⋅¸
¸
¹
·
¨
¨
©
§
×=    equation 1
For pretreated patients:
( ) ( ) 8617100
PCntpretreatme
PNdesired-PCntpretreatme
BSA
CL
091.0Dose
CR
+
»
»
¼
º
«
«
¬
ª
−¸¸¹
·
¨¨©
§
⋅⋅¸
¸
¹
·
¨
¨
©
§
×=  
 equation 2
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where the BSA is measured in m2; CL
CR
 in ml/min; dose in mg/m2 and platelet count (PC) 
in cells/µl). 
These equations have been validated prospectively in studies of single-agent and 
combination chemotherapy, which demonstrated their usefulness.[28,29] 
Calvert and co-workers[23] developed a dosage formula by retrospective analysis of 
carboplatin administration in 18 patients with a GFR range of 33 to 136 ml/min (determined 
by the 51chromium-ethylenediaminetetra-acetic acid excretion (51Cr-EDTA) method):
( )25GFRAUC target =Dose free +⋅       equation 3
where the dose is measured in mg, AUC
free
 is the area under the free carboplatin plasma 
concentration-time curve in mg/ml*min and GFR is in ml/min.
As the clearance of carboplatin is mainly determined by CL
cr
, GFR can be replaced by 
CL
cr
.[30] The value ‘25’ accounts for carboplatin clearance by non-GFR routes. Calvert et al 
validated this formula in a prospective study of 31 patients with solid tumours with a target 
Table 2. Studies of carboplatin (single agent) showing a correlation between area under the 
concentration-time curve (AUC) and pharmacodynamics 
Carboplatin dose 
determined by 
Effect Comments References 
Patients with lung cancer 
BSA
BSA
WBC↓, PLT↓
PLT↓
Low correlation AUC-myelotoxicity 
In combination with thoracic irradiation, 
prospective evaluation of the correlation 
AUC-response is warranted 
31
32
Patients with solid tumours 
Calvert formula PLT↓ 51Cr-EDTA clearance to measure GFR is 
also more accurate than calculated CLCR in 
patients pretreated with nephrotoxic  
chemotherapy
23
Patients with ovarian cancer 
Calvert formula WBC↓, PLT↓,
response
AUC ≥5 mg/ml does not increase response 33
Calvert formula PLT↓ Further elevation of AUC with stem-cell 
transplantation 
34
Calvert formula WBC↓, ANC↓,
PLT↓, response 
Survival rates may be increased by a target 
AUC >12 mg/ml*min (with haematological 
support)
35
ANC↓ = neutropenia; BSA = body surface area; CLCR = creatinine clearance; 51CrEDTA = determination of 
clearance of 51Cr-labelled EDTA; GFR = glomerular filtration rate; PLT↓ = thrombocytopenia; WBC↓ = leucopenia.
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AUC escalating from 3 to 8 mg/ml*min and concluded that this formula predicted the AUC 
accurately.[23] On the basis of the observed toxicities, they recommended a target AUC of 7 
mg/ml*min for non-pretreated patients and 5 mg/ml*min for pretreated patients.[23] 
Table 2 lists the pharmacokinetic studies of carboplatin infusion in which a correlation 
between AUC and toxicity has been observed.[23,31-35] In 4 of these studies the Calvert 
formula has been applied to achieve a target AUC.[23,33-35] In 2 other studies the AUC of 
ultrafi ltrable carboplatin was calculated by the trapezoidal rule.[32,33] In a retrospective 
study of 1028 patients with ovarian cancer, Jodrell and co-workers reported that tumour 
response, in contrast with myelotoxicity, does not increase above a carboplatin AUC of 
5 to 7 mg/ml*min.[33] Two studies in patients with ovarian cancer have demonstrated that 
an increase of the target AUC from 4 to 8[36] or 6 to 12[35] mg/ml*min resulted in enhanced 
myelotoxicity, whereas the observed response remained constant. In a study by Lind and 
colleagues further escalation of the target AUC above 9 mg/ml*min with granulocyte colony-
stimulating factor (G-CSF) was impossible because of haematological toxicity.[34] The authors 
concluded that an AUC of 7 mg/ml*min every 14 days for 4 cycles is the maximum tolerated 
AUC that can be achieved with G-CSF. They suggested that a further increase in the AUC 
may be possible using a combination of cytokines or haematological support by peripheral 
stem-cell transplantations.[34] Shea and co-workers demonstrated that non-haematological 
toxicities are dose-limiting at a target AUC of 25 mg/ml*min with autologous bone marrow 
transplantation.[37] AUC-based administration of high-dose carboplatin in combination with 
haematological support should be further investigated to establish a relationship between a 
high target AUC and therapeutic effi cacy. 
In a prospective study, Ghazal-Aswad et al. have demonstrated that carboplatin dose 
calculated by the Calvert formula (GFR calculated by the 51Cr-EDTA method) predicts the 
dose required to achieve the target AUC of the free carboplatin concentration (AUC of 5,7 
and 9 mg/ml*min).[38]
In conclusion, the Calvert formula can be applied in exploring the relationship between 
target AUCs of 5 to 25 mg/ml*min and pharmacodynamics, and is instrumental in AUC-
guided carboplatin administration. 
2.1.2 Calculation of carboplatin clearance
The application of the Calvert formula results in dose reduction in patients with low renal 
clearance and dose increase in patients with higher than average renal clearance.[23]
Accurate AUC-guided carboplatin administration is dependent on precise measurement of the 
GFR. The reference standard for GFR is the renal clearance of inulin at steady-state concentration 
during a continuous inulin intravenous infusion.[36] However, this method is rarely used in clinical 
practice since it is very inconvenient and time-consuming. Kinowski et al. have reported a 
simplifi ed method in which the number of blood samples was reduced to only one at 2 hours 
after infusion.[39] A Bayesian estimate of the CL
CR
 was obtained after a 10-minute intravenous 
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infusion of inulin. This approach resulted in a less inconvenient 1-sample strategy with a good 
precision and low bias [CL
CR
 7.85 ± 1.96 L/h, bias 0.397, 95% confi dence interval (CI): -0.414, 
1.21; precision 1.97, 95% CI: -0.59, 4.53]. Nevertheless, it is not a standard method in clinical 
practice, probably since it is still time-consuming in comparison with other methods.[39]
The determination of CL
CR
 by 51Cr-EDTA is accurate but is an invasive method, and therefore 
of limited use in clinical practice.[40-42] In comparison, 24-hour urine collection to measure 
CL
CR-24h
 may result in inaccurate estimation of the GFR. Hence, over- or under-exposure to 
carboplatin can occur when this method is applied, which may be because of an incomplete 
24-hour urine collection and/or fl uctuation in the endogenous creatinine production.[43-45] 
Alternatively, CL
CR
 can be calculated by the Cockcroft-Gault (CG) or Jelliffe (J) formulae 
based on patient characteristics, including serum creatinine level (S
CR
), age, gender and 
bodyweight (BW):[46,47]
( ) ( )femaleif85.0
S
BWage-1401.23
=CL
CR
CG-CR ⋅
⋅⋅
     equation 4
( )femaleif9.0
S
20
20-age
1689
=CL
CR
J-CR ⋅
¸
¹
·¨
©
§
⋅−
     equation 5
where CL
CR
 is measured in ml/min, age in years, S
CR
 in µmol/L and bodyweight in kg.
In a similar manner, Chatelut and co-workers[24] included these patient characteristics in a 
formula to predict carboplatin clearance (CL
carboplatin
) that was developed from a population 
pharmacokinetic analysis in 70 patients: 
( ) ( )
S
gender0.314-1age0.00457-1BW182
BW0.134=CL
CR
nCarboplati
⋅⋅⋅⋅⋅
+⋅
    equation 6
where CL
carboplatin
 is measured in ml/min, age in years, Scr in µmol/L, bodyweight in kg and 
gender has the value 0 if male and 1 if female.
Consequently, the dose to be administered can be calculated using:
AUCCL=Dose ncarboplati ⋅         equation 7
where dose is in mg; CL
carboplatin
 in ml/min and AUC in mg/ml*min.
Chatelut and co-workers concluded that CL
carboplatin
 calculated by their method was almost 
as accurate as that calculated by the Calvert method when the 51Cr-EDTA clearance 
measurement of clearance was used.[24] However, both Calvert et al. and Chatelut et al. 
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reported that the CL
CR-CG
 and CL
CR-J
 both underestimate the GFR determined by the 51Cr-
EDTA method.[24,42] Van Warmerdam et al. reported that the AUC calculated by using the 
Calvert formula with a GFR based on CL
CR-CG
 (S
CR
 determined by the Jaffé method) or CL
CR-24h
 
resulted in an overprediction of 10% and an underprediction of 10%, respectively, compared 
with the observed AUC.[48] The AUC calculated by the Chatelut formula showed an accurate 
prediction of the AUC.[48] However, Okamoto et al. reported in a comparable study that the 
Calvert formula based on CL
CR-CG
 or CL
CR-24h
 predicted the observed carboplatin clearance 
better than the Chatelut formula.[30] These discrepant results may be attributed to the 
application of different assays for the measurement of serum creatinine, the determination 
of a non-steady-state concentration of serum creatinine, pretreatment with nephrotoxic 
drugs, and the different patient populations.[23,30,36,46,49-51] Currently, the Jaffé method (alkaline 
picrate) and the enzymatic method (e.g. EKTACHEM Clinical Chemistry Slides) are applied 
in clinical practice for the measurement of S
CR
. The Jaffé method overestimates the S
CR
 
because of interference by non-creatinine chromogens whereas the enzymatic method is 
more accurate.[51,52] The Calvert formula was originally based on the GFR measured by the 
51Cr-EDTA method, whereas CL
CR-CG
 is based on the Jaffé method and the Chatelut formula 
for CL
carboplatin 
is based on the enzymatic method.[23,24,46]
In two recent studies, new formulae were developed and validated to calculate the GFR 
derived from the 51Cr-EDTA plasma concentration-time curves. Data were analysed according 
to a population pharmacokinetic analysis by using the nonlinear mixed effects modelling 
approach (NONMEM).[53,54] The formula derived by Martin et al.[53] is:
( ) ( )
CRS
gender252.01age0.00496-1ABW163
=GFR
⋅−⋅⋅⋅⋅
    equation 8
where GFR is in ml/min, ABW is the actual bodyweight in kg, age is in years, gender has 
the value 0 if male and 1 if female and S
CR
 is in µmol/L.
The formula derived by Wright et al.[54] is:
( )
CRS
BSAgender0.17-1age)40-(6600
=GFR
⋅⋅⋅⋅
     equation 9
where GFR is in ml/min, age is in years, gender has the value 0 if male and 1 if female, BSA 
is in m2 and S
CR
 is in µmol/L.
The formula derived by Martin et al. (NONMEM formula) resulted in a more accurate 
prediction of the individual GFR than did CL
CR-CG
. The ratio between the GFR predicted by 
the NONMEM formula and observed GFR in the validation group was 0.95 ± 0.23 (mean 
± SD), whereas the ratio with CL
CR-CG
 was 0.86 ± 0.21. The Wright et al. formula was more 
accurate than CL
CR-J
 and CL
CR-CG
 (bias -3% vs -18% and -11%, precision 20% vs 24% and 25%, 
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respectively).[54] Thus, the formulae derived by Martin et al. and Wright et al. predicted the 
individual patients’ GFR more accurately than did CL
CR-CG
 in their study populations.[53,54]
2.1.3 Application of AUC based carboplatin administration formulae in combination chemotherapy
The Calvert formula has been applied by other investigators and appears accurate if 
carboplatin is infused in combination chemotherapy.[20,34,36,43,55-73] In Table 3, studies 
are listed in which a signifi cant correlation between the AUC and the severity of bone 
marrow toxicity and/or therapeutic effi cacy was demonstrated.[20,37,42,56-60,62,63,68,70-72] These 
are mainly retrospective studies in which the dose was based on BSA, and the AUC 
was calculated after administration by inverting the Calvert formula [AUC = Dose/(GFR 
+ 25)]. However, retrospective analysis may result in overlooking confounding factors in 
the relationship between AUC and therapeutic effect. These factors may be the observed 
variation in the methods applied to determine the GFR and the S
CR
 values. Also, a high 
retrospectively calculated AUC may be attributed to a poor renal function, which can be 
caused by pretreatment with cisplatin. Pretreated patients may not respond to carboplatin 
chemotherapy because of cross-resistance between carboplatin and cisplatin.[74] 
In conclusion, the Calvert and Cockcroft-Gault formulae are widely used to calculate the 
carboplatin dose based on a target AUC and the GFR, respectively. The application of 
the Cockcroft-Gault formula in combination with the Calvert formula also results in less 
variability in AUC of carboplatin in single-drug and combination chemotherapy than does 
administration per unit of BSA, despite the outlined limitations.[43] Preferably, the formulae 
for carboplatin administration and the S
CR 
assays should be standardised to prevent variations 
in dose calculations and to facilitate the comparison of the dose and GFR of patients treated 
in different centres.
2.1.4 Limited sampling models in AUC-guided dosing
LSMs have been developed to limit the frequency of blood sampling needed for the 
quantifi cation of AUC. After blood sampling the concentrations at each individual sample 
time are correlated to the AUC value by multivariate analysis. The sample times that show 
the highest correlation with the AUC can be included in a corresponding regression line. 
Consequently, the LSMs enable the prediction of AUC based on a single or multiple time-
point(s). After blood sampling at specifi c time-points during the fi rst course, the AUC can 
be calculated and dose can be adjusted during the following courses to reach the target 
AUC. However, a limitation of the LSMs is that they need to be applied and prospectively 
validated in treatments using the same anticancer agents, doses, administration schedules 
and duration of infusion as the original study from which the LSM was established.[11,12,75-77]
Several LSMs for carboplatin have been developed. These models are listed in Table 4, 
and have also been validated by other investigators.[25-27,78] Sørensen ‘s single sample model 
was validated by van Warmerdam et al. in 9 patients treated with high dose chemotherapy 
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(carboplatin, cyclophosphamide and thiothepa).[76] The model proved to be accurate despite 
a different administration schedule and carboplatin dose. 
The single sample model of Ghazal-Aswad et al. was validated by Nannan Panday et al., 
who proved the inability of this model to predict the AUC of carboplatin in combination 
with paclitaxel and in high dose chemotherapy (cyclophosphamide and thiothepa).[26,79] They 
developed a new LSM in order to refi ne the carboplatin dose when given in combination 
with paclitaxel. This validated single-sample model appeared to be precise and showed low 
bias (bias 3.4%, precision 10.1%).[78] 
A Bayesian approach may allow optimal interpretation of limited sample information, 
since it combines pharmacokinetic information from an individual patient with that of the 
population. During the following courses, dose adjustment can be carried out with the 
intention of achieving a target AUC. Guillet et al. demonstrated the feasibility of the Bayesian 
approach in carboplatin combination chemotherapy (120-hour infusion).[80] Bayesian 
estimation of the individual pharmacokinetic parameters based on 2 individual drug plasma 
concentrations (1 and 12 hours after the start of the 120-hour carboplatin infusion) enabled 
estimation of the plasma carboplatin concentration at the end of the infusion. In 36 patients, 
dose adjustment was performed to achieve concentrations of 1.0, 1.5 or 1.8 mg/L at 24 hours 
after the start of the infusion. This method showed good precision and acceptable bias for 
the 3 target concentrations. Thrombocytopenia was most frequently observed in the group 
with the highest concentration at the end of the infusion.[80]
Duffull et al. have developed a sequential Bayesian algorithm to estimate the carboplatin 
dose (single agent, target AUC 5 to 7 mg/ml*min, 30-minute infusion) in 12 patients.[81] 
Recent total carboplatin concentrations weighted more than earlier concentrations in the 
dose adjustment of individual patients.
Very recently, a Bayesian approach was developed and validated by our group for the 
estimation of carboplatin AUC in high dose chemotherapy.[82] This method was compared 
with the LSM developed by Sørensen et al. and the Chatelut and Calvert formulae (using 
CL
CR-CG
, CL
CR-J
 and the Wright formula to calculate CL
CR
) for the prediction of the AUC.[23-
25,46,47,54]. The Bayesian analysis (bias <4%, precision <18%) and the Sørensen LSM (bias 
-13.7%, precision 17.8%) predicted the AUC better than the Chatelut and Calvert formulae 
(bias <12%, precision >22%). As a result, the Calvert or Chatelut formulae may be used for 
calculation of the fi rst dose of carboplatin. For subsequent courses the Bayesian approach 
or the Sørensen model can be applied to estimate the AUC. 
In general, the Bayesian approach may be recommended, as it is more fl exible in infusion 
duration and sampling times than LSMs such as the Sørensen model.[12,82,83]
2.2 Other anticancer agents 
The relationships between the AUC and pharmacodynamics of other anticancer agents are 
listed in Table 5.
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2.2.1 Busulfan
Busulfan is an alkylating agent orally administered in patients as part of preparative regimens 
for patients undergoing bone marrow transplantation. The dose-limiting toxicity is hepatic 
veno-occlusive disease (VOD), which is experienced in 20% of the patients and results in a 
mortality of 40%.[128] The absorption and clearance of busulfan show a high interindividual 
variability. The therapeutic effi cacy and toxicity of the agent has been correlated with the AUC 
of busulfan in patients with cancer.[128-130] Grochow and associates reported a high correlation 
between the AUC of busulfan and the occurrence of dose-limiting VOD in 15 patients.[85] 
Several investigators have observed the same phenomenon. However, they also reported 
a higher incidence of VOD in patients treated with higher doses of cyclophosphamide in 
combination with busulfan (without an increased AUC of busulfan).[86,87]
2.2.2 Cisplatin
Cisplatin, a platinum compound, is primarily eliminated by renal clearance. The drug has 
dose-limiting toxicities including nephrotoxicity, ototoxicity, and peripheral neuropathy. 
Elevated plasma concentrations of ultrafi lterable platinum (Pt
U
) may result in decreased 
renal clearance.[131,132] Reece and colleagues reported a signifi cant correlation between the 
C
max
 and the AUC of Pt
U
 in 12 of 22 patients treated with cisplatin in a 2- hour infusion.[93] 
This may demonstrate that this single plasma sample may predict the nephrotoxicity in this 
small group of patients. They proposed increasing the AUC of Pt
U
 and decreasing the Cmax 
of Pt
U
 by increasing the dose in combination with a longer duration of infusion.
Cisplatin can bind covalently to DNA bases, so-called intra- and interstand cross-links or 
platinum-DNA (Pt-DNA) adducts. Several clinical studies revealed a signifi cant correlation 
between white blood cells (WBC) and buccal cells Pt-DNA adduct concentration and 
response.[94,133-137] Moreover, Schellens et al. reported a signifi cant correlation between 
the AUC of free cisplatin, area under the DNA-adduct time curve (AUA) in WBC and 
response.[94]
 
2.2.3 Cyclophosphamide
Cyclophosphamide is an alkylating drug that requires bioactivation before exerting its 
cytotoxic effects.[95,138,139] An LSM has been developed to defi ne the AUC without frequent 
blood sampling. Validation of the LSM resulted in an accurate prediction of the AUC 
(bias 3.3 ± 3.6%, precision 9.3 ± 2.7) despite different dose levels in the 2 groups (1000 
mg/m2 as a 1-hour intravenous infusion vs 300, 600 or 1200 mg/m2 as 1-hour intravenous 
infusions).[138] This LSM has been applied in a study of high dose cyclophosphamide (1.5, 
3.0, 4.5 and 6.0 g/m2) in combination with granulocyte-macrophage colony-stimulating 
factor (2.5, 5 and 10 µg/kg). No relationship between the AUC of cyclophosphamide and 
degree of myelosuppression could be established.[139] Ayash et al. have demonstrate a 
negative correlation between the plasma concentrations of total cyclophosphamide and 
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the development of cardiac dysfunction in 19 patients with breast cancer (with no signs 
of cardiotoxicity before treatment) treated with high dose combination chemotherapy 
(cyclophosphamide 6000 mg/m2 as a 96-hour infusion) and autologous bone marrow 
transplant.[95] They also observed a longer median duration of response of 22 months 
in patients with lower AUC values (<5000 µmol/L*h) compared with 5 months in 
patients with higher AUC values (>5000 µmol/L*h). These data support that a higher 
concentration of active cyclophosphamide metabolite contributes to more cytotoxicity 
and cardiotoxicity.
2.2.4 Docetaxel
Docetaxel is a semisynthetic taxoid drug. The precursor is extracted from the needles of 
the western yew, Taxus baccata. The drug enhances microtubule assembly and inhibits the 
depolymerisation of tubulin. Docetaxel is active in patients with solid tumours, including 
non-small-cell lung cancer (NSCLC), breast cancer, and head and neck cancers.[140-142] 
Hudis et al. performed a pharmacokinetic-pharmacodynamic analysis of docetaxel after 
infusion (1-hour intravenous infusion, 100 mg/m2) in 35 patients with breast cancer during 
the fi rst cycle of a phase II study.[143] Although no overall correlation was observed between 
AUC and toxicity, a high AUC was observed in 1 patient (with hepatic metastases) who 
experienced severe toxicity (neutropenia and mucositis) and died.
Bruno et al. performed a population pharmacokinetic-pharmacodynamic analysis of 
docetaxel during the fi rst course of phase II studies.[96] They used a Bayesian approach to 
estimate individual pharmacokinetic parameters in patients with breast cancer (n=231) and 
NSCLC (n=189) who received docetaxel at doses of 75 or 100 mg/m2 (1-hour infusion). They 
demonstrated that the AUC was a signifi cant predictor of the time to progression in patients 
with NSCLC (using Cox and logistic regression analysis). This study proved the feasibility of 
population pharmacokinetic-pharmacodynamic evaluation based on LSMs.
2.2.5 Epirubicin
Epirubicin is an anthracycline that shows an antitumour activity analogous to doxorubicin but 
has less cardiotoxicity. Jakobsen and colleagues have demonstrated a signifi cant correlation 
between the AUC of epirubicin and its metabolite epirubicinol and the decrease in WBC 
count.[97] They used a previously validated single sample model for 2- or 4-hour infusions, 
and single-sample or 2-sample models for 10-minute infusions to calculate the AUC. The 
calculated AUC was retrospectively correlated with the WBC decrease and resulted in 2 
models to predict the WBC decrease based on 1 or 2 plasma concentrations. These models 
enable prediction of  myelotoxicity from 1 or 2 samples and allow adjustment of the dosage, 
which may result in a safer therapeutic regimen:
0.14-C0.0073 WBClog= WBClog 6initialnadir ⋅−     equation 10
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where C
6
 is the plasma concentration at 6 hours after administration in µg/L. 
Future studies should be directed to validate the correlation between the severity of toxicity 
and the therapeutic effect of epirubicin.
2.2.6 Etoposide
Etoposide is a topoisomerase II inhibitor that belongs to the epipodophyllotoxins. It is 
used for treatment of patients with solid tumours and as a part of preparative regimens for 
bone marrow transplantation. Previous studies have demonstrated a signifi cant relationship 
between the AUC of etoposide and its myelotoxicity or therapeutic effi cacy in patients 
treated with doses based on the BSA.[88,98,99,101] Miller and colleagues have confi rmed the 
relationship between AUC and toxicity by an LSM and a pharmacodynamic model, which 
enables the estimation of the clearance and the neutrophil nadir.[100] 
Lowis and colleagues have validated an LSM based on one plasma concentration in 13 
children.[144] They concluded that administration based on estimation of the AUC guided by 
a single blood sample resulted in a signifi cant reduction in the variation of AUC seen with 
administration based on BSA.[144] Two studies have proven the feasibility of adaptive dosing 
of etoposide, which resulted in less pharmacokinetic variability.[145,146] Lowis and co-workers 
studied adaptive dosing in 9 children using their LSM and a predefi ned target AUC.[145] 
The AUC of the fi rst etoposide dose was estimated using the LSM. Subsequent doses were 
calculated according to the equation:
( )
2dayonAUCtarget
1dayonAUC
1dayondose
=2dayonDose ⋅      equation 11
where dose is in mg and AUC is in mg/ml*min.
As the interpatient variability in pharmacokinetic parameters was already low after 
administration of the fi rst dose, they concluded that future pharmacokinetic studies should 
be performed in patients who may benefi t from pharmacokinetically guided dosing, for 
example patients with renal dysfunction.[145]
2.2.7 Fluorouracil
Fluorouracil, an antimetabolite, is applied in the treatment of primarily gastrointestinal, breast, 
and head and neck carcinomas. The drug shows a high interpatient variability in metabolism 
which is related to the genetic polymorphism of dihydropyrimidine dehydrogenase. This is 
the key enzyme of endogenous pyrijmidine metabolism; defi ciencies of this enzyme result in 
high concentrations of fl uorouracil with severe toxicity. Moreover, toxicity is dependent on the 
duration of infusion. Myelosuppression is dose-limiting after bolus intravenous injection, and 
diarrhoea and oral ulceration are mainly dose-limiting after continuous infusion.[109,147]
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A signifi cant correlation between the AUC of fl uorouracil and the drug-induced toxicity after 
intravenous and hepatic intra-arterial administration has been demonstrated.[102-104,127] In these 
studies, the AUC-guided dose was based on retrospective calculation of pharmacokinetic 
parameters after conventional administration. Further research revealed higher complete 
response rates and longer survival in patients after adaptive administration guided by the 
AUC of fl uorouracil.[105-107] Fety and colleagues have compared prospectively AUC-guided 
dosing (pharmacokinetic arm) with conventional administration (standard arm, 4 g/m2) of 
fl uorouracil in 122 patients with head and neck carcinomas.[16] In the fi rst course there was 
no difference in AUC between the pharmacokinetic and standard arms. During the following 
courses (2 and 3), the AUC values were signifi cantly lower in the pharmacokinetic arm 
with less interpatient variability for AUC values. More frequent toxicity and a larger variety 
of symptoms of severe toxicity [thrombocytopenia, neutropenia, and mucositis grade 3-4 
according to common toxicity criteria (CTC)] were seen in the standard arm. The objective 
response rate was comparable in both arms.[16] 
Gamelin et al. reported that acute toxicity (hand-foot syndrome and diarrhoea) was correlated 
with plasma fl uorouracil concentrations >3000 µg/L during a weekly 8-hour infusion of the 
drug at different dose levels in combination with high dose leucovorin.[108] The quality of 
response was better in 40 patients with higher than mean plasma concentrations at the 
different dose levels. Consequently, they defi ned an optimal therapeutic and nontoxic 
range of 2000 to 3000 µg/L, which equates to an AUC of 16 to 24 mg/L*h. They then 
modifi ed the fl uorouracil dose according to previous plasma concentrations and doses using 
dosage normograms, and observed the resulting toxicity in 152 patients with colorectal 
cancer. The correlation between plasma fl uorouracil concentration and acute toxicity 
was confi rmed, and a high response rate and overall survival was reported.[108,109] In these 
studies, pharmacokinetically guided administration of fl uouroucil resulted in less toxicity 
than did conventional administration.[16,108,109] Moreover, Ychou et al. showed that individual 
fl uorouracil dose adjustment guided by AUC using normograms was feasible in patients with 
colorectal cancer treated with fl uorouracil and leucovorin with a 14-day interval.[148]
Recently, a population pharmacokinetic model has been developed in 65 patients with 
colorectal cancer treated with the same dosage schedule.[149] Bayesian estimation (based 
on 2 individual samples) has been performed to estimate the individual pharmacokinetic 
parameters in 20 patients. The Bayesian approach was reported to be a more fl exible 
method than the normogram method since it could optimise the fl uorouracil dose in every 
treatment schedule.[149] Nevertheless, randomised studies should be performed to validate 
the effi cacy of this approach.
2.2.8 Hexamethylene bisacetamide
Hexamethylene bisacetamide belongs to the hybrid polar compounds, which are potent 
inducer of differentiation in cell lines in vitro.[150] Several phase I studies have shown that 
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the dose-limiting thrombocytopenia is correlated with the C
ss
 and AUC.[110-112] Conley and 
associates combined these features in an individualised administration study of the drug 
in the presence of concurrent alkalinisation with sodium bicarbonate.[150] The dose-limiting 
toxicity was neurotoxicity at a C
ss
 of >2 mmol/L. Consequently, the C
ss
 was set at 1.5 to 2 
mmol/L in combination with an increased duration of infusion to maximise the exposure 
in relation to the observed thrombocytopenia. The target AUC was set at 7.5 mmol/L*day 
because of dose-limiting neurotoxicity.[150]
2.2.9 Idarubicin
Idarubicin is an anthracycline derivative that can be administered orally, mainly for the 
treatment of breast cancer and leukaemia. Elbæk and associates demonstrated a positive 
correlation between the cumulative AUC of idarubicin and its metabolite idarubicinol and 
the effect (leucopenia and response).[89,151] More recently, Schleyer and colleagues showed a 
signifi cant correlation between plasma concentration at 24 hours after oral administration of 
idarubicin and the AUC, which may result in a potent prediction parameter of toxicity and 
therapeutic effect.[152]
2.2.10  4’-Iodo-4’-deoxydoxorubicin
The relationship between the AUC and effect for 4’-Iodo-4’-deoxydoxorubicin (IDOX), a 
less toxic analogue of doxorubicin, has also been studied.[113,114] The dose-limiting toxicities 
thrombocytopenia and, mainly, granulocytopenia are correlated with the AUC of IDOX and 
probably the AUC of its metabolite 4’-iodo-4’-deoxy-doxorubicinol (IDOXOL). However, 
phase II studies have shown a low therapeutic effect in combination with severe toxicities 
which prohibits further escalation of the dose intensity.[153,154]
2.2.11 Menogaril
Menogaril is a derivative of the antibiotic anthracycline nogalamycin and is less cardiotoxic 
compared with the other antibiotic anthracyclines doxorubicin and daunorubicin. The 
pharmacokinetic parameters of menogaril have been investigated in relation to its dose-
limiting toxicity leukocytopenia after intravenous and oral administration.[90,115,116] Egorin 
and colleagues reported a positive correlation between the AUC of menogaril and toxicity 
(leckopenia and neutropenia) in cancer patients with and without hepatic dysfunction.[115,116] 
Patients with liver dysfunction showed more leukocytopenia than those with normal liver 
function. As no difference was observed in the relationship between leukocytopenia 
and AUC, they concluded that a dosage reduction might not be necessary in patients 
with hepatic dysfunction (elevated concentrations of bilirubin, ALT, AST and/or alkaline 
phosphatase).[115,116] 
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2.2.12 Paclitaxel
Paclitaxel is a taxane antimicrotubule agent that is used in the treatment of ovarian, breast, 
and lung cancers. Several studies have explored the relationship between the AUC and 
toxicity. Non-hematological toxicities including musculoskeletal and neurotoxicity have 
been correlated with AUC in children.[117] A signifi cant correlation between the exposure and 
hematological toxicity or response has not yet been reported.[69,73,118,155] However, Huizing 
et al. and later Gianni et al. reported a relationship between the duration of the plasma 
concentration above a defi ned threshold and pharmacodynamics, which will be discussed 
further in section 3.2.[69,73,155]
2.2.13 Teniposide 
Teniposide, which belongs to the group of the epipodophyllotoxins, is highly bound 
to plasma proteins (>95%). The unbound concentration exerts the cytotoxic activity. A 
correlation between the exposure and pharmacodynamics has been reported in patients 
with leukaemia.[119,156,157] In a subsequent trial, pharmacokinetic analysis by TDM was 
conducted daily during the fi rst administration of teniposide (200 mg/m2 as a 4-hour infusion 
for 3 consecutive days). The aim of the study was to decrease the interpatient variability, 
resulting in a higher dose intensity without increased toxicity. The second and third doses 
were adapted to yield a target AUC of 1060 µmol/L*h. In subsequent patient cohorts the 
target AUC was increased to 1656 µmol/L*h which was not accompanied with an observed 
increase in toxicity.[120]
2.2.14 Topotecan
Topotecan is a semisynthetic camptothecin analogue that inhibits the DNA-topoisomerase 
I enzyme causing persistent DNA strand breaks. The dose limiting toxicities (leucopenia, 
neutropenia, thromboctyopenia and diarrhoea) were shown to be closely correlated with 
the AUC of topotecan or the cytotoxic lactone form (T
m
), and also with the dose in some 
schedules.[91,92,121-126] This relationship has resulted in the development and validation of 
an optimal sample strategy utilising one plasma concentration. A plasma concentration 
determined at 2 hours after the end of a 30-minute infusion of topotecan (dose 0.5 to 
1.5 mg/m2/day) was used to estimate the sum AUC of (total) topotecan and Tm on 5 
consecutive days.[158] In a phase II study (36 patients) using LSM, the mean AUC of topotecan 
was 8.71 µmol/min*day and the mean AUC of Tm was 11.49 µmol/min*day when topotecan 
1.5 mg/m2/day was given as 30-minute infusions on 5 consecutive days. As large interpatient 
pharmacokinetic variability was observed, but only small pharmacodynamic variability, 
the authors concluded that TDM of topotecan may not be very valuable in this treatment 
schedule.[125]
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2.3 Practical considerations
Systemic exposure to several anticancer agents has been studied in relation to 
pharmacodynamics, but AUC-guided administration has been limited to clinical trials 
except for carboplatin. The investigated relationships between the systemic exposure, 
toxicity and clinical response need to be validated in prospective studies in a suffi cient 
number of patients. In these studies, it is important to consider that the correlation 
between AUC and effect may be dependent on the treatment schedule. Consequently, this 
correlation should be validated in various treatment schedules. We conclude that LSMs 
and Bayesian analysis are pharmacokinetic strategies well suited for AUC-guided dosing in 
the clinical experimental setting. Further studies are warranted to determine the potential 
therapeutic benefi t of use of these strategies under conditions more refl ective of routine 
clinical practice.
3. Other targets for pharmacokinetically guided dosing
AUC has been extensively studied as the pharmacokinetic parameter that correlates with 
the pharmacodynamics. However, relationships between effect and other pharmacokinetic 
parameters have been reported as well. For some anticancer agents more than one 
pharmacokinetic parameter can be correlated with pharmacodynamics.
3.1 Steady-state plasma drug concentration
The therapeutic window may be used as a target for adaptive administration. The 
response can be increased by keeping the plasma concentration or C
ss
 above a certain 
value, whereas toxicity can be avoided by keeping the C
ss
 below the plasma level where 
unacceptable toxicity develops.  Methotrexate is a drug for which TDM is routinely used 
clinically to identify patients at high risk for developing signifi cant toxicity. In general, 
serum drug concentrations above 0.1 µmol/L at 48 hours after administration, and/or any 
serum concentrations above 10 µmol/L require intensifi ed standard leucovorin rescue.[159-
163] Furthermore, several investigators have studied adaptive administration based on a 
target C
ss
 of high-dose methotrexate compared with fi xed-dose administration of the drug. 
The individualised treatment group showed less variation in the serum methotrexate 
concentrations with a marked reduction in the severity of toxicity and/or a lower risk of 
relapse compared to the standard treated group (Table 6).[14,15] 
C
ss
 has been related to the pharmacodynamics of other anticancer agents. A signifi cant 
correlation has been demonstrated when the dose was guided by the target C
ss
 in relation to 
toxicity and, to a minor extent, response.[17,18,89,110-113,118,131,147,150-152,156,164-168,170-172] These anticancer 
agents , including etoposide, doxorubicin, cisplatin, fl uorouracil, teniposide, vinblastine, 
thymidine, and hexamethylene bisacetamide are also listed in Table 6.[14,15,108-112,131,156,157,159,160,
164-168,170,172] However, these drugs need to be investigated in prospective randomized studies 
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Table 6. Anticancer agents for which a relationship between steady-state and defined plasma 
concentration and pharmacodynamics has been demonstrated 
Anticancer agent Indication PK parameter Effect References 
Cisplatin  Solid tumour  Css  Nephrotoxicity 81 
 Neuroblastoma C48h Ototoxicity 164 
Doxorubicin Solid tumour Css WBC nadir 165 
Etoposide Solid tumour Css WBC↓, PLT↓ 166
Fluorouracil Colorectal carcinoma Css WBC↓ 167
 Colorectal carcinoma Css WBC↓,
stomatitis
147
Hexamethylene  
bisacetamide Solid tumour Css PLT↓ 110
 Solid tumour Css PLT↓,
neurotoxicity,
nephrotoxicity
111
 Solid tumour Css PLT↓,
neurotoxicity,
nephrotoxicity
112
 Solid tumour Css Neurotoxicity, 
nephrotoxicity
168
Methotrexate Solid tumour C48h WBC↓, PLT↓,
nephrotoxicity,
mucositis 
159
 ALL Css Period of 
remission
14
 ALL Css Period of 
remission
15
 Head and neck carcinoma C36h Mucositis, 
nephrotoxicity
160
Teniposide Leukaemia Css  Mucositis 157
 Leukaemia Css WBC↓,peripheral
neuropathy
156
Thymidine Solid tumour, lymphoma Css Response 169 
Vinblastine Solid tumour, melanoma, 
lymphoma
Css PLT↓ 170
ALL = acute lymphocytic leukemia; Cx = plasma concentration at x hours after administration; Css = steady state 
concentration; 5FU = fluorouracil; PD = pharmacodynamics; PK = pharmacokinetic; PLT↓ = thrombocytopenia; 
WBC↓ = leucopenia.
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to confi rm these pharmacokinetic-pharmacodynamic correlations before implementation of 
adaptive control algorithms in clinical practice.
3.2 Drug exposure time above a defi ned threshold concentration
As previously mentioned in section 2.2.12, the toxicity and therapeutic effect of paclitaxel 
are correlated with the duration of the drug concentration above a certain level (Table 
7). Huizing et al. reported a correlation between median survival and duration of the 
serum paclitaxel concentration above a threshold value of 0.1 µmol/L that was proven 
to be pharmacologically active in vitro and related with bone marrow toxicity.[69,169] This 
relationship could be described mathematically by a sigmoidal E
max
 model, and a duration 
of 15 hours or more above 0.1 µmol/L resulted in a lower leukocyte nadir and potentially 
higher response rates.[69,73] Other investigators demonstrated a correlation between 
myelosuppression, especially neutropenia, and the duration of plasma levels above 0.05 
µmol/L.[117] Furthermore, van Warmerdam and colleagues reported a signifi cant correlation 
between duration of topotecan concentration above 10 nmol/L and neutropenia.[123] 
Further investigation to confi rm these pharmacokinetic-pharmacodynamic correlations is 
warranted.
4. Conclusions 
Standardised administration of anticancer agents is complicated by pharmacokinetic 
variability and the small therapeutic window. It is common practice to calculate doses of 
chemotherapeutic agents guided on the basis of BSA and to reduce the dose if signifi cant 
toxicity occurs. This may result in inappropriate dosage and suboptimal treatment in some 
patients or exposure resulting in unacceptable toxicity in others. The therapeutic effi cacy and 
toxicity of many anticancer agents may be more closely related to the exposure than to the 
dose adjusted on the basis of BSA.[3,12] As a result of extensive pharmacological research of 
antineoplastic agents, our knowledge of pharmacokinetic parameters and clinical effects has 
increased markedly in recent years. An impressive number of reports has been published on 
the pharmacokinetic-pharmacodynamic relationships of anticancer drugs, and in particular 
the relationship between pharmacokinetic parameters and toxicity has been extensively 
studied. AUC-guided administration has a prominent role in these studies, as AUC and effect 
(mainly toxicity) are closely related for many anticancer agents. A priori prediction of AUC, 
LSMs and Bayesian analysis based on population pharmacokinetic parameters and resulting 
adaptive administration have been investigated widely. Carboplatin has been extensively 
studied, since carboplatin clearance is highly correlated with the GFR which can be 
determined relatively easily. Formulae have been derived for individualised dose calculation 
according to renal function, resulting in AUC-guided administration. Methotrexate is another 
anticancer agent for which TDM is clinical routine. For other antineoplastic agents, such 
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as fl uorouracil, cisplatin, topotecan, etoposide and teniposide, AUC has been correlated 
with toxicity in clinical trials. Application of administration algorithms for these agents is 
not current clinical practice, since the more complex elimination of these anticancer agents 
complicates the derivation of a simple formula. 
Prospective randomised pharmacodynamic studies of individualised administration of 
these other anticancer agents should be performed to demonstrate whether individualised 
administration results in a clinical benefi t. The validation of the correlation between 
pharmacokinetic parameters and the clinical effect should be performed in various 
populations and treatment schedules. Future studies should also focus on the development 
of population pharmacokinetic models and Bayesian analysis for adaptive control. Bayesian 
analysis is recommended for pharmacokinetic-pharmacodynamic studies because of its 
fl exibility, whereas LSMs may be more convenient for TDM in clinical practice. Moreover, 
mathematical formulations to calculate the individualised dosage of anticancer agents should 
be made accessible to practicing clinicians.[12,173,174] Pharmacokinetic-pharmacodynamic 
research to improve and refi ne administration procedures should be extended to 
demonstrate whether adaptive dosing has therapeutic benefi t and whether individual 
administration algorithms can be implemented in daily clinical practice.
Table 7. Anticancer agents for which a relationship between drug exposure time above a defined threshold concentration and
pharmacodynamics has been demonstrated 
Anticancer agent Type of cancer Treshold plasma concentration Effect References
Paclitaxel Ovarian 0.1 µmol/L WBC↓, ANC↓ 74
Paclitaxel Lung 0.1 µmol/L Response rate, 
survival
70
Paclitaxel Ovarian and breast 0.05 µmol/L ANC↓ 145
Topotecan Solid tumours 10 nmol/L ANC↓ 155
ANC↓ = neutropenia; WBC↓ = leucopenia. 
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Chapter 2.1.1
An excretion balance and pharmacokinetic study of the novel anticancer 
agent E7070 in cancer patients
HJG Desirée van den Bongard, Dick Pluim, Hilde Rosing, Lianda Nan-Offeringa, 
Margaret Schot, Miroslav Ravic, Jan HM Schellens and Jos H Beijnen.
Summary
E7070 is a novel sulphonamide anticancer agent that arrests the G
1
-S phase of the cell cycle. 
Preclinical and phase I studies have demonstrated non-linear pharmacokinetics of the drug. 
The objective of this study was to quantify the excretion of E7070 and the metabolite 1,4 
benzene-sulphonamide (M1) in cancer patients. 1000 mg of E7070 radiolabelled by carbon-
14 (14C) in the benzenedisulphonamide moiety (cohort 1, n=6) or in the indole moiety 
(cohort 2, n=7) was intravenously (iv) infused over 1 hour. The levels of radioactivity (RA) 
in plasma, red blood cells, urine and faeces were determined by liquid scintillation counting, 
and the E7070 and M1 concentrations in plasma, urine and faeces were determined by 
coupled liquid chromatography-tandem mass spectrometry (LC/ESI-MS/MS). In plasma, the 
mean area under the concentration-time curve (AUC) based on RA measurements (32.5 
and 28.9 h*mmol/L in cohort 1 and 2, respectively) was substantially higher than the mean 
AUC of E7070 (3.8 h*mmol/L) and M1 (0.1 h*mmol/L) in all patients. The excretion of RA 
(mean±SD%) as a percentage of administered radioactivity was higher in urine (63.7±9.8% 
(cohort 1) and 61.5±5.5% (cohort 2)) than in faeces (22.7±2.6% (1) and 21.1±3.1% (2)) 
during a mean collection period of 11 days. In both cohorts, the contribution of urinary and 
faecal recovery of E7070 (2.3% and 2.7%, respectively) and M1 (5.3% and 5.1%, respectively) 
was low. Subsequent HPLC analysis with online radioisotope detection of urine showed that 
the high radioactivity levels are caused by other compounds than E7070 and M1. The major 
metabolite is formed by glucuronidation of a hydroxylated metabolite of E7070.
In conclusion, the excretion of the benzene-sulphonamide and the indole moieties of E7070 
was the same with a higher renal than gastro-intestinal excretion. E7070 is extensively 
converted into currently unidentifi ed metabolites. Glucuronidation is a major metabolic 
pathway.
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Chapter 2.1.1
Introduction
Several sulphonamide derivatives have been synthesised to develop novel cytotoxic 
agents against solid tumours.[1,2] Sulphonamide agents are well known to have a variety of 
pharmacological activities including antibacterial, carbonic anhydrase-inhibitory, antidiabetic, 
diuretic, and antithyroid.[3] The fi rst sulphonamide derivative that has been studied for its 
antitumour activity is E7010 (N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenz
enesulphonamide), an antimitotic agent that inhibits tubulin polymerisation.[4,5] A follow 
up compound, E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide), is another 
sulphonamide derivative that has been studied for its antitumour activity. E7070 exhibited a 
potent antitumour activity in in vitro (in murine and human tumour cell lines) and in vivo 
(in human xenografts) studies. Most antitumour activity was observed in colorectal and lung 
cancer xenografts (HCT116 colorectal cancer and LX-1 lung cancer models). The drug arrests 
the transition of the G1- to the S-phase of the cell cycle by inhibiting the phosphorylation 
step of cyclin E and activation of cyclin dependant kinase 2.[6-8]
To determine the toxicity and maximum tolerated dose of E7070 in humans, phase I trials 
were initiated using four different infusion schedules in 127 patients with solid tumours.[9,10] 
The dose-limiting toxicity was mainly haematological. Partial and minor responses 
were observed in patients with breast, endometrial, renal, and ovarian carcinoma. Non-
compartmental PK analysis of these phase I trials revealed non-linear pharmacokinetics with 
a more than dose-proportional increase of the AUC at higher dose-levels.[9,10] A population 
pharmacokinetic analysis of E7070 in four phase I studies (n=143) revealed that the 
concentration-time data could be best fi tted to a three-compartment model with saturable 
transport to one compartment and two parallel pathway of elimination from the central 
compartment: a linear and a saturable pathway.[11] Phase II studies, with the dosing schemes 
one hour intravenous (iv) infusion every 3 weeks (700 mg/m2) and 5-day continuous iv 
infusion every 3 weeks (130 mg/m2), are currently ongoing in patients with solid tumours. 
To provide a better understanding of the excretion pathway of E7070 and its metabolite 
1,4 benzene-sulphonamide (M1) in humans, which is pivotal information for the further 
development of the drug, a mass balance study was performed following a single dose of 
radiolabelled carbon-14 (14C) E7070 in patients with solid tumours.
Materials and Methods
Patients
This prospective, non-randomised, single-centre study was performed between November 
1999 and August 2000 at the Antoni van Leeuwenhoek hospital/The Netherlands Cancer 
Institute in Amsterdam, The Netherlands. The institutional Medical Ethics Committee 
approved the study. All patients were required to give written informed consent prior to 
participation in the trial.
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Patients with a histologically or cytologically confi rmed diagnosis of a solid tumour not 
amenable to established forms of treatment were eligible for the study. Prior chemotherapy 
other than E7070, immunotherapy or radiotherapy was allowed, provided that the last 
treatment was at least four weeks prior to study entry (six weeks for nitrosoureas and 
extensive radiotherapy) and any resulting toxicities were resolved. Patients of child-bearing 
potential had to use adequate contraceptives and in fertile females a pregnancy test had to 
be performed within 1 week before study entry. Other eligibility criteria included: age ≥ 18 
years, life expectancy of ≥ 3 months, performance status ≤ 2 according to the World Health 
Organisation (WHO) scale, acceptable bone marrow function (absolute neutrophil count 
≥ 1,500/mm3, platelet count ≥ 100,000/mm3), adequate renal function (serum creatinine ≤ 
120 µmol/L (1.4 mg/dl) or creatinine clearance ≥ 50 ml/min), adequate hepatic function 
(serum bilirubin < 25 µmol/L (1.5 mg/dl), serum alanine-aminotransferase (ALT) and 
aspartate-aminotransferase (AST) ≤ 2.5 times the upper normal limit, or ≤ 5 times the upper 
normal limit in the case of liver metastases). Exclusion criteria included the presence of 
active infections, the presence of symptomatic brain metastases, or glaucoma, presence of 
alcoholism, treatment with sulphonylurea agent for diabetes, any anti-arrhythmic agent or 
cisapride, pregnancy or breast-feeding, clinical signs of urinary and/or faecal incontinence.
Trial treatment
The patient population consisted of two cohorts because E7070 was radiolabelled at two 
different locations in the molecule. In the fi rst cohort it was radiolabelled at the benzene 
sulphonamide moiety, and in the second cohort it was radiolabelled at the indole moiety 
to study the elimination routes of each part of the molecule. In the fi rst cohort each patient 
received a single dose of 1000 mg E7070 containing 3.7 MBq 14C-labelled E7070 ([benzene 
sulphonamide-14C]ER-35744) (Figure 1A) in 1 hour infused iv through a central venous 
catheter. In the second cohort a single dose of 1000 mg E7070 containing 3.7 MBq 14C-
labelled E7070 ([indole ring-U-14C]ER-35744) (Figure 1B) was iv administered in one hour 
through a central venous catheter. Subsequent courses consisted of 700 mg/m2 E7070 
iv in one hour every three weeks. Eligibility criteria with regard to performance status, 
A.
14C
NHSO2
SO2NH2
NH
Cl
B.
14
C
NHSO2
SO2NH2
NH
Cl
Figure 1. Chemical structure of E7070 [benzene sulphonamide-14C]ER-35744 (A) and [indole ring-U-14C]ER-35744 (B)
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haematological, hepatic, renal functions, intercurrent complications, and medication were 
checked for re-treatment. Toxicity evaluation was performed every course according to 
the National Cancer Institute Common Toxicity Criteria (NCI CTC). If toxicity occurred, the 
patient was retreated upon recovery. Treatment was continued at the same dose provided 
no serious toxicity and no progressive disease was observed.
E7070 was supplied (Eisai Limited, London, United Kingdom) as a white to pale yellow 
freeze dried cake, in glass vials containing 100 mg of E7070 with 380 mg of meglumine 
and 475 mg of mannitol. Vials were stored at 2-8°C in the dark. Ten E7070 vials were 
reconstituted by adding 5 ml of water to each vial. The E7070 radiolabelled compounds 
([benzene sulphonamide-14C]ER-35744 and [indole ring-U-14C]ER-35744) were supplied in 
glass vials each containing 3.7 Mbq 14C-labelled compound with a specifi c activity of 2.52 
and 2.74 GBq/mmol, respectively (Amersham International Ltd. of Little Chalfont, Amersham, 
Buckinghamshire, United Kingdom). One vial containing radiolabelled compound and ten 
reconstituted vials (1000 mg E7070) were added to saline (fi nal volume of 1000 ml) for iv 
infusion under sterile conditions at the radioisotope laboratory in the Netherlands Cancer 
Institute. Quality control included endotoxin, sterility testing, and radio-chemical purity 
testing with HPLC, and was conducted before the administration to the patients.
Sample collection
Blood samples of each 10 ml were collected from a peripheral venous catheter during 
the fi rst course. Blood samples for E7070 analysis were collected in heparinised tubes 
immediately pre-dose (0 hours), at 30 minutes after the start of the infusion, at the end of the 
infusion, at 10, 30 minutes, 1, 2, 4, 6, 8, 12, 24, 36 hours, after the end of the infusion, and at 
2, 3, 4, 5, 6,7,8, 13 and 20 days after the day of the infusion. Blood samples were centrifuged 
(5 minutes, 3,000 rpm), and the plasma layer was separated and immediately stored at -20°C 
in polypropylene tubes until analysis. The buffy coats with the leukocytes were removed 
carefully with suffi cient margins and discarded, followed by transfer of the red blood cells in 
polypropylene tubes. After one wash step with ice-cold isotonic phosphate buffered saline 
(PBS) the red blood cells were centrifuged at 3,000 rpm for 15 minutes and the supernatant 
was discarded. The washed red blood cells were immediately stored in polypropylene tubes 
at -20°C until analysis.
Urine was collected pre-dose and in 12-hour intervals between time 0 and 96 hours after the 
start of the E7070 infusion followed by additional 24 hour cumulative collections. The urine 
collection was continued until the E7070 concentration in urine and faeces had returned to 
below 1% in combination with a cumulative excretion percentage higher than 80% of the 
administered dose (1000 mg). The actual times of the pre-dose urine collection, the times of the 
urine collection intervals, and the volumes of the urine cumulative collections were recorded. 
Three aliquots of urine (20 ml) were removed, frozen and stored at -20°C until analysis.
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One pre-dose faeces portion and all faeces produced following the administration of E7070 
were collected, and the actual time and weight of each collection were recorded. The faecal 
samples were homogenised in distilled water (1:3, v/v) and stored at -20°C.
Bio-analysis
The detection of beta radiation in plasma, red blood cells, and PBS was performed by a 
liquid scintillation counter (LSC) (Tri-CARB 2100 CA; Packard Instrument Company, Meriden, 
USA) with an energy range of 0-2000 keV. Prior to the infusion of E7070 to all patients, a 25 
µL aliquot of the infusion solution was removed followed by accurate determination of the 
radioactivity level by the LSC. Each sample was mixed with 10 ml of Ultima Gold LSC-cocktail 
(Packard Instrument Company, Meriden, USA) in a plastic vial. The counting-time was 5 
minutes per vial. Before the measurement of radioactivity in red blood cells and faeces, red 
blood cell samples (200 µl) were dissolved and decolourised using 1 ml Solvable™ (Packard 
Bioscience B.V. Groningen, The Netherlands), 100 µL 0.1 M ethylenediaminetetraaceticacid 
(EDTA, Titriplex ) (Merck, Darmstadt, Germany), and 500 µl hydrogen peroxide (Perhydrol ) 
(Merck KGaA, Darmstadt, Germany). Faecal homogenates were decolourised using 1 ml 
Solvable™, 1 ml isopropanol (2-propanol ) (Biosolve B.V., Valkenswaard, The Netherlands) 
and 0.4 ml hydrogen peroxide (Perhydrol ). The samples were analysed together with 
calibration standards and QC standards in the LSC. Calibration curves were fi tted using least-
squares regression analysis. The equation of the calibration curve was used to calculate the 
radioactivity concentration in all samples in disintegrations per minute (dpm). The lower and 
upper limits of quantifi cation were 1 and 1,000 µg/ml E7070, respectively.
The concentrations of E7070 and the metabolite 1,4-benzenesulphonamide (M1) in 
plasma, urine and faecal homogenates were measured using high-performance liquid 
chromatography coupled to an electrospray ionisation tandem mass spectrometer (LC/ESI-
MS/MS).[12] Before shipment from the C laboratory to the non-radioactive laboratory, the 
plasma, urine and faecal homogenate samples were diluted with blank plasma, blank urine 
and distilled water, respectively, to a radioactivity concentration of less than 100 Bq/ml. 
Samples were stored at –20°C until analysis.
Pre-treatment of the plasma and urine samples involved solid-phase extraction (SPE) on 60 
mg Oasis cartridges (Waters, Milford, MA, USA). Faecal homogenates were extracted twice 
with ethylacetate. Reconstituted extracts were injected onto an Apex Octyl column (Jones 
Chromatography, Hengoed, Mid Glamorgan, UK) and a water/acetonitrile gradient containing 
2.5 mM ammonium acetate was used to transfer the analytes to the TurboIonSprayTM sample 
inlet (Sciex, Thornhill, ON, Canada). Negative ions were created at atmospheric pressure 
and the parent ions were fragmented in the API 365 triple quadrupole mass spectrometer 
(Sciex). The transitions for E7070 were selected from m/z 383.9 to 319.8 and for M1 from 
235 to 170.5. Deuterated  internal standards were used for the quantitation. The lower limits 
of quantifi cation for E7070 and M1 were 0.10 µg/ml and 0.01 µg/ml in plasma, respectively. 
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In urine and faeces, the lower limits of quantifi cation for both analytes were 0.05 µg/ml and 
0.05 µg/g, respectively. The upper limits of quantifi cation for E7070 and M1 were 10 µg/ml 
in urine and 10 µg/g in faeces.
Pharmacokinetic analysis
The E7070 and M1 concentrations in plasma were expressed in mmol/L by dividing the 
concentration in µg/ml by their molecular weights (385.9 and 236.3, respectively). The 
radioactivity levels in plasma were expressed in mmol/L as the amount of radioactivity 
expressed in Bq/ml divided by the radioactivity level of the infusion solution in Bq and 
multiplied by the molarity of the infusion solution (in mmoles).
The pharmacokinetic parameters were calculated by applying a non-compartmental analysis 
using the pharmacokinetic computer program WINNONLIN (Standard Edition version 3.0, 
1999, Pharsight Corporation, California, USA). The maximal drug concentration (C
max
) was 
derived directly from the experimental data. The fi rst order rate constant λ
z
 associated with the 
terminal elimination portion was calculated by log-linear regression analysis of the concentration 
versus time curve. The area under the plasma concentration-time curve (AUC
inf
) was calculated 
by the linear trapezoidal rule up to the last sampling time point with detectable concentration 
(C
last
) with extrapolation to infi nity of the terminal elimination phase. The terminal half-life (t
1/2
) 
was calculated by the equation ln2/λ
z.
 The apparent clearance (CL) was calculated by dividing 
the administered dose by the AUC
inf
. The apparent volume of distribution at steady state (Vss) 
by multiplying CL by the mean residence time extrapolated to infi nity (MRT
inf
). MRT
inf 
 is 
determined as MRT
inf
 = (AUMC
inf
/AUC
inf
) – (1/2 x duration of infusion), where AUMC
inf
 is the 
area under the fi rst moment curve with extrapolation to infi nity.
The excretion of total radioactivity in urine and faeces (in mmoles) was calculated as the 
total amount of excreted radioactivity in Bq divided by the radioactivity of the administered 
dose in Bq and multiplied by the molarity of the infusion (in mmoles). The excretion of 
E7070 and M1 in urine and faeces as a percentage of the administered dose was calculated 
as the total amount of excreted drug (in mmoles) and metabolite (in mmoles) divided by the 
molarity of the infusion (in mmoles) times 100.
All pharmacokinetic parameters (Cmax, AUC
inf
, CL, t
1/2
 and Vss) and the excretion of the 
total radioactivity, E7070 and M1 in urine and faeces are expressed in mean ± standard 
deviation (SD).
Results
Patients and treatment
Thirteen patients were enrolled in the study. Six patients were included in the fi rst cohort 
that received 1000 mg of E7070 radiolabelled with [benzene sulphonamide-14C]ER-35744 
during the fi rst course. Seven patients were included in the second cohort that received 
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1000 mg of E7070 radiolabelled with [indole ring-U-14C]ER-35744 during the fi rst course. The 
patient characteristics are summarised in Table 1.
Pharmacokinetics
The individual plasma concentrations of total radioactivity in both cohorts (determined by 
the LSC method) versus the mean of the E7070 (determined by the LC/ESI-MS/MS method) 
as a function of time are depicted in Figure 2A (cohort 1) and in Figure 2B (cohort 2). In 
both cohorts the radioactivity levels (expressed as E7070 equivalents in mmol/L) in plasma 
are much higher than can be explained by E7070 (and M1) alone. The E7070 concentrations 
were substantially higher than the M1 concentrations in plasma in both cohorts of patients. 
The calculated plasma AUC
inf 
of E7070 (3.75±2.02 h*mmol/L) is higher than the AUC
inf 
of 
M1 (0.14±0.05 h*mmol/L) (Table 2). The radioactivity levels in plasma and red blood cells 
(as determined by the LSC method) of all patients (n=13) are outlined in Figure 3. The 
radioactivity concentration in plasma was higher than in RBC during and shortly after the 
Table 1. Patient characteristics 
Characteristics Cohort 1a Cohort 2b
No. of patients 6 7
Sex 
male
female
5
1
4
3
Age in years 
mean
SD
56
8.8
51
11.3
WHO PS
     0 
1
2
0
5
1
2
5
0
Primary tumour 
lung
gastric 
colorectal 
pancreas 
melanoma
ovarian
carcinoid 
hypopharynx 
primary unknown 
1
2
1
1
0
0
0
0
1
1
1
1
0
1
1
1
1
0
Prior treatment 
prior surgery 
prior radiotherapy 
prior chemotherapy 
prior immunotherapy 
4
2
6
0
4
3
7
1
a
 The patients in cohort 1 received [benzene sulphonamide-14C]ER-35744. 
b
 The patients in cohort 2 received [indole ring-U-14C]ER-35744. 
PS = Performance status (PS) according to the World Health Organisation (WHO) scale. 
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Radioactivity concentration
Figure 2. Individual plasma concentrations of total radioactivity and the contribution of E7070 as a function of time after the 
administration of 1000 mg E7070 containing 3.7 MBq of 14C-labelled E7070 in the fi rst cohort (n=6) (A) and in the second cohort 
(n=7) (B)
Figure 3. Red blood cell concentrations and plasma concentrations of radioactivity in all patients (n=13)
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infusion of 14C-labelled E7070. Later, the radioactivity concentrations in both compartments 
are in the same range. The courses of the distribution and elimination phases of radioactivity 
in plasma and red blood cells are synchronic.
The mean urinary and faecal excretion of radioactivity as a percentage of the administered 
dose in the fi rst and the second cohort is presented in Table 3 (a and b). After the iv infusion 
of 14C-labelled E7070 the urinary recovery of radioactivity is higher than the faecal recovery 
in cohort 1 (63.7 ±9.8% and 22.7 ±2.6%, respectively) and in cohort 2 (61.5 ±5.5% and 21.1 
±3.1%, respectively) over a mean collection period of 11 and 10 days, respectively. The total 
recovery of radioactivity in urine and faeces is 86.4 ±9.0% (cohort 1) and 82.6 ±4.6% (cohort 
2) of the administered dose. In the fi rst 48 hours post dosing only 41% (cohort 1) and 43% 
(cohort 2) of the administered dose was excreted in urine and faeces which illustrates the 
slow excretion of E7070 and its metabolites. The cumulative urinary and faecal recovery 
of total radioactivity, E7070 and M1 are shown in Table 4. The total radioactivity levels 
are much higher (86.4% and 82.6% in cohort 1 and 2, respectively) than the cumulative 
recovery of E7070 (2.3% and 2.7% in cohort 1 and 2, respectively) and M1 (5.3% and 5.1%, 
respectively) in urine and faeces. The cumulative recovery of E7070 is almost equal in urine 
(1.2 ±0.7% and 1.5 ±0.8%) and faeces (1.1 ±0.4% and 1.2 ±0.6%) whereas the cumulative 
recovery of M1 is higher in faeces (3.7 ±1.6% and 3.5 ±1.1%) than in urine (1.7 ±0.6% and 1.7 
±0.6%) in both cohorts. For the whole patient population (n=13), the cumulative recovery of 
E7070 and M1 (mean±SD) is 1.4 ±0.8% (E7070) and 1.7 ±0.6% (M1) in urine and 1.1 ±0.5% 
(E7070) and 3.6 ±1.3% (M1) in faeces. With reference to the high total radioactivity levels 
that cannot be explained by E7070 and M1, the detection of metabolites other than M1 was 
Table 2. Pharmacokinetic parameters of E7070 and M1 in plasma after intravenous administration of 
1000 mg 14C-labelled E7070 (n=13) 
Pharmacokinetic parameter E7070 M1 
Cmax (mmol/L) 
Mean
SD
0.20
0.05
0.0026
0.0008
t1/2 (h)
mean
SD
19.4
7.7
117.2
47.7
AUCINF (h*mmol/L) 
Mean
SD
3.75
2.02
0.14
0.05
CL (ml/min) 
Mean
SD
17.3
15.6
NA
NA
Vss (L) 
Mean
SD
21.5
4.4
NA
NA
AUCINF = area under the concentration-time curve extrapolated to infinity; CL = clearance; Cmax = maximal 
concentration; NA = not applicable; t1/2 = terminal half-life; Vss = distribution volume at steady state. 
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Table 4. Urinary and faecal excretion values of total radioactivity, E7070 and M1 following intravenous 
administration of 1000 mg containing 3.7 MBq 
14
C-labelled E7070 (cohort 1 and 2) 
Total radioactivity 
(mean% ± SD) 
E7070
(mean% ± SD) 
M1
(mean% ± SD) 
Cohort 1 (n=6) 
Urine 
Faeces
Total
63.7 ± 9.8 
22.7 ± 2.6 
86.4 ± 9.0 
1.2 ± 0.7 
1.1 ± 0.4 
2.3 ± 0.9 
1.7 ± 0.6 
3.7 ± 1.6 
5.3 ± 1.6 
Cohort 2 (n=7) 
Urine 
Faeces
Total
61.5 ± 5.5 
21.1 ± 3.1 
82.6 ± 4.6 
1.5 ± 0.8 
1.2 ± 0.6 
2.7 ± 1.2 
1.7 ± 0.6 
3.5 ± 1.2 
5.1 ± 0.8 
Table 3b. Percentage of the radioactive dose recovered in faeces after intravenous administration of 
1000 mg 
14
C-labelled E7070 (cohort 1 and 2)
Time after the E7070 administration 
(hours) 
Cohort 1: n=6 
(mean% ± SD) 
Cohort 2: n=7 
(mean% ± SD) 
0-48 5.28 ± 3.61 4.46 ± 2.50 
48-96 8.94 ± 2.49 6.75 ± 2.33 
96-144 5.22 ± 1.54 6.39 ± 2.60 
144-192 3.42 ± 2.10 2.72 ± 2.11 
192-240 2.23 ± 2.41 0.85 ± 0.51 
240-288 0.72 ± 0.61 0.61 ± 0.48 
288-336 0.29 ± 0.05 0.34 
Total faecal excretion 22.7 ± 2.6 21.1 ± 3.1 
Table 3a. Percentage of the radioactive dose recovered in urine after intravenous administration of 
1000 mg 
14
C-labelled E7070 (cohort 1 and 2) 
Time after the E7070 administration 
(hours) 
Cohort 1: n=6 
(mean% ± SD) 
Cohort 2: n=7 
(mean% ± SD) 
0-12 14.18 ± 8.2 18.73 ± 12.2 
12-24 9.75 ± 4.4 8.97 ± 4.7 
24-36 6.89 ± 2.0 6.39 ± 1.5 
36-48 4.58 ± 0.8 4.08 ± 0.9 
48-60 4.64 ± 0.8 3.65 ± 0.9 
60-72 3.73 ± 0.6 2.61 ± 0.9 
72-84 3.66 ± 0.9 2.93 ± 1.5 
84-96 2.80 ± 1.6 2.04 ± 1.3 
96-120 4.25 ± 1.4 3.22 ± 1.8 
120-144 3.39 ± 1.2 2.67 ± 1.0 
144-168 2.86 ± 1.3 2.08 ± 0.7 
168-192 2.00 ± 0.8 1.82 ± 0.9 
192-216 1.92 ± 0.9 1.71 ± 0.5 
216-240 1.48 ± 0.4 1.33 ± 0.5 
240-264 0.80 ± 0.7 1.50 ± 0.9 
264-288 1.09 ± 0.2 1.19 ± 0.09 
288-312 0.93 ± 0.02 0.98 ± 0.4 
312-336 ND 1.05 
Total urinary excretion 63.7 ± 9.8 61.5 ± 5.5 
ND = not determined.
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performed in urine. Therefore, a mixed urine sample (100 µl) obtained in 6 patients (3 of the 
fi rst cohort, and 3 of the second cohort) from 0 to 24 hours after the infusion of radiolabelled 
E7070, was injected on an HPLC system coupled online with a radio-isotope detector. The 
results are depicted in Figure 4 showing a chromatogram with 15 peaks. E7070 and M1 are 
represented by the peaks numbered 15 and 3, respectively. The major peak (number 7) 
represents a metabolite that is formed by glucuronidation after hydroxylation of E7070. This 
glucuronidated metabolite has a m/z value of 576.3 as identifi ed by mass spectrometry.
In addition, in one patient with malignant ascites an ascites drainage was performed prior to 
the start of the E7070 infusion, and 7 days after the E7070 administration. The total volume 
of the evacuated ascites post-dosing was 5.5 L containing a radioactivity level of 3% of the 
administered dose.
Safety
During this mass balance study the toxicities (related to E7070) observed following the fi rst 
course of 14C-labelled E7070 were generally mild (maximally CTC grade 1-2). The toxicities 
included anaemia (n=1), sinus tachycardia (n=1), nausea (n=1), stomatitis (n=1), diarrhoea 
(n=1), fatigue (n=2), and paresthesias in the face (n=1). All patients continued treatment at 
a dose of 700 mg/m2 E7070 infused iv in 1 hour every 3 weeks.
Discussion
The aim of this mass balance study was to determine quantitatively the (metabolic) 
disposition of E7070 and its metabolite M1 after intravenous administration. Based on the 
elimination half-life of E7070 as determined in phase I studies, the anticipated collection time 
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Figure 4. Chromatogram of a urine sample analysed by a HPLC method with online radioisotope detection. 15 = E7070, 3 = M1 
metabolite, 7 = metabolite formed by glucuronidation of E7070
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for urine and faeces was 7 days.[9,10] However, due to the prolonged retention of radioactivity 
in plasma the collection time had to be extended to a maximum of 14 days. The urinary and 
faecal recovery of total radioactivity (86.4% in cohort 1, 82.6% in cohort 2) indicates that the 
duration of urinary and faecal collection was suffi ciently long to characterise the excretion 
of E7070 and its metabolite M1 despite the slow rate of elimination of radioactivity from 
the central compartment. Following the iv administration of 14C-labelled E7070 the major 
route of elimination of the radioactive tracers is by the kidneys with a mean cumulative 
urinary recovery of 63.7% (cohort 1) and 61.5% (cohort 2) of the administered dose. We 
may conclude that the benzene-sulphonamide and indole moieties of E7070 show the same 
elimination pattern, which probably indicates that the majority of metabolites contain an 
intact sulphonamide link. E7070 is excreted by the renal and gastro-intestinal routes to 
the same extent, but its metabolite M1 is primarily excreted by the gut (Table 4). Only a 
minority of the excreted radioactivity is represented by E7070 and M1. Further detection of 
metabolites in urine showed that the high total radioactivity levels are caused by 13 other 
compounds than E7070 and M1. Glucuronidation appears to be an important metabolic 
route in humans in contrast to preclinical studies in which this metabolite was not identifi ed. 
Further research is ongoing to elucidate the chemical structures of all metabolites.
From the measured radioactivity level in ascites (3% of the administered dose) at one 
week post-dosing in one patient, we may conclude that E7070 and/or its metabolites can 
accumulate in third ‘spaces’. However, further clinical studies should demonstrate whether 
this observation has any therapeutic or toxic consequences.
Preclinical pharmacokinetic studies have been performed to elucidate the disposition of E7070 
after a single intravenous administration of 14C-labelled E7070 in mice and rats. In contrast 
to the observations in humans, the mean cumulative faecal excretion of radioactivity (86% 
and 67%, respectively) was higher than the urinary excretion (13% and 39%, respectively) 
calculated as a percentage of the administered dose during a collection period of 7 days in 
rats and 14 days in mice. In urine, the majority of excreted radioactivity represented polar 
metabolites and only a minority of radioactivity was excreted as unchanged E7070 and M1. 
Preliminary indications are that the majority of radioactivity in faeces was associated with 
E7070 and M1.
In human plasma, the radioactivity levels were substantially higher than can be explained by 
E7070 (and M1 in the fi rst cohort) which indicates that E7070 is extensively metabolised. The 
M1 concentration is also very low compared to the E7070 concentrations. In combination 
with the low recovery of M1 in urine and faeces we may conclude that M1 is only a minor 
metabolite in man. Based on the higher radioactivity concentrations in plasma compared to 
red blood cells in humans during and shortly after the infusion, E7070 and its metabolites 
possessing the benzene-sulphonamide moiety and the indole moiety reached higher initital 
concentrations in plasma than in red blood cells (Figure 3). In contrast, the pharmacokinetic 
studies in rodents showed that the radioactivity concentration in red blood cells was higher 
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than the radioactivity concentration in plasma after administration of 14C-labelled E7070. It 
remains unclear why the red blood cell-plasma ratio is higher in rodents than in humans.
In conclusion, the results of this mass balance study demonstrate that radiolabelled E7070 
given by iv infusion is slowly excreted via urinary and faecal routes. E7070 is excreted by 
the renal and gastro-intestinal routes but M1 is primarily excreted by the gut. The total 
radioactivity was primarily excreted by the renal route. A high proportion of the radioactivity 
in human plasma, urine and faeces is represented by compounds other than E7070 and M1. 
These high radioactivity levels are caused by the extensive formation of metabolites other 
than M1. Thus, E7070 is primarily eliminated by metabolism. Glucuronidation appears a 
major metabolic pathway. Currently, studies are ongoing to identify the chemical structures 
and pharmacological activities of the other metabolites.
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An in vitro pharmacokinetic study of the novel anticancer agent E7070: 
red blood cell and plasma protein binding in human blood
HJG Desirée van den Bongard, Dick Pluim, Robert CAM van Waardenburg, Miroslav 
Ravic, Jos H Beijnen and Jan HM Schellens
Summary
E7070 is a novel sulphonamide anticancer agent that arrests the G
1
-S phase of the cell cycle. 
Preclinical and phase I studies have demonstrated non-linear pharmacokinetics of the drug. 
A population pharmacokinetic (PK) analysis revealed that the human plasma concentration-
time data were best described by a 3-compartment model with non-linear distribution. 
We have studied the in vitro interaction of carbon-14 (14C)-radiolabelled E7070 with red 
blood cells (RBC) and its binding to plasma proteins in the concentration range where non-
linearity in disposition was observed in humans to get more insight into the behaviour of the 
drug. After the addition of E7070 to whole blood at 37°C, the drug is taken up or binds to 
RBC in a concentration-dependent manner. The addition of sodium azide, however, did not 
result in a decrease of drug uptake by RBC indicating passive diffusion processes. A non-
linear increase in drug uptake was observed at incubation concentrations > 4 µg/ml E7070 in 
whole blood. This non-linearity was confi rmed by lower partition coeffi cients between RBC 
and plasma at higher incubation concentrations (from 2.37 at 4 µg/ml to 0.31 at 200 µg/ml). 
The plasma protein binding of E7070 was high (98-99%) and linear in the concentration 
range studied (20-200 µg/ml). In conclusion, E7070 in whole blood is preferentially bound 
to RBC, and exhibits high plasma protein binding. The non-linear distribution of E7070 in 
humans can be caused, in part at least, by saturable binding of E7070 to RBC. 
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Introduction
Several sulphonamide derivatives have been synthesised to develop novel cytotoxic agents 
against solid tumours.[1,2] Sulphonamides are well known to have a variety of pharmacologic 
activities including antibacterial, carbonic anhydrase-inhibitory, antidiabetic, diuretic, 
and antithyroid.[3] The novel sulphonamide derivative E7070 (N-(3-chloro-7-indolyl)-1,4-
benzenedisulphonamide) arrests the transition of the G1- to S-phase of the cell cycle by 
inhibiting the phosphorylation of cyclin E and activation of cyclin dependent kinase 2.[1,2,4,5] 
E7070 exhibited a potent antitumour activity in murine and human tumour cell lines and in 
human xenograft studies. The highest antitumour activity was observed in colorectal and 
lung cancer xenografts (HCT116 colorectal cancer and LX-1 lung cancer models).[6]
Phase I trials of E7070 in patients with solid tumours using four different infusion schedules revealed 
non-linear pharmacokinetics of the drug. There was a pronounced disproportional increase of 
the area under the concentration-time curve with dose.[7,8] A population pharmacokinetic (PK) 
analysis of E7070 in phase I studies (n=143) revealed that the concentration-time data could best 
be described by a three-compartment model with saturable distribution to one compartment and 
both linear and Michaelis-Menten elimination from the central compartment.[9]
In general, non-linear drug distribution can be caused by saturable plasma protein 
binding, saturable binding to blood cells or saturation of tissue uptake or binding sites.[10] 
Sulphonamide agents are well known to bind to carbonic anhydrase, an enzyme abundant 
in RBC.[11-13] We hypothesised that non-linear binding of E7070 either to RBC or to plasma 
proteins may explain its PK behaviour. Therefore, we studied the in vitro distribution of 
E7070 in human whole blood and human plasma protein binding within the concentration 
range observed during the phase I studies. 
Materials and methods
Materials
E7070 was supplied by Eisai Limited, London, United Kingdom. The carbon-14 (14C)-
radiolabelled E7070 compound ([indole ring-U-14C]ER-35744, Figure 1) was manufactured 
by Amersham International Ltd. of Little Chalfont, Amersham, Buckinghamshire, United 
Kingdom. The 14C-radiolabelled compound was dissolved in saline to a fi nal concentration 
Figure 1. Chemical structure of 14C-radiolabelled E7070 ([indole ring-U-14C]ER-35744)
14C
NHSO2
SO2NH2
NH
Cl
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of 1 mg/ml. The radiochemical purity and the chemical purity were at least 98%. The 
radiolabelled drug was stored at –20°C until use. Isotonic phosphate buffered saline (PBS, 
pH 7.4) was prepared. Solvable was purchased from Packard Bioscience B.V. (Groningen, 
The Netherlands). Ethylene diamine tetra acetic acid (EDTA, Titriplex®) and hydrogen 
peroxide (Perhydrol®) were purchased from Merck (Darmstadt, Germany).
Fresh whole blood samples from seven drug-free healthy volunteers were collected from 
an antecubital vein into heparinized tubes. Additional blood samples were taken from these 
volunteers to determine the haematological and chemical parameters of the collected blood.
Methods
Uptake of 14C-radiolabelled E7070 in RBC
The uptake of E7070 in RBC was studied at various drug concentrations. Uptake studies were 
performed in vitro by incubation of whole blood with 14C-radiolabelled E7070 in 50 ml falcon 
tubes in a water bath at 37°C (n=6) and at approximately 0°C (melting ice water, n=6) on a 
plate with gentle shaking. After pre-incubation of whole blood for 10 minutes, radiolabelled 
compound was added to yield a fi nal concentration of 200 µg/ml and incubated for 24 
hours to determine the time when distribution equilibrium was achieved between plasma 
and RBC. To determine whether the E7070 uptake in RBC was an adenosine triphosphate 
(ATP)-dependent transport, the effect of sodium azide on uptake was determined at 37°C 
(in duplicate). Sodium azide produces a decrease in the intracellular ATP concentration, 
and was added to give a fi nal concentration of 20 mM which is suffi cient to inhibit ATP-
dependent systems.[14,15] Whole blood samples (2.5 ml) were taken immediately after the 
addition of 14C-radiolabelled E7070, at 30, 60 minutes, and at 3, 7 and 24 hours after the 
addition of 14C-radiolabelled E7070. After the whole blood samples were taken, they were 
immediately centrifuged at approximately 1600 g for 5 minutes (at 4°C). Fifty µl of plasma 
was transferred to a plastic vial. The rest of the plasma layers and the buffy coats with the 
leukocytes were carefully removed with suffi cient margins, followed by transfer of 200 µl of 
RBC in 15 ml falcon tubes. After one wash step of the RBC with ice-cold isotonic PBS wash-
solvent (1800 µl), the RBC were centrifuged at approximately 1600 g for 15 minutes (at 0°C), 
and the supernatant was discarded. RBC samples (200 µl) were dissolved and decolourised 
using Solvable™ (1 ml), 0.1 M EDTA (100 µl), and hydrogen peroxide (500 µl).
This experiment was followed by the incubation of 2 ml of whole blood without sodium 
azide (in triplicate) with 14C-radiolabelled E7070 at concentrations in the range of 0 (blank), 4, 
20, 50, 100, 150, 200 µg/ml in 15 ml falcon tubes in a water bath at 37°C, or at approximately 
0°C (melting ice water) on a plate with gentle shaking. All whole blood samples were 
centrifuged (at 1600 g for 5 minutes at 4°C) after the equilibrium between plasma and RBC 
was attained as determined in the previous experiment. After the centrifugation, 100 µl of 
plasma was transferred from each falcon tube to a plastic vial, and the rest of the plasma 
layers and buffy coats were carefully removed with suffi cient margins. This was followed 
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by transfer of 500 µl of the RBC samples in 15 ml falcon tubes. After one wash step of 
the RBC with ice-cold isotonic PBS wash-solvent (4500 µl), the RBC were centrifuged at 
approximately 1600 g for 15 minutes (at 0°C), and the supernatant was discarded. Two 
hundred µl of the washed RBC samples was dissolved and decolourised using Solvable™ (1 
ml), 0.1 M EDTA (100 µl), and hydrogen peroxide (500 µl) in a plastic vial.
Effl ux of 14C-radiolabelled E7070 from RBC to plasma
After one wash step of the RBC with ice-cold isotonic PBS, the RBC were incubated (in 
triplicate) with 14C-radiolabelled E7070 to yield fi nal concentrations of 0 (blank), 6, 50 and 
100 µg/ml in 15 ml falcon tubes in a water bath at 37°C with gentle shaking. After 2 hours 
of incubation, 4 ml of blank plasma was added to each falcon tube with the incubated 
RBC. At each incubation concentration, 1 sample (2 ml) was taken just before the addition 
of blank plasma, and samples (2 ml) were taken at 20 minutes, 3 and 24 hours after the 
addition of blank plasma. Samples were centrifuged at 1600 g for 5 minutes (at 4°C). After 
centrifugation, 100 µl of plasma was transferred from each falcon tube to a plastic vial, and 
the rest of the plasma layers and buffy coats were carefully removed with suffi cient margins. 
200 µl of the RBC samples was transferred to 15 ml falcon tubes. After one wash step of 
the RBC with ice-cold isotonic PBS wash-solvent (1800 µl), the RBC were centrifuged at 
approximately 1600 g for 15 minutes (at 4°C), and the supernatant was discarded. Two 
hundred µl of the washed RBC samples was dissolved and decolourised using Solvable™ (1 
ml), 0.1 M EDTA (100 µl), and hydrogen peroxide (500 µl) in a plastic vial.
Plasma protein binding of 14C-radiolabelled E7070
The binding of E7070 to plasma proteins was determined by the ultrafi ltration method after 
incubation of plasma with 14C-radiolabelled E7070 in a gently shaking water bath. The entire 
procedure was conducted at 37°C (in triplicate). Amicon micropartition systems (Amicon 
Corporation, Danvers MA, USA) with membrane discs with a cut off level of 30,000 MW 
(Millipore Corporation, Amicon, Beverly MA, USA) to separate bound from free E7070 in 
plasma. Preliminary experiments revealed negligible binding to the ultrafi ltration device 
(3%). After pre-incubation of plasma for 10 minutes, 14C-radiolabelled E7070 was added 
to plasma to yield a fi nal concentration of 200 µg/ml, and incubated for 24 hours in 50 
ml falcon tubes to determine the ratio between the total and free E7070 concentrations in 
plasma, with time. Plasma samples were taken just before the addition of 14C-radiolabelled 
E7070, at 5, 10, 20, 30, 45, 60 minutes, and at 2, 3, 4, 5, 6, 7, and 24 hours after the start of 
the incubation. After the plasma samples (50 and 100 µl) were taken and transferred to a 
plastic vial, 1 ml plasma samples were immediately transferred into ultrafi ltration devices in 
duplicate. The plasma samples were ultracentrifuged at approximately 1100 g for 15 minutes 
at room temperature, and approximately 200 µl of plasma ultrafi ltrate was obtained. 100 µl 
of plasma ultrafi ltrate was transferred to a plastic vial.
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After establishing the time when equilibrium is achieved between the total and free drug 
concentration in plasma in the previous experiment, plasma was incubated (in triplicate) 
with 14C-radiolabelled E7070 in a concentration range of 20 to 200 µg/ml and at 0 µg/ml. 
Plasma samples were taken after the time to reach equilibrium between the total and free 
drug concentration in plasma. 
At each incubation concentration, the plasma samples (50 and 100 µl) were taken and 
transferred to a plastic vial. The rest of the plasma was immediately transferred to 2 
ultrafi ltration devices and centrifuged at approximately 1100 g for 15 minutes at room 
temperature. Approximately 200 µl of plasma ultrafi ltrate was obtained. 100 µl of plasma 
ultrafi ltrate was transferred to a plastic vial.
Bio-analysis
The detection of beta radiation in plasma, RBC and PBS wash solvent was performed 
by a liquid scintillation counter (LSC) (Tri-CARB 2100 CA; Packard Instrument Company, 
Meriden, USA) with an energy range of 0-2,000 keV on the same day as the experiments. 
Each sample was mixed with 10 ml of Ultima Gold cocktail (Packard Instrument Company, 
Meridine, USA) in a plastic vial. The counting-time was 5 minutes per vial.
The samples were analysed together with calibration standards and quality control (QC) 
standards in the LSC. Calibration curves were fi tted using least-squares regression analysis. 
According to the disintegration per minute (dpm) level in the in vitro samples and the QC 
control samples as determined by the LSC, the equation of the calibration curve was used 
to calculate the E7070 concentration in all samples. The calibration standards consisted of 1, 
2, 4, 10, 20, 40, 100, 200, 400, 1,000 µg/ml E7070 dissolved in 0.9% NaCl. The QC standards 
consisted of 20, 100, 500 µg/ml E7070 dissolved in 0.9% NaCl. Results of batches analysed 
were accepted if at least 2 of the 3 QC standards were within ±20% of their respective 
nominal values. Sample analysis was performed in duplicate and was repeated if the 
deviation in measured dpm was more than 10%. 
Data analysis
A partition coeffi cient value between RBC and plasma (P
RBC/plasma
) was defi ned and used as 
an indicator for the distribution of E7070 between the RBC and plasma under the various 
tested conditions. The P
RBC/plasma
 was calculated by the ratio of the E7070 concentration in 
RBC (C
RBC
) and plasma (C
p
).
C
C
=P
p
RBC
RBC/plasma        equation 1
where C
RBC
 and C
p
 are expressed in µg/ml.
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The uptake of E7070 to RBC was calculated as the E7070 fraction in whole blood bound 
to RBC (F
RBC
) taking into account the differences in haematocrit level (Ht) of the blood 
samples. The following equation was used:
Ht)-(1CHtC
HtC
=F
PRBC
RBC
RBC
⋅+⋅
⋅
       equation 2
where C
RBC
 and C
p
 are expressed in µg/ml.
The plasma protein binding of E7070 was calculated by dividing the free (Cf) and total (Cp) 
E7070 concentrations in plasma.
¸¸¹
·
¨¨©
§
⋅100
Cp
C-C
=bindingproteinPlasma
fp
      equation 3
where plasma protein binding is expressed in %, and C
p
 and C
f
 in µg/ml.
Statistical analysis
Statistical analysis was performed with the Statistical Product and Service Solutions (SPSS) 
for windows, version 10.0.7 (SPSS Inc., Chicago, IL., USA).
Differences between the RBC uptake in different conditions were determined using the 
Student’s t-test with a signifi cance level of < 0.05.
Results
The E7070 concentrations in plasma and RBC were calculated from the radioactivity 
measurements. No degradation of radioactivity was observed in human RBC and plasma 
during a 24-hour incubation at 37°C. Validation experiments of the coupled liquid 
chromatography-tandem mass spectrometry method to determine the E7070 concentrations 
in human plasma, urine and faeces, showed that E7070 was stable for 24 hours at room 
temperature.[16] Consequently, we assumed that the radioactivity determinations are an 
accurate refl ection of the E7070 concentrations in human RBC and plasma in this study. 
After the addition of E7070 to whole blood in vitro at 37°C the drug was taken up by RBC 
from plasma (Figure 2). The addition of sodium azide to deplete ATP did not result in a 
signifi cant inhibition of the uptake (data not shown). It was impossible, however, to quantify 
the ATP-depletion (caused by the addition of sodium azide to whole blood) by a luciferase 
assay due to interference by haemoglobin. Previous reports indicate that a sodium azide 
concentration of 20 mM would be suffi cient to deplete ATP in RBC.[14] Equilibrium between 
the E7070 concentration in RBC and plasma was achieved within 2 hours at 37°C. After the 
incubation of whole blood with various E7070 concentrations for 2 hours at 37°C, the E7070 
concentration in RBC achieved a plateau at higher incubation concentrations (Figure 3A). In 
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Figure 2. E7070 concentration in RBC (A) and in plasma (B) during the incubation with 200 µg/ml E7070 in whole blood at 
37°C in vitro. Each value is the mean of 6 experiments
Figure 3. E7070 uptake in RBC (A) and E7070 concentration in plasma (B) following incubation with E7070 in whole blood for 2 
hours at 37°C and at approximately 0°C. Each value is the mean ± SD of 3 experiments
Figure 4. The in vitro E7070 effl ux from RBC (A) to plasma (B) at various concentrations at 37°C. Each value is the mean of 3 
experiments
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contrast, the plasma concentration continued to increase at higher incubation concentrations 
(Figure 3B). Simultaneously, a non-linear increase of the E7070 concentration in PBS (that 
was used in the washstep of RBC) was observed at higher incubation concentrations in 
whole blood (data not shown). This indicates that at higher incubation concentrations of 
E7070 in whole blood, more E7070 was lost in the wash step. This may be explained by 
non-linear binding of E7070 to other components of whole blood (excluding plasma) at 
higher incubation concentrations, e.g. leukocytes or platelets.
The drug uptake in RBC was signifi cantly decreased at approximately 0°C compared to 
37°C with a corresponding higher E7070 concentration in plasma at 0°C compared to 37°C 
(Figure 3). 
The in vitro partition coeffi cient (P
RBC/plasma
) between RBC and plasma decreased at higher 
incubation concentrations at 37°C (Table 1). Since the haematocrit of the blood samples 
ranged from 0.39 to 0.43, the E7070 recovery percentage in whole blood bound to RBC 
following incubation for 2 hours at 37°C was determined. This percentage decreased from 
61.8 ± 6.3% at 4 µg/ml to 17.6 ± 0.5% at 200 µg/ml (Table 1). These data confi rm that there is 
a non-linear increase of the drug uptake into RBC at higher drug concentrations. In Figure 4 
the results of the effl ux experiments are summarised. The E7070 effl ux from RBC to plasma 
takes place in a concentration- and time-dependent manner.
E7070 showed a high plasma protein binding (98-99%) which was constant over the 
measured time-period of 24 hours after the addition of 200 µg/ml E7070 to plasma (data not 
Table 1. The in vitro partition coefficient between RBC and plasma (PRBC/plasma) and the fraction of 
E7070 in RBC following incubation in whole blood for 2 hours at 37°C (n = 3) 
Incubation concentration 
(µg/ml) 
PRBC/plasma
(mean ± SD)
Recovery in RBC (%) 
(mean ± SD) 
4 2.37 ± 0.42 61.8 ± 6.3 
20 2.03 ± 0.28 58.2 ± 5.4 
50 1.22 ± 0.10 45.8 ±4.0 
100 0.48 ± 0.07 25.0 ± 3.3  
150 0.34 ± 0.02 19.1 ± 0.5 
200 0.31 ± 0.04 17.6 ± 0.5 
Table 2. Plasma protein binding of E7070 after incubation of plasma with E7070 for 30 minutes at 
37°C (n = 3) 
Incubation concentration 
(µg/ml) 
Mean plasma protein binding 
(%) 
SD
(%) 
20 98.0 0.66
50 98.8 0.16 
100 99.0 0.05 
150 99.0 0.16 
200 99.0 0.07 
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shown). The in vitro binding was independent of the incubation concentration over a wide 
range of 20 to 200 µg/ml after 30 minutes of incubation with E7070 (Table 2).
Discussion
The results of these in vitro incubation experiments with E7070 in human blood revealed 
that the equilibrium between RBC and plasma is reached within approximately two hours. 
The addition of sodium azide caused no signifi cant decrease of the E7070 uptake in RBC. 
We may thus conclude that the infl ux of E7070 from plasma into RBC occurs by passive 
diffusion. The E7070 uptake in RBC occurred in a concentration-dependent manner and RBC 
became saturated in the concentration range studied (4-200 µg/ml). This non-linearity also 
appears from the lower mean partition coeffi cient values between RBC and plasma (2.37 at 
the 4 µg/ml to 0.31 at the 200 µg/ml concentration), and the lower E7070 fraction in RBC 
in whole blood (61.8 ± 6.3% at 4 µg/ml to 17.6 ± 0.5% at 200 µg/ml) at higher incubation 
concentrations. This indicates that E7070 is preferentially bound to RBC when present in 
whole blood, and that the distribution in the RBC compartment can become saturated. The 
protein binding of E7070 in plasma was high (98-99%) and showed no signs of non-linearity 
or saturation in the concentration range of 20 to 200 µg/ml.
From these experiments we can conclude that the non-linear distribution of E7070 in blood 
is probably, in part at least, caused by a saturable distribution to the RBC compartment. 
Sulphonamide agents bind to carbonic anhydrase, an intracellular enzyme that is present 
throughout the body, although RBC account for >90% of this enzyme.[11-13] Recently, several 
novel sulphonamides with high affi nity for the enzyme carbonic anhydrase were synthesised 
that resemble E7070 and showed antitumour activity.[12] It is possible that E7070 binds to 
carbonic anhydrase and this binding becomes saturated when blood concentration of drug 
is higher than the available binding sites of the enzyme in the RBC. This can result in a 
non-linear distribution of E7070 in the RBC compartment, as has been described for another 
sulphonamide agent, the carbonic anhydrase inhibitor MK-417.[11]
Recently, a mass balance study of 14C-radiolabelled E7070 in patients with solid tumours has 
been completed in our institute.[17] The maximal concentration of total radioactivity in plasma 
was higher compared to that in RBC during and shortly after the infusion of 14C-radiolabelled 
E7070. At later time-points the radioactivity concentration in both plasma and RBC were in the 
same range. Consequently, the exposure to radioactivity in plasma was higher than in RBC. 
We assume that the binding sites of the enzyme carbonic anhydrase in RBC become saturated 
when relatively high E7070 levels are reached, during and shortly after infusion. Moreover, 
according to this observation in the mass balance study, and considering the results of the in 
vitro E7070 effl ux experiments, we may conclude that E7070 will diffuse from the RBC into 
plasma during the elimination process in humans. The drug in RBC may not be easily available 
for extraction by the eliminating organs (i.e. the kidneys and the liver), and the expression 
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of the pharmacologic activity may be infl uenced.[18,19] We observed no degradation of 
radioactivity in RBC during 24 hours of incubation with 14C-radiolabelled E7070. However, we 
do not know whether E7070 alone or E7070 and its metabolites contribute to this radioactivity. 
Consequently, we cannot exclude that there might be metabolism of E7070 in the RBC.
In conclusion, E7070 is preferentially bound to RBC in whole blood. This binding is 
a saturable process at higher concentrations in whole blood. There is no evidence of 
saturation of protein binding of E7070 in plasma at the concentrations tested. It is postulated 
that the binding site of E7070 within the RBC is the enzyme carbonic anhydrase. 
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Pharmacokinetic drug-drug interaction of the novel anticancer agent 
E7070 and acenocoumarol
HJG Desirée van den Bongard, Rolf W Sparidans, David JP Critchley, Jos H Beijnen 
and Jan HM Schellens
Summary
E7070 is a novel sulphonamide anticancer agent that arrests cancer cells at the G1-S 
boundary of the cell cycle. Three patients who were receiving prophylactic daily oral 
maintenance therapy with the anticoagulant acenocoumarol experienced bleeding and/or a 
prolonged prothrombin time after treatment with E7070 at a dose of 700 mg/m2 given as a 
1-hour infusion. In vitro studies have shown that E7070 has the potential to inhibit several 
cytochrome P450 (CYP)-enzymes, including CYP2C9, CYP2C19, CYP2D6, CYP2E1, and 
CYP3A4. The major enzyme involved in the metabolism of acenocoumarol in man is CYP2C9. 
This study was performed to investigate the interaction between E7070 and acenocoumarol. 
Blood samples were obtained from 2 patients receiving daily oral maintenance treatment 
with acenocoumarol both prior to and following treatment with E7070. Pharmacokinetic 
parameters of acenocoumarol were calculated by non-compartmental analysis and revealed 
that in both patients the area under the concentration-time curve up to 24 hours after 
the acenocoumarol administration was higher following E7070 (2.56 and 1.58 h*µmol/L) 
compared to the systemic exposure in the absence of E7070 (1.87 and 1.23 h*µmol/L). 
In addition, we incubated acenocoumarol enantiomers with pooled human microsomes with 
and without E7070 and measured the in vitro plasma protein binding of acenocoumarol after 
incubation with E7070. The formation of acenocoumarol metabolites was retarded by E7070 
at already low concentrations (2.1 µM). The plasma protein binding of acenocoumarol was 
reduced at higher concentrations of E7070 (259 µM).
In conclusion, these results indicate that E7070 may primarily interact with acenocoumarol 
by reducing its systemic clearance, and by reducing the plasma protein binding to a 
minor extent. In the absence of careful monitoring this drug-drug interaction may result in 
hypoprothrombinaemia and a haemorrhagic tendency. 
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Introduction
E7070 (N-(3-chloro-7-indolyl)-1,4-benzendisulphonamide, GOAL) is a novel sulphonamide 
anticancer agent (Figure 1) that acts on the G1 phase by inhibiting both the phosphorylation 
of cyclin E and the activation of cyclin dependent kinase 2 needed for the transition to 
the S-phase of the cell cycle.[1-3] Phase I trials employing four different infusion schedules 
in 127 patients with solid tumours showed that the dose-limiting toxicity of E7070 was 
predominantly haematological. Partial and minor responses were observed in patients 
with breast, endometrial, renal, and ovarian carcinoma.[4,5] The pharmacokinetics of E7070 
are non-linear with a disproportional increase in systemic exposure with increasing 
administered dose (Figure 2).[4-6] Phase II studies employing two different dosing schedules, 
a 1-hour administration intravenously (iv) every 3 weeks (700 mg/m2) and a daily 1-hour iv 
infusion for 5 consecutive days, repeated every 3 weeks (130 mg/m2) are currently ongoing 
in patients with solid tumours.
During the phase I program, three patients who were receiving prophylactic daily oral 
maintenance therapy with acenocoumarol (Sintrom®) developed a haemorrhagic tendency 
and/or a prolonged prothrombin time following treatment with 700 mg/m2 of E7070. 
Acenocoumarol is frequently involved in drug-drug interactions as a result of its narrow 
Figure 1. Molecular structure of E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)
NHSO2
SO2NH2
NH
Cl
Figure 2. Typical plasma concentration-time curve of E7070 after 1-hour iv infusion of E7070 (1000 mg)
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therapeutic index and cytochrome P-450 (CYP)-dependent, hepatic clearance.[7-9] Although, 
acenocoumarol is administered as a racemic mixture of R(+)- and S(-)-enantiomers, only 
R(+)-acenocoumarol is active.[7-9] The main metabolic pathways of the enantiomers are 6- 
and 7-hydroxylation producing 6- and 7-hydroxy-acenocoumarol, respectively. The major 
enzyme involved in this pathway is CYP2C9.[8-11] Serum protein binding of acenocoumarol 
(mainly to albumin) is known to be as high as 98.7%.[9,11] 
An in vitro study performed in our institute indicated that human plasma protein binding 
for E7070 is also very high (ca. 99%). Moreover, other in vitro studies have demonstrated 
that E7070 may inhibit the activity of several cytochrome P450-related enzymes including 
CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 (E7070; GOAL, Investigators Brochure). 
Clinically signifi cant inhibition of CYP2C9 has been reported by existing sulphonamides e.g. 
sulphaphenazole.[12]
Most pharmacokinetic drug-drug interactions involving oral anticoagulants result from 
modifi cations in absorption, protein binding and/or elimination.[9,11] We investigated 
the potential of E7070 to displace acenocoumarol from its plasma protein binding sites 
and/or inhibit its hepatic metabolism. To this end, we studied the pharmacokinetics of 
acenocoumarol with and without E7070 in two patients. In addition, we performed in vitro 
studies to determine whether the plasma protein binding of acenocoumarol and the CYP450 
mediated metabolism of acenocoumarol are infl uenced by the presence of E7070.
Materials and Methods
Drugs and chemicals
Racemic acenocoumarol and 7-hydroxy-acenocoumarol were kindly donated by Novartis 
Pharma (Basel, Switzerland). E7070 was obtained from Eisai Ltd. (London, UK). 
Ethyl acetate and acetonitrile (gradient grade) were obtained from Biosolve (Valkenswaard, 
The Netherlands) and ammonia (25% (v/v), p.a.), dichloromethane and n-hexane from 
Merck (Darmstadt, Germany). Further, potassium hydroxide (p.a.) was provided by Lamers 
& Pleuger (‘s Hertogenbosch, The Netherlands) and acetic acid (extra pure) by Riedel-de 
Haën (Seelze, Germany). 
Monosodium D-glucose-6-phosphate, glucose-6-phosphate dehydrogenase, ß-NADP sodium 
salt and sodium hydrogencarbonate were all purchased from Sigma (St. Louis, MO, USA). 
Pooled, gender mixed, human liver microsomes (20 mg/ml, lot. 0110032, pooled from 16 
donors) were purchased from XenoTech (Cambridge, Kansas City, KS, USA). Blank, drug-free 
human plasma was obtained from the Blood Transfusion Service (Utrecht, The Netherlands) 
and water was home-purifi ed by reversed-osmosis on a multi-laboratory scale.
Stock solutions of racemic acenocoumarol were prepared in 10 mM potassium hydroxide and 
stock solutions of E7070 were prepared in methanol. A 200-µl volume of 15 U/ml glucose-6-
phosphate dehydrogenase (Type VII, from bakers yeast), 200 µl of 5 mg/ml ß-NADP sodium 
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salt and 200 µl of 40 mg/ml monosodium D-glucose-6-phosphate (all in 2% (w/v) sodium 
hydrogencarbonate) were mixed with 1400 µl water to obtain the NADPH regenerating system 
(NRS). Human plasma was pooled using equal portions from 4 healthy donors. 
Patients
In 3 patients receiving oral maintenance therapy with acenocoumarol, symptoms of 
hypoprothrombinaemia were observed after treatment with E7070. Bleeding was also 
observed in other patients treated with E7070 in the phase I programme but this was 
thought to be related to thrombocytopenia. One patient with advanced rectal cancer (patient 
#1) was included in a phase I study of E7070 and received a dose of 800 mg/m2 as a 1-hour 
administration iv repeated every 3 weeks. The other 2 patients were enrolled in a mass 
balance study of E7070 and received a dose of 700 mg/m2 as a 1-hour infusion iv repeated 
every 3 weeks. Patient #2 had an advanced abdominal gastro-intestinal autonomic nerve cell 
tumour, and the patient #3 had advanced non-small cell lung cancer. The results of these 
studies are presented elsewhere.[4-6,13] 
Pharmacokinetic sampling
Patients #1 and #2 underwent pharmacokinetic analysis of acenocoumarol with and without 
E7070. They were maintained on acenocoumarol at an oral dose of 3 mg (#1) and 1 mg (#2) 
given once daily. Blood samples for acenocoumarol analysis were collected in heparinised 
tubes just before acenocoumarol administration (0 hours) and at 1, 2, 3, 4, 6, 8, and 11.5 
hours after the administration of acenocoumarol with and without E7070. To avoid any effect 
of E7070 on the absorption of acenocoumarol, the E7070 infusion was started at 3 hours 
after the administration of acenocoumarol. Blood samples were centrifuged for 5 minutes at 
approximately 1600 g, and the plasma layer was separated. Plasma was immediately stored 
at –20°C in polypropylene tubes until analysis. 
Microsomal incubation
All incubations were performed in triplicate. Fifty µl of an aqueous dilution of acenocoumarol 
alone (fi nal concentrations in the incubation mixture were 1.5, 2, 3, 5 and 20 µM) or a 
combination of acenocoumarol (1.5, 3 and 20 µM) with E7070 (2.1, 5.2 and 20.9 µM) was 
transferred to a polypropylene micro tube on ice. Twenty-fi ve µl of a 0.5 M potassium 
phosphate buffer (pH 7.4) and 50 µl of the NRS solution were added. After vortex mixing, 
the tubes were conditioned at 37°C for 2 min. Next, 5 µl of the microsomal suspension 
was added, the tube was vortex-mixed and incubated at 37°C for 15 min. The reaction was 
terminated by adding 125 µl methanol followed by vortex-mixing. Finally, proteins were 
removed by centrifugation for 1 min at 104 g at 4°C. Next, 200 µl of the supernatant was 
evaporated using nitrogen at 40ºC and the residue was reconstituted in 100 µl of 10 mM 
potassium hydroxide using vortex-mixing prior to injection onto the analytical column.
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Plasma protein binding experiments
Racemic acenocoumarol (13.3, 53.8 and 133 µM) was mixed with pooled blank plasma 
(obtained from 3 healthy volunteers) and E7070 at incubation concentrations of 0, 2.59, 
25.92, 259.2 µM (in triplicate). The mixture was placed at room temperature for at least 15 
minutes followed by transfer of 400 µl of plasma before fi ltration (at 10000 g, 20°C) with 
Centrisart C4G Centrifugal Concentrators (10 kD MWCO, Supelco, Bellefonte, PA, USA) to 
separate protein-bound from free drug in plasma. 
HPLC analysis
Patient samples
A validated HPLC analysis as described elsewhere was used to determine the acenocoumarol 
concentrations in patient plasma samples as has been published elsewhere.[14] For plasma 
samples containing E7070, the internal standard warfarin was replaced by phenprocoumon 
due to co-elution of E7070 and warfarin. 
In vitro samples
For the in vitro samples a similar chromatographic assay was employed. Partial-loop 
injections (50 µl) were made on a Symmetry C
18
 column (100×4.6 mm, d
p 
= 3.5µm, average 
pore diameter = 10 nm, Waters) with a Symmetry C
18
 pre-column (20×3.8 mm, d
p
 = 5 µm, 
Waters). The column was used at 50°C and the eluent (pumped at 1 ml/min) comprised 
a mixture of 0.1% (v/v) acetic acid and acetonitrile (pH adjusted to 4.7 using 25% (w/v) 
ammonia). A model 616 pump with column thermostat (Waters Chromatography, Milford, 
MA, USA), a Waters in-line degasser, a Waters 717 plus autosampler and a Spectrofl ow 
variable wavelength detector (Kratos Analytical, Ramsey, NJ, USA) were used. The 
micosomal samples were analysed using 25% (v/v) acetonitrile (retention times of 6-
hydroxy-acenocoumarol, 7-hydroxy-acenocoumarol, acenocoumarol and E7070 are 6.3, 
8.9, 16 and 27 min, respectively) and the ultrafi ltrate samples using 30% (v/v) acetonitrile 
(retention times of acenocoumarol and E7070 are 5.9 and 8.6 min, respectively) in the 
eluent. The calibration standards of E7070 were prepared in 50 mM phosphate (pH 7.4) 
and were in the range of 0.1 to 100 µmol/L. Detection was performed using ultraviolet 
absorption at 305 nm. 
Pharmacokinetic analysis
Patient samples
The pharmacokinetic parameters were calculated by applying a non-compartmental analysis 
using the pharmacokinetic computer program WINNONLIN (Standard Edition version 
3.0, 1999, Pharsight Corporation, California, USA). The time of the maximum observed 
concentration (T
max
) and the concentration corresponding to T
max
, the maximal drug 
concentration (C
max
), were derived directly from the experimental data. The fi rst order rate 
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constant λ
z
 associated with the terminal elimination was calculated by log-linear regression 
analysis of the concentration versus time curve. The terminal half-life (t
1/2
) was calculated 
by the equation ln(2)/λ
z.
 The area under the plasma concentration versus time curve (AUC) 
was obtained using the trapezoidal rule from 0 to 24 hours (AUC
0-24h
). The apparent oral 
clearance (CL/F) was calculated by dividing the administered dose by the AUC
INF
 where 
F represents the oral bioavailability. AUC
INF
 is the AUC from the time of dosing to the last 
sampling point extrapolated to infi nity. The apparent volume of distribution (Vz/F) was 
based on the terminal phase (Vz/F = Dose/λ
z 
*AUC
INF
). 
In vitro samples
The apparent values of the kinetic parameters Km and Vmax were calculated according to 
the rate of formation of 7- and 6-hydroxy-acenocoumarol from acenocoumarol at various 
incubated racemic acenocoumarol concentrations in combination with a range of E7070 
concentrations using Lineweaver-Burk plots. Because the 6-hydroxy-acenocoumarol 
reference compound was not available, the 6-hydroxy-acenocoumarol concentrations were 
quantifi ed using the 7-hydroxy-acenocoumarol concentrations in the calibration samples 
as determined by HPLC and the reported ratio of the ultraviolet absorption of 7- and 6-
hydroxy-acenocoumarol.[8]
The plasma protein binding of acenocoumarol and E7070 was calculated by dividing the 
determined free (Cf) and total added (Cp) acenocoumarol and E7070 concentrations in 
plasma.
¸
¸
¹
·
¨
¨
©
§
⋅100
C
C-C
=bindingproteinPlasma
p
fp
      equation 1
where plasma protein binding is expressed in %, and C
p
 and C
f
 in µmol/L.
Results
Patients
In all 3 patients, symptoms of hypoprothrombinaemia were observed (Table 1), with 2 
patients (#1 and #2) experiencing bleeding (epistaxis, menorrhagia, bleeding at central 
venous catheter insertion). A prolonged prothrombin time was observed in patient #1 (>34) 
and in patient #3 (15.4). The prothrombin time values are expressed in the International 
Normalised Ratio (INR [0.9-1.15]) according to the equation:
INR = (Pt
observed
/Pt
control
)ISI      equation  2 
 
where ISI = international Sensitivity index.[15]
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The prolonged prothrombin times were decreased by vitamin K administration and daily 
frequent measurements of the prothrombin time were performed. Using this approach 
further bleeding episodes were not observed despite continuing therapy with E7070.
Pharmacokinetic studies in patients
The concentration-time curves of acenocoumarol with and without E7070 are depicted in 
Figure 3. The pharmacokinetic parameters are summarised in Table 2. After co-administration 
of E7070, the half-life increased from 18.3 h to 27.5 h in patient #2 and decreased from 17.7 h 
to 13.6 h in patient #1. After treatment with E7070, the apparent clearance of acenocoumarol 
decreased in both patients (from 2.26 L/h to 1.77 L/h and from 1.15 L/h to 0.695 L/h), 
Table 1. Symptoms of increased hypoprothrombinemia in three patients treated with daily maintenance therapy of
acenocoumarol with co-infusion of E7070
Symptoms E7070 dose (course number) Co-medication
Patient #1 
Bleeding
a
Prolonged PT-INR (>34)
c
800 mg/m
2
(3) methadone
clonazepam
meloxicam
paracetamol
Patient #2
Bleeding
b 700 mg/m
2
(4) metoprolol
lorazepam
triamterene/hydrochlorthiazide
microgynon 30
Patient #3
Prolonged PT-INR (15.4) 1000 mg (3) morphin retard
lactulose
a
 epistaxis.
b
 epistaxis, menorrhagia, bleeding from central venous catheter insertion.
PT-INR = prothrombin time value expressed as the International Normalised Ratio. 
Table 2. Pharmacokinetic parameters after oral administration of acenocoumarol as a single agent 
and with E7070 treatment (n=2) 
Pharmacokinetic parameters  
Dose (mg) 
Patient #1 
3
Patient #2 
1
Single agent    
   Cmax (µmol/L) 0.243 0.127
   Tmax (h) 3.00 1.02 
   t1/2 (h) 17.7 18.3 
   AUC3-24h (h*µmol/L) 1.87 1.23 
   Vz/F (L) 57.9 30.3 
   CL/F (L/h) 2.26 1.15 
Co-infusion of E7070 
   Cmax (µmol/L) 0.425 0.105
   Tmax (h) 1.05 2.23 
   t1/2 (h) 13.6 27.5 
   AUC3-24h (h*µmol/L) 2.56 1.58 
   Vz/F (L) 34.8 27.6 
   CL/F (L/h) 1.77 0.695 
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and the apparent volume of distribution (Vz/F) of acenocoumarol showed a decrease in 
1 patient (from 57.9 L to 34.8 L). In the other patient, almost no difference in the volume of 
distribution was observed following E7070 (30.3 L without E7070, and 27.6 L with E7070). 
In both patients, the AUC
3-24h
 of acenocoumarol was 37% and 28% higher following  E7070 
(from 1.87 to 2.56 h*µmol/L and from 1.23 to 1.58 h*µmol/L, respectively). 
In vitro studies
Km and Vmax were calculated according to Michaelis-Menten enzyme kinetics using 
least-squares linear regression with the squared concentration (c2 or X-2) as the weighting 
factor for the formation of 6- and 7-hydroxy-acenocoumarol at various incubated racemic 
acenocoumarol concentrations and at various E7070 concentrations. The infl uence of the 
presence of E7070 on the apparent Km and Vmax values of 6- and 7-hydroxy-acenocoumarol 
is depicted in Table 3. The in vitro intrinsic clearance of racemic acenocoumarol was 10.0 
µl/(min*mg) without E7070, and decreased to 6.0 µl/(min*mg) in the presence of 20.9 µM 
E7070.
The plasma protein binding of acenocoumarol, both alone and in combination with E7070 
are given in Table 4A. Plasma protein binding of E7070 in the presence of acenocoumarol is 
detailed in Table 4B. The plasma protein binding of acenocoumarol at 133 µM, was 97.3% 
without and 94.0% in the presence of 259.2 µM E7070 (Table 4A). The binding of E7070 
to plasma proteins was not affected by acenocoumarol within the range of acenocoumarol 
concentrations tested (Table 4B). 
Figure 3. Concentration-time curves of acenocoumarol after administration as a single agent and with co-infusion of E7070 in 
patient #1 (A) and patient #2 (B) 
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Discussion
Oral anticoagulants are widely used in the treatment and prophylaxis of thromboembolic 
disease.[9,11] Their narrow therapeutic index and extensive plasma protein binding has led 
to numerous reports of clinically signifi cant drug-drug interactions involving these agents. 
Interactions between oral anticoagulants and both cardiovascular and cholesterol lowering 
drugs are well documented.[9,11] These interactions can result in hypoprothrombinaemia, 
and to a lesser extent hyperprothrombinemia. The purpose of this study was to determine 
whether a pharmacokinetic interaction occurred between acenocoumarol and E7070. In 
three patients receiving daily oral maintenance therapy of acenocoumarol, symptoms 
of hypoprothrombinaemia, bleeding and/or a prolonged prothrombin time were 
observed following treatment with E7070. No other patients were treated with E7070 and 
acenocoumarol concomitantly at our institution. 
Table 3. The influence of E7070 on the apparent kinetic parameters for the metabolism of racemic 
acenocoumarol 
 7-hydroxy-
acenocoumarol 
6-hydroxy-
acenocoumarol 
Racemic 
acenocoumarol 
E7070 concentration
a
  Km
a
 Vmax
b
 Km
a
 Vmax
b
 Cli
c
      
0 2.0 11.5 2.7 11.4 10.0 
2.1 2.9 11.5 3.8 12.0 7.1 
5.2 4.0 13.7 5.5 15.2 6.2 
20.9 3.4 11.3 5.4 14.4 6.0 
a
 in µmol/L 
b
 in pmol/(min*mg) 
c
 in µl/min*mg 
Cli = intrinsic clearance, sum of Vmax/Km values of the 6- and 7-hydroxylations of racemic acenocoumarol. 
Table 4A. In vitro plasma protein binding (%) of acenocoumarol with and without the presence of  
E7070. Incubations were performed in triplicate 
 Acenocoumarol concentration (µmol/L) 
E7070 concentration (µmol/L) 13.3
mean ± SD 
53.8
mean ± SD 
133
mean ± SD 
0 97.9 ± 0.4 98.1
a
97.3 ± 0.4 
2.59 97.7 ± 0.1 98.0 ± 0.5 97.1 ± 0.4 
25.92 97.6 ± 0.1 97.6 ± 0.5 97.2
a
259.2 96.1 ± 0.6 94.9 ± 0.04 94.0 ± 0.4 
a
 in duplicate. 
Table 4B. In vitro plasma protein binding (%) of E7070 (100 µg/ml) in combination with acenocou- 
marol. Incubations were performed in triplicate 
Acenocoumarol concentration (µmol/L) E7070 protein binding (%) 
13.3 99.9
a
53.8 99.8 ± 0.04 
133 99.8 ± 0.07 
a
in duplicate. 
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Since E7070 is a sulphonamide derivative, a pharmacokinetic drug-drug interaction was 
anticipated because several pharmacokinetic interactions between coumarin derivatives and 
sulphonamides, e.g. co-trimoxazole, have been reported previously.[9,11] These drug-drug 
interactions include both displacement of acenocoumarol from plasma protein binding sites 
and inhibition of acenocoumarol metabolism.[9,11] 
Acenocoumarol belongs to the group of coumarin derivatives including warfarin 
and phenprocoumon, which exist as two enantiomers.[7] The elimination half-life of 
acenocoumarol is 3 to 9 hours and its duration of action following a single oral administration 
is 48 to 72 hours.[7,16] In our study, the half-lives of acenocoumarol in patients without E7070 
were longer than the reported half-life of acenocoumarol in the literature. In both patients 
the AUC
3-24h
 of acenocoumarol was increased following E7070. This can be attributed to 
a combined increase of the Cmax and a lower clearance in one patient, and a decreased 
clearance in the other patient. The results of our experiments indicate the increase in 
acenocoumarol AUC in both patients following E7070 co-administration is probably caused 
by a reduction in metabolic clearance specifi cally the hydroxylation of acenocoumarol to 7- 
and 6-hydroxy-acenocoumarol by CYP2C9 (Table 3).[17] Previous studies have demonstrated 
that E7070 is a potential inhibitor of CYP2C9 and our results suggest that this is the most 
likely explanation for the interaction reported here. A further potentiation of acenocoumarol 
may also result from a decrease in its plasma protein binding following displacement by 
E7070 (Table 4A). Our experiments show that the plasma protein binding of acenocoumarol 
is reduced in plasma spiked with a high concentration E7070 (259 µM), whereas the 
inhibitory effect of E7070 on the acenocoumarol metabolism is evident at concentrations 
as low as 2.1 µM. Consequently, the effect of E7070 on the metabolism of acenocoumarol 
may be of more relevance than the effect of E7070 on the acenocoumarol protein binding 
in plasma. 
In Table 1 the concomitant treatment during the E7070 administration of the patients is 
detailed. In the literature, no pharmacokinetic interactions between acenocoumarol and 
any of the listed medications have been reported other than oral contraceptives.[9,11] In 
twelve women treated with acenocoumarol, withdrawal of oral contraceptives resulted in a 
reduction in anticoagulant activity.[11] In contrast, it has been reported that oral contraceptives 
can increase the clearance of phenprocoumon, and may produce hyperprothrombinemia 
when used simultaneously with warfarin.[9,11] Although none of the concomitant medication 
is known to interact specifi cally with acenocoumarol several of the agents listed in Table 
1 have been reported to alter the disposition of coumarin anticoagulants. Paracetamol 
has been shown to prolong the prothrombin time when administered concomitantly 
with warfarin although the mechanism of this interaction has yet to be defi ned.[9,11] A 
pharmacokinetic interaction between phenprocoumon and metoprolol has been reported 
possibly caused by the displacement of phenprocoumon from its plasma protein binding 
sites by metoprolol.[11] Nonsteroidal anti-infl ammatory drugs including indomethacin, 
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ketoprofen, piroxicam, sulindac, and topical methylsalicylate ointment, can interact with 
warfarin causing an increased anticoagulant effect.[9] Consequently, a pharmacodynamic 
interaction between acenocoumarol and meloxicam may have contributed to the bleeding 
reported in patient #1. The other drugs listed in Table 1 have not been reported to interact 
with coumarin anticoagulants. All listed drugs were used prior to the start of the E7070 
infusions, and no prior symptoms of hypoprothrombinaemia were observed in the period 
following the start of the co-medication and before receiving E7070. Thus, it is likely that 
the increased acenocoumarol-induced anticoagulation is due to E7070 rather than existing 
medication. 
As part of the phase I program a group of patients with advanced cancer received E7070 
administered as a continuous infusion for fi ve days at another European institution[18]. Two 
of these patients were receiving oral maintenance therapy with acenocoumarol. Neither of 
these patients experienced an increase in prothrombin time or exhibited clinical evidence of 
a bleeding tendency. No changes in the dose of anticoagulants given to these patients were 
required. This pattern of administration achieved signifi cantly lower peak concentrations 
than a single dose given every three weeks. This suggests that any interaction between 
E7070 and oral acenocoumarin is schedule dependent and may only occur at relatively high 
concentrations of the drug. Despite protocol warnings a further patient with non-small cell 
lung cancer who was receiving chronic therapy with phenprocoumon was inappropriately 
entered into a phase II study of E7070 administered at a dose of 700 mg/m2 as a 1-hour 
iv infusion repeated every 3 weeks. No adverse events were reported nor was the dose 
of phenprocoumon altered. It is thus possible that the interaction between E7070 and 
acenocoumarol is more marked than with other anticoagulants of this class.
In conclusion, E7070 appears to increase the anticoagulant effect of acenocoumarol. This 
effect may be caused by a pharmacokinetic interaction between the two drugs. Limited 
pharmacokinetic data for acenocoumarol from two patients offer some support for this 
assertion. Data from in vitro investigations presented here suggest that a pharmacokinetic 
interaction is likely, with the probable primary mechanism for the interaction being an 
inhibitory effect of E7070 on the hepatic hydroxylation of acenocoumarol. Displacement of 
acenocoumarol from its plasma protein binding sites might also play a role.  For practical 
purposes, patients who are receiving coumarin anticoagulants should either undergo intense 
monitoring of their prothrombin time or change to heparin anticoagulants upon starting 
therapy with E7070. 
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Successful rescue with leucovorin and thymidine in a patient with 
high-dose methotrexate induced acute renal failure
HJG Desirée van den Bongard, Ron AA Mathôt, Willem Boogerd, Jan H Schornagel, 
Marcel Soesan, Jan HM Schellens and Jos H Beijnen
Summary
A 54-year old patient with primary cerebral lymphoma was treated with two 4-weekly cycles 
of high-dose intravenous cytarabine (12 g/m2) and methotrexate (3 g/m2). The administration 
of the fi rst course proceeded without notable complications. Before the administration of 
methotrexate in the second cycle blood cell counts and chemistry showed no abnormalities 
except for slightly increased alkaline phosphatase and gamma-glutamyl-transpeptidase 
(GGT) levels which was attributed to diphantoin comedication. The patient developed 
symptoms of acute renal failure 7 hours after methotrexate infusion which resulted in a 
very high serum methotrexate level (39.8 µmol/L) at 20 hours after infusion. Rescue therapy 
was intensifi ed: leucovorin dosage was increased (1200 mg continuous iv infusion every 
24 hours) and combined with thymidine rescue therapy (8 g/m2 per day continuous iv 
infusion every 24 hours). Urine alkalisation was increased and diphantoin therapy was 
stopped. Leucovorin eye drops and mouth washes were started 5 days after methotrexate 
administration to prevent conjunctivitis and mucositis as a result of high methotrexate levels 
(>2.4 µmol/L). In spite of the fact that serum methotrexate levels remained persistently 
higher than 0.1 µmol/L for 12 days, the patient experienced no further short-term systemic 
toxicity except for anaemia (grade 3 according to NCI Common Toxicity Criteria). After day 
12 intensifi ed rescue therapy and the frequency of alkalisation were decreased to standard 
procedures and stopped on day 19. It is concluded that iv administration with high-dose 
methotrexate can result in unpredictable acute toxicity. In our patient, acute methotrexate 
toxicity was treated successfully by intensifi cation of classical leucovorin rescue therapy in 
combination with thymidine infusion. In addition, leucovorin mouth washes and eye drops 
may have prevented mucositis and conjunctivitis, respectively.
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Introduction
High-dose methotrexate administered as an intravenous (iv) infusion is used to treat a variety 
of malignancies in single or combination therapy. Methotrexate belongs to the group of 
antimetabolites. It binds to and inhibits dihydrofolate reductase (DHFR) in the cytoplasm 
leading to intracellular depletion of reduced folates. Inhibition of thymidylate and de novo purine 
synthesis occur resulting in decreased RNA and DNA synthesis as a function of both extracellular 
methotrexate level and the duration of exposure.[1,2] The pharmacokinetics of methotrexate vary 
considerably among patients mainly due to high interindividual variation in renal excretion 
of methotrexate and its metabolite 7-hydroxy-methotrexate.[2,3] Administration of high-dose 
methotrexate may result in acute renal failure possibly due to precipitation of methotrexate 
and/or 7-hydroxy-methotrexate in the renal tubules, especially when the urinary pH is <7.0. 
This nephrotoxicity leads to delayed methotrexate elimination, and consequently to toxicities 
including myelosuppression, gastrointestinal toxicity, dermatitis, hepatitis and/or mucositis.[1,2] 
In order to prevent (lethal) methotrexate toxicity the patient is vigorously hydrated and 
alkalinised to enhance the solubility and excretion of the drug in the urine. Standard leucovorin 
therapy has to be initiated within 24 hours of methotrexate infusion to rescue the systemic 
organs. Leucovorin (N
5
-formyl-FH
4
), the biochemical antidote of methotrexate, replenishes 
tetrahydrofolate (FH
4
). Serum methotrexate levels above 0.1 µmol/L at 48 hours after iv drug 
administration are considered to be toxic and require higher doses and/or a sustained period of 
leucovorin (D,L diastereomers) rescue therapy due to the short half-life of the L-diastereomers.[4-
6] Alternative rescue therapy may comprise thymidine administration which restores the 
intracellular thymidylate pool, and can be combined with leucovorin in patients with toxic 
serum methotrexate levels. It must be administered in high doses by continuous infusion due 
to its rapid clearance.[7-10] Rescue therapy may also comprise carboxypeptidase G
 
(CPDG)
 
which 
decreases extracellular methotrexate concentrations by cleaving it to the inactive metabolites 
glutamate and 4-deoxy-4-amino-N
10
-methylpteroic acid (DAMPA). Extrarenal methods, e.g. 
haemodialysis, haemoperfusion, and haemodiafi ltration have also been investigated.[11-21]
In the current report, we describe a patient who developed unpredictable acute renal 
failure after iv administration of high-dose methotrexate despite adequate hydration, pre-
alkalisation of the urine, and standard leucovorin rescue therapy. Despite high serum 
methotrexate levels over a long period, the patient experienced no further short-term 
toxicity as a consequence of intensifi cation of intracellular rescue therapy comprising 
leucovorin in combination with thymidine infusion. 
Patient and methods 
Case history
A 54-year-old patient with primary cerebral lymphoma was treated with high-dose 
chemotherapy. Previously the diagnosis had been confi rmed by resection of an occipital 
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parenchymal lesion. Chemotherapy consisted of two 4-weekly courses of cytarabine given 
as a 2-hour iv infusion every 12 hours (2 g/m2 twice daily, days 1 to 3), and methotrexate 
as a 1-hour iv infusion (3 g/m2, day 21) together with dexamethasone (days 1-15) and 
leucovorin rescue therapy (fi rst administration 30 mg iv then 30 mg orally every 6 hours) 
beginning 24 hours after the start of infusion until the serum methotrexate level was below 
0.1 µmol/L. Both cycles of methotrexate were preceded by iv fl uid hydration, and urine 
alkalisation with sodium bicarbonate tablets (1 g orally every 6 hours). 
Prior to methotrexate infusion, blood cell counts, serum creatinine, and urea nitrogen level 
were within normal limits. Only hepatic enzymes were elevated before both methotrexate 
infusions. Serum alanine-amino transferase (ALT) and alkaline phosphatase levels were 45 
U/L (upper limit of normal (ULN), 21 U/L) and 130 U/L (ULN 124 U/L), respectively. Before 
the second infusion, alkaline phosphatase and gamma-glutamyl-transpeptidase (GGT) 
levels were 149 and 235 U/L (ULN 25 U/L) which was attributed to concomitant diphantoin 
medication (150 mg orally twice daily). Before and during infusion of methotrexate urinary 
pH and fl uid balance were monitored. After the fi rst administration, the serum methotrexate 
levels were determined at 24, 48 and 72 hours by fl uorescence polarization immunoassay 
(FPIA). Corresponding values were 0.8, 0.090, and 0.060 µmol/L. Creatinine levels and blood 
cell counts were monitored during both cycles. The fi rst cycle was complicated by grade 3 
(NCI Common Toxicity Criteria) neutropenia (nadir day 11) and grade 4 thrombocytopenia 
(nadir day 11). Thrombocytopenia was treated with platelet transfusions. On day 15 the 
patient developed neutropenic fever which was treated with iv antibiotics (Penicillin 1 
MU every 4 h). Furthermore, a mild transient dermatitis was noted two days after the fi rst 
methotrexate infusion.
After the second course of cytarabine the patient developed grade 3 neutropenia (nadir 
day 10) without fever, grade 2 anaemia (nadirs day 1 and day 12; probably due to the 
fi rst course) and grade 4 thrombocytopenia (nadir day 12) which were treated with red 
blood cell and platelet transfusions. During the 7 hours following the second infusion 
of methotrexate the patient developed abdominal cramps with fever (38.7°C) and later 
dyspnoea, coughing and a urinary pH of 6.5. Abdominal X-ray and ultrasonography showed 
no abnormalities, and chest radiography revealed pleural effusion on both sides and signs of 
interstitial congestion. Treatment with iv antibiotics (imipenem 500 mg every 6 hours) and 
diuretics (furosemide 80 mg every 24 hours) was started.
The next day (day 1) the serum creatinine level had increased from 87 to 281 µmol/L 
(Figure 1). The serum methotrexate concentration was 39.8 µmol/L at 20 hours after the start 
of the infusion. Acute renal failure was diagnosed and treated with increased leucovorin 
rescue therapy of 1200 mg every 24 hours as a continuous iv administration. Furthermore, 
alkalisation was intensifi ed (100 ml sodium bicarbonate 8.4% iv every 4 hours), and 
diphantoin comedication was stopped. Serum methotrexate levels were determined daily 
(Figure 1). The serum creatinine level was 423 µmol/L (maximum) 3 days after methotrexate 
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administration and a continuous infused thymidine rescue therapy (8 g/m2 per 24 hours) 
was started in addition. On day 5 the serum methotrexate levels remained around 2.40 
µmol/L. Leucovorin eye drops (0.03%, three drops every 6 hours) and leucovorin mouth 
washes with swallowing (30 mg every 6 hours) were started to prevent conjunctivitis and 
mucositis. 
The serum level was 0.150 µmol/L at 11 days after methotrexate administration. The 
leucovorin dosage was then reduced to 600 mg every 24 hours, and the thymidine dosage to 
5 g/m2  every 24 hours. On day 13 the serum drug level was 0.080 µmol/L, so the leucovorin 
dosage was further reduced to 300 mg every 24 hours and thymidine to 2.5 g/m2 every 24 
hours, and the alkalisation frequency was decreased (200 ml sodium bicarbonate 8.4 % iv 
every 24 hours). The patient developed grade 3 anaemia (nadir day 12 after methotrexate 
infusion; probably due to the fi rst course) which was treated with red blood cell transfusion. 
In comparison with course one, the methotrexate half-life was increased from 13 hours 
(days 0-3) to 32 hours (days 0-13). Serum methotrexate and creatinine concentrations were 
decreased to <0.020 µmol/L and 147 µmol/L, respectively, at 17 days after administration. 
On day 19 serum hepatic enzymes levels were normal and alkalisation of urine, and 
leucovorin and thymidine rescues were stopped. The patient was discharged 21 days after 
iv high-dose methotrexate administration. According to the treatment protocol whole brain 
radiation therapy (17 x 1.8 Gy) was given 1 month after the second course of chemotherapy 
with a surdosage (8 x 1.8 Gy). Complete remission of lymphoma was achieved that persisted 
for three years. Unfortunately, the patient suffered from impairment of cognitive functioning 
which seriously affected the quality of life.
Methods
Leucovorin (HPS, Zaandam, The Netherlands) 1.2 g was added with aseptic fi ltration to 
500 ml of saline for iv infusion. Fifteen g of thymidine (Sigma Chemical Co., St. Louis, Mo.) 
Figure 1. Serum concentration-time profi les obtained during two 4-week courses of methotrexate
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was added with aseptic fi ltration to 1000 ml saline for iv infusion. Quality control of both 
agents was performed by standard laboratory procedures in the laboratory of the hospital 
pharmacy. 
A medline literature search was performed to fi nd other cases using the following 
search items: high-dose methotrexate, toxicity, pharmacokinetics, leucovorin, thymidine, 
carboxypeptidase G
2
, hemodialysis, hemoperfusion, hemodiafi ltration, and plasma 
perfusion.
Results and discussion
Treatment with high-dose methotrexate may result in unpredictable acute toxicity despite 
hydration, alkalisation of urine, and rescue therapy. Patients who are not suffi ciently hydrated 
and/or have a urinary pH < 7.0 are at increased risk for development of renal dysfunction. 
Decreased renal excretion may then lead to more severe toxicity. Intensifi ed hydration and 
alkalisation of urine may decrease the risk of methotrexate toxicity in these patients. Each 
patient’s creatinine clearance, hydration status and urinary pH has to be known prior to drug 
administration. Furthermore, serum methotrexate levels have to be carefully monitored and 
standard leucovorin rescue therapy has to be initiated within 24 hours after the methotrexate 
infusion. In general, in patients with serum methotrexate levels exceeding 0.1 µmol/L 48 
hours after drug administration and/or acute drug-induced toxicity the rescue therapy needs 
to be intensifi ed. Leucovorin rescue therapy alone may not prevent acute methotrexate 
toxicity in serum concentrations exceeding 10 µmol/L.[20,22] Our literature search yields a 
large number of reports on pharmacological research and clinical aspects of methotrexate 
administration and its rescue therapy.[4,5,7-9,11,13-21,23] In our patient leucovorin rescue therapy 
was intensifi ed by continuous iv administration in combination with leucovorin mouth 
washes and eye drops. On day 3, the intracellular rescue was intensifi ed by continuous 
thymidine infusion since the serum methotrexate concentration persisted at a toxic level 
(6.0 µmol/L) together with a high serum creatinine level (423 µmol/L). Alternative rescue 
therapy including CPDG and extrarenal procedures, e.g. haemodialysis were not used 
because these methods only lower the extracellular methotrexate concentration. Moreover, 
extrarenal methods result in transient decreases in extracellular methotrexate concentration 
which necessitates repeated and/or combined use of haemodialysis, haemoperfusion and 
haemodiafi ltration to effi ciently lower methotrexate concentration.[12,14,17,24] In our patient 
acute renal failure occurred unexpectedly after administration of the second cycle of high-
dose methotrexate. This might be attributable to the urinary pH of 6.5 at a certain time 
which decreases the solubilities of methotrexate and in particular 7-hydroxy-methotrexate 
and can result in tubular epithelial damage. Interaction of methotrexate with diphantoin and 
antibiotics may have decreased the plasma protein binding of methotrexate. All these factors 
may have contributed to higher free methotrexate levels and renal toxicity. Furthermore, 
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the presence of a third compartment (pleural effusion) may have contributed to the long-
term high serum methotrexate concentrations due to the retarded distribution in and from 
extravascular fl uid accumulations.[1,2]
In conclusion, high dose methotrexate-induced acute severe renal failure was followed 
by high serum methotrexate levels during a long period of 12 days. Intensifi cation of the 
leukovorin rescue therapy, administration of thymidine, increased frequency of alkalisation, 
and cessation of diphantoin therapy was suffi cient to prevent further toxicity. Renal 
clearance improved and serum methotrexate levels decreased to nontoxic levels, and no 
additional extracellular rescue therapy was needed to prevent further short-term toxicity. 
It should be noted that the observed loss of the cognitive function in our patient may 
be related to the prolonged high serum methotrexate concentration in combination with 
whole-brain radiotherapy. Nevertheless, there is as yet no defi ned schedule and optimal 
dosage of rescue therapy in patients with high methotrexate serum concentrations. We 
would recommend intensifi cation of leucovorin rescue therapy by continuous infusion, eye 
drops and mouth washes in combination with continuous administration of thymidine to 
prevent methotrexate toxicity in these patients.
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Population pharmacokinetics of methotrexate and its major metabolite 
7-hydroxy-methotrexate in cancer patients treated with high-dose 
methotrexate
HJG Desirée van den Bongard, Alwin DR Huitema, Olaf van Tellingen, Paul Baas, 
Jan H Schornagel, Jan HM Schellens and Jos H Beijnen 
Summary
An integrated population pharmacokinetic model for methotrexate and 7-hydroxy-
methotrexate was developed to study the infl uence of demographic factors, biochemical 
parameters and use of concomitant medication, on the pharmacokinetic parameters of both 
compounds. Serum concentration-time data of methotrexate and its 7-hydroxy metabolite 
from 76 patients (308 courses) treated with high-dose methotrexate (400 mg-12,000 mg/m2) 
were simultaneously fi tted to selected pharmacokinetic models using non-linear mixed-
effect modelling (NONMEM). The infl uence of several covariates on the pharmacokinetics 
of both compounds was investigated. Furthermore, the pharmacokinetics of methotrexate 
and 7-hydroxy-methotrexate in 4 patients (7 courses) with pleural effusion and a pleural 
drain were studied.
The data were best described using an integrated 3-compartment model for methotrexate 
and a 2-compartment model for 7-hydroxy-methotrexate with fi rst-order elimination from the 
central compartment and the central metabolite compartment, respectively. The investigated 
covariates had no signifi cant infl uence on the pharmacokinetics of both compounds. 
The maximal concentration of 7-hydroxy-methotrexate was lower compared to that of 
methotrexate, and the elimination of the metabolite was slower than that of the parent 
compound. The methotrexate fraction that diffused to pleural effusion ranged from 
0.00019% to 0.13% of the administered dose. In conclusion, the integrated population model 
could accurately describe the pharmacokinetic parameters of methotrexate and 7-hydroxy-
methotrexate. This population model may aid further research to elucidate the relationship 
between the pharmacokinetics of both compounds and their induced toxicity and drug-drug 
interactions.
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Introduction 
High-dose methotrexate is used in combination chemotherapy schemes in the treatment 
of osteosarcoma, certain non-Hodgkin lymphomas (NHL), acute lymphocytic leukaemia 
(ALL) and malignant mesothelioma.[1-4] Its elimination occurs by renal excretion consisting 
of glomerular fi ltration and concentration dependent tubular reabsorption and secretion.[1,2] 
Methotrexate is primarily converted to 7-hydroxy-methotrexate by the hepatic enzyme 
aldehyde oxidase. The conversion shows interpatient variability due to variations in the 
amount of aldehyde oxidase present.[2,5] Both compounds show fi rst-order kinetics.[1,2,6-12] 
The elimination of 7-hydroxy-methotrexate, however, is slower than that of the parent 
compound resulting in higher 7-hydroxy-methotrexate concentrations than methotrexate at 
later time-points after drug infusion.[6,7]
The pharmacokinetics of methotrexate and 7-hydroxy-methotrexate vary considerably 
among patients.[2,6,7] The elimination of methotrexate is prolonged in patients with renal 
dysfunction or third space collections of fl uid, i.e. pleural effusion or ascites, due to 
the delayed distribution in and from these extravascular fl uid accumulations.[1-3] The 
methotrexate concentrations are routinely monitored clinically, to identify patients at 
high risk for developing signifi cant toxicity after intravenous high-dose methotrexate 
administration. Several normograms based on the elimination of methotrexate from serum 
are clinically used to identify the patients at high risk for toxicity. These normograms vary in 
the serum concentrations and time-points that are used to determine when to intensify the 
rescue therapy to prevent or minimise toxicity.[3,13]
Methotrexate and 7-hydroxy-methotrexate can both cause renal and hepatic toxicity.[14-16] 
Precipitation of 7-hydroxy-methotrexate in renal tubuli at low urinary pH values is thought 
to be the mechanism responsible for the nephrotoxicity of high-dose methotrexate.[6,7,16] 
The hydroxylated metabolite can reduce the cellular uptake of methotrexate by 
interference with membrane transport but it can also increase the effl ux of methotrexate 
from cells.[17,18] Several drug-dug interactions have been reported for methotrexate. Drugs 
including non-steroidal anti-infl ammatory drugs (NSAIDs), salicylates, sulphonamides, 
penicillin, gastric hydrogen pump inhibitors and probenecid can increase the exposure 
to methotrexate.[19-26] Moreover, naproxen and pantoprazole may inhibit the 7-hydroxy-
methotrexate clearance.[27-29]
The aim of this study was to develop an integrated population pharmacokinetic 
model of 7-hydroxy-methotrexate and methotrexate and to study the infl uence of 
demographic factors, biochemical parameters and use of concomitant medication, on 
the pharmacokinetic parameters of both compounds. In addition, the pharmacokinetic 
behaviour of both compounds was studied in pleural effusion in patients with a pleural 
drain, after the administration of high-dose methotrexate. The presented model may 
aid further optimisation of methotrexate therapy to increase the drug’s effi cacy and to 
minimise its toxicity.
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Materials and methods
Patient population and data collection
Data were obtained from cancer patients treated with methotrexate as single agent or in 
combination chemotherapy in various treatment schedules between November 1994 until 
October 2001. In all these courses methotrexate was administered intravenously. A part 
of the patient population consisted of patients with malignant mesothelioma who were 
included in a phase II study that consisted of treatment with methotrexate (fi xed dose of 
3000 mg 3-hour iv inf) as single agent or in combination with doxorubicin (fi xed dose 40 mg 
iv bolus inf every 2 weeks). All patients gave informed consent and the study protocol was 
approved by the Medical Ethics Committee of the Institute. The toxicity and effi cacy results 
of this treatment schedule in malignant mesothelioma patients will be published elsewhere. 
The other part of the patients was treated with methotrexate as implemented in regular 
treatment schedules, e.g. for NHL, ALL and osteosarcoma.
Each course consisted of prehydration and urine alkalisation with sodium bicarbonate 1.4% 
administered orally and iv. Methotrexate administration was not started until the urinary pH 
of the patient was higher than 7. If the urinary pH remained ≤ 7, prehydration had to be 
continued with 500 ml sodium bicarbonate 1.4% (administered iv in 1 hour). Methotrexate 
was dissolved in 1000 ml sodium chloride 0.9%, followed by a continuous iv infusion of 
sodium chloride 0.45%/glucose 2.5% during 22 hours. Hydration and alkalisation were 
continued for 3 days with 4 x daily 1 gram of sodium bicarbonate in capsules. Briefl y, 
inclusion criteria included suffi cient blood cell counts (leukocytes ≥ 4.0 * 106/L, granulocytes 
≥ 2.0 * 106/L, platelets ≥ 100 * 106/L) and normal renal (serum creatinine < 120 µmol/L) and 
liver function/enzymes (serum bilirubin < 25 µmol/L), performance status according to the 
World Health Organisation (PS) ≤ 2. 
Twenty-four hours after the start of the methotrexate infusion leucovorin rescue therapy was 
started (15 mg every 6 hours po). In each patient, routine 24- and 48-hour blood samples 
were collected after the start of the methotrexate infusion. If the serum drug concentration 
was < 0.04 µmol/L, the leucovorin therapy was discontinued, if the serum drug concentration 
was > 0.04 µmol/L and < 0.1 µmol/L, the leucovorin therapy was continued for another 
24 hours (15 mg every 6 hours po). If the serum drug concentration was ≥ 0.1 µmol/L at 
48 hours, the blood sampling was continued in combination with intensifi cation of the 
rescue therapy until the serum drug concentration was below 0.1 µmol/L. Additional blood 
samples were obtained at the following time-points: before the start of the methotrexate 
infusion, at the end of the methotrexate infusion, 2 and 4 hours after the end of the infusion. 
Each blood sample was collected in serum tubes (5 ml). Blood was allowed to clot at room 
temperature (20 min) and then centrifuged at 1600 g for 5 minutes. Serum was stored at 
–20°C until analysis. 
In patients with pleural effusion and a pleural drain, pleural effusion samples were obtained 
before the start of the methotrexate infusion, at 3 hours after the end of the methotrexate 
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infusion, and at 24 and 48 hours after the end of the infusion. Pleural effusion sampling 
was continued every 24 hours until hospital discharge. The fraction of the administered 
methotrexate dose that diffused into pleural volume was calculated by multiplying the 
methotrexate and 7-hydroxy-methotrexate concentrations with the collected pleural volume 
between each concentration-time point.
Methotrexate and 7-hydroxy-methotrexate concentrations were measured in serum and 
pleural effusion using a validated reverse-phase high-pressure liquid chromatography 
(HPLC) method as published elsewhere.[30] The pre-treatment procedure of the serum 
samples consists of a deproteinisation method. The lower detection limit of the HPLC assay 
is 0.04 µmol/L for both methotrexate and 7-hydroxy-methotrexate and the between-day 
precision was ≤ 7.0%.[30]
Population pharmacokinetic analysis
The program NONMEM (non-linear mixed-effect modelling, version V level 1.1, double 
precision) using the NMTRAN pre-processor and the PREDPP package (ADVAN5), operating 
on an MS-DOS computer, was used for the analysis.[31] The concentration-time data of both 
compounds were logarithmically transformed and were simultaneously described by the 
pharmacokinetic models. The fi rst order method was used in all of the analysis processes. 
The model building procedure consisted of a three-step approach.
      
           
                     V5 
        
           Infusion 
   k54   k45                
                V2 
    k12   
          V4              k14     V1                k21 
              k13 
                  
                 k31   
       V3  
CL7-OH-MTX         CLMTX 
Figure 1. Graphical representation of the pharmacokinetic model of methotrexate and 7- hydroxy-methotrexate. V1, V2 and V3 
indicate the apparent volume of the central compartment, the fi rst peripheral compartment and the second peripheral com-
partment. V4 and V5 indicate the apparent volume of the fi rst metabolite compartment and second metabolite compartment, 
respectively. CLMTX and CL7-OH-MTX indicate the clearance of methotrexate and 7-hydroxy-methotrexate, respectively. k12, k21, 
k13, k31, k14, k45 and k54 indicate the intercompartmental rate constants 
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Basic population pharmacokinetic model
The fi rst step consisted of the development of a basic population pharmacokinetic model. The 
methotrexate concentration-time data were best described by a linear 3-compartment model 
with fi rst-order elimination from the central compartment using ADVAN 5. The 7-hydroxy-
methotrexate concentration-time data were best described by a linear 2-compartment model 
with fi rst-order elimination of the metabolite from this central compartment (Figure 1). The 
following pharmacokinetic parameters were estimated: volume of the central compartment 
(V1
MTX
 in L), volume of the fi rst peripheral compartment (V2
MTX
 in L), volume of the second 
peripheral compartment (V3
MTX
 in L), apparent volume of the fi rst metabolite compartment 
(V1
7-OH-MTX
 in L), apparent volume of the second metabolite compartment (V2
7-OH-MTX
 in 
L), intercompartmental clearance between the central compartment and the peripheral 
compartments of methotrexate (Q1
MTX
 and Q2
MTX
 in L/h), apparent intercompartmental 
clearance between the fi rst and second metabolite compartment (Q
7-OH-MTX
 in L/h), clearance 
from the central compartment (CL
MTX
 in ml/h) and apparent clearance from the metabolite 
compartment (CL
7-OH-MTX
 in ml/h). 
Standard errors for all parameters were calculated using the COVARIANCE option in the 
NONMEM program. Interindividual variability in V2
MTX
, CL
MTX
, CL
7-OH-MTX
, Q2
MTX
 and Q
7-OH-MTX
 
and interoccasion variability in CL
MTX
 and CL
7-OH-MTX
 were estimated using a proportional 
error model. 
For instance, interindividual and interoccasion variability in CL
7-OH-MTX
 were defi ned as in 
equation 1:
CL
7-OH-MTX i
 = CL
7-OH-MTX, pop
 *(1+ η
i
CL7-OH-MTX + κ
i
CL7-OH-MTX)   equation 1
where CL
7-OH-MTX
 
i 
represents the CL
7-OH-MTX
 of the ith individual, CL
7-OH-MTX,
 
pop
 is the typical 
population value of CL
7-OH-MTX
,
 
η
i
CL7-OH-MTX is the interindividual random effect that is normally 
distributed with mean zero and variance ω2, and κ
i
CL7-OH-MTX is the interoccasion random effect 
that is normally distributed with mean zero and variance π2.
The residual variability, i.e. the difference between the logarithmically transformed measured 
concentration in an individual and its respective prediction was modelled using a combined 
additive and proportional model.
Selection of basic models was based on the minimum value of the objective function 
(OFV) that is equal to minus twice the log likelihood of the data, reliability of parameter 
estimates (according to the standard error values of the parameters estimates), and the fi t 
of the model to the data (goodness of fi t plots). The difference in the OFV of hierarchical 
models, that is equal to minus twice the log likelihood of the data, approximates to a chi-
squared-distribution with 1 degree of freedom. The signifi cance level was set at p < 0.001, 
which is associated with an OFV decrease of 10.8. Furthermore, the goodness of fi t plots 
were examined in the program Xpose (Xpose, version 2.0, Uppsala University, Sweden) 
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as implemented in the S-PLUS statistical package (version 2000, Mathsoft, Cambridge, 
Mass.).[32]
Intermediate model
The second step consisted of the individual Bayesian regression analysis. For each subject, 
individual pharmacokinetic parameters were calculated using the individual methotrexate 
and 7-hydroxy-methotrexate serum concentration-time data and the population 
pharmacokinetic parameter estimates obtained in the fi rst step. The individual Bayesian 
estimates were plotted against the demographic factors, blood chemistry parameters and 
use of concomitant medication that might cause a drug-drug interaction with methotrexate 
(=covariates). Relevant covariates were investigated for their correlation with the 
pharmacokinetic parameters of both compounds (age, gender, body surface area (BSA), PS, 
serum creatinine, serum alanine-aminotransferase (ALT), serum aspartate-aminotransferase 
(AST), serum alkaline phosphatase, serum albumin, serum bilirubin and serum lactate 
dehydrogenase (LDH), concomitant use of medication that can interact with methotrexate 
and/or 7-hydroxymethotrexate, and presence of pleural effusion or ascites. The relations 
between the covariates and the Bayesian parameter estimates of each individual patient 
were investigated graphically.
The selected covariates that showed a graphical relation with a pharmacokinetic parameter 
were tested by univariate analysis. These covariates were entered individually into the basic 
population pharmacokinetic model by forward inclusion. Continuous covariates, e.g. BSA, 
were centred to their median values. For instance, the relationship between CL
MTX 
and BSA 
was described as in equation 2:
CL
MTX 
= θ
2
 * (1 + θ
3
 * (BSA – 1.94))     equation 2
where CL
MTX
 represents the value of CL
MTX
 in L/h, θ
2
 the CL
MTX
 value of a (median) patient 
with a BSA of 1.94 m2, and θ
3
 is the increase or decrease in CL
MTX
 per m2 BSA difference.
Dichotomous covariates were modelled as described in equation 3:
V2
MTX
 = θ
1
 * θ
2
 FLAG1      equation 3
where V2
MTX
 represents the value of V2
MTX
 in L, θ
1
 the V2
MTX
 value in females (FLAG1 =0), 
and θ
2
 the change in V2
MTX
 in males (FLAG1=1).
The difference in the OFV was evaluated after the introduction of a covariate in the model. 
During the forward inclusion of the covariates in the basic model, the signifi cance level was 
Desirée van den Bongard 14-10   106 15-10-2002, 10:39:39
Population pharmacokinetics of methotrexate and its major metabolite 7-hydroxy-methotrexate
107
set at p < 0.005 that is associated with an OFV decrease of > 7.83. All signifi cant covariates 
were incorporated into an intermediate multivariate model.
Final population pharmacokinetic model
The development of the intermediate model was followed by multivariate analysis that 
consisted of a stepwise backward elimination procedure. Covariates retained in the model 
when elimination of the covariate caused an OFV increase of > 10.8 that is associated with 
a signifi cance level of p < 0.001. 
The validity of the interindividual variability model was checked by evaluating correlations 
between the individual random effects (η) of the pharmacokinetic parameters that were 
included in the model.
Results
Patient population and dataset
In total, concentration-time data were obtained from 76 patients (308 courses). The 
administered dose ranged from 400 mg to 12000 mg/m2 and the duration of infusion 
ranged from a 1-hour iv infusion to a 24-hour iv infusion. The patient characteristics are 
summarised in Table 1. Patients with various malignancies and treatment schedules were 
included in the dataset: 29 patients with malignant mesothelioma, 10 of these patients 
were treated with methotrexate (3000 mg 3-hour iv inf) as single agent, and 19 patients 
were treated with methotrexate (3000 mg 3-hour iv inf) in combination with doxorubicin. 
Furthermore, 20 patients with esophageal/gastric carcinoma were treated with methotrexate 
(1500 mg/m2 2-hour iv inf) in combination with doxorubicin and fl uorouracil. Ten patients 
with head and neck carcinoma were treated with methotrexate as single agent (400 mg 
24-hour iv inf). Patients with NHL (n=12) were treated with methotrexate (1-3 g/m2 1 to 
24-hour iv inf) in combination chemotherapy with lomustine, procarbazine and intrathecal 
administration of cytosine arabinoside and methotrexate. One patient with ALL was treated 
with methotrexate (2150 mg/m2 24-hour iv inf), teniposide, mercaptopurine and cytosine 
arabinoside. One osteosarcoma patient was treated with methotrexate (12 g/m2 6-hour 
iv inf) in combination with ifosfamide and etoposide. One patient with a trophoblastic 
tumour was treated with methotrexate (1000 mg/m2 12-hour iv inf) in combination with 
etoposide, actinomycin, cyclofosfamide and vincristin. Two patients with choriocarcinoma 
were treated with methotrexate (300 mg/m2 12-hour iv inf) in combination with cisplatin, 
etoposide, cyclofosfamide and actinomycin.
In 21 of these patients additional blood samples were taken. This part of the patient 
population consisted of 3 patients (malignant mesothelioma) treated with methotrexate 
as single agent (fi xed dose of 3000 mg, 3-hour iv infusion), 16 patients (malignant 
mesothelioma) treated with methotrexate (fi xed dose of 3000 mg) in combination with 
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doxorubicin, 1 patient (NHL) was treated with methotrexate (1000 mg/m2, 3-hour iv 
infusion) in combination with lomustin and cytosine arabinoside, and 1 patient (gastric 
carcinoma) was treated with methotrexate (1500 mg/m2-hour iv infusion) in combination 
with fl uorouracil and doxorubicin.
In total, 984 serum methotrexate and 994 serum 7-hydroxy-methotrexate concentration-time 
points were obtained during 308 courses. From these data, complete concentration-time 
curves of methotrexate and 7-hydroxy-methotrexate (206 and 204 concentration-time points, 
respectively) were obtained during 33 courses of intensive sampling in 21 patients. In Figure 
2, these data are detailed including an additional curve that represents concentration-time 
data as obtained in 1 patients at 24 hour after the start of the infusion (). The 2 upper 
curves (,) are obtained in 2 patients who died due to methotrexate (and 7-hydroxy-
methotrexate) induced toxicity (stomatitis, nephrotoxicity, rash). Both patients had 
Table 1. Patient characteristics and baseline values of the covariates 
 Number Median value Range 
Patient characteristics 
   Male 
   Female 
   Age (years) 
   WHO Performance status 
      0 
      1 
      2 
   Body surface area (m2)
   Tumour type 
      Malignant mesothelioma 
      Esophageal/Gastric cancer 
      Head and neck cancer 
      Non-Hodgkin lymphoma 
      Choriocarcinoma 
      Acute lymphocytic leukaemia 
      Osteosarcoma 
      Trophoblastic tumour 
   Pre-treatment 
      None 
      Prior chemotherapy    
      Local radiotherapy 
      Surgical therapy 
      Photo-dynamic therapy 
62
14
10
58
8
1.94
29
20
10
12
2
1
1
1
36
15
19
16
1
51 17-77 
1.56-2.45 
   Dose    400 mg-12000 mg/m2
Biochemical parameters 
   Creatinine (µmol/L) 
   Blood urea nitrogen (mmol/L) 
   Total bilirubin (mmol/L) 
   AST (U/L) 
   ALT (U/L) 
   Alkaline Phosphatase (U/L) 
   GGT (U/L) 
   Albumin (g/L) 
   LDH (U/L)
72
4.0
7.0
15
19
107
56
40
269
32-120 
3.0-8.0
2.0-6.0
4-139 
5.0-368 
10-519 
7.0-675 
22-128 
134-2786 
Third compartment 
   Pleural effusion (present/not present)a
   Ascites (present/not present) 
12/64
3/73
a
 Four of these patients had a pleural drain during the methotrexate infusion until hospital discharge. 
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malignant mesothelioma and were treated with a fi xed dose of 3000 mg of methotrexate in 
combination with a fi xed dose of adriamycin (40 mg). One of these patients () developed 
pleural effusion after the methotrexate infusion. The other patient () developed ascitic 
fl uid after the administration. In the latter patient a pneumectomy was performed in the 
past. Consequently, the additional lung cavity might have contributed to the development 
of third space fl uids.
Pleural effusion samples were obtained in 4 patients (during 7 courses) with a pleural 
drain (in total, 36 samples). The total production of pleural volume ranged from 36 ml to 
1960 ml. The methotrexate and 7-hydroxy-methotrexate concentrations in pleural effusion 
is depicted in Figure 3. The maximal concentration (Cmax) of 7-hydroxy-metabolite was 
lower than the Cmax of methotrexate (1/10 of the Cmax of methotrexate) in pleural effusion. 
The fraction of the administered methotrexate dose that diffused into pleural effusion 
Figure 2. Concentration-time curves of patients in the intensively sampled group (n=21, 33 courses) (■ and ) for methotrexate 
(A) and 7-hydroxy-methotrexate (B). One of these patients showed prolonged elimination of both compounds (). A concen-
tration-time curve (samples are obtained from 24 hours after the methotrexate infusion) of 1 patient who showed prolonged 
elimination is depicted (). All concentration-time points, as obtained after the administration of methotrexate, are depicted with 
the start of the administration at time zero
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ranged from 0.00019% to 0.13 %. The serum concentrations of the 2 compounds in these 
patients during the same courses are depicted in Figure 4. The 7-hydroxy metabolite is 
rapidly formed with maximal concentrations being approximately 1/10 of the methotrexate 
concentrations in serum. The elimination of 7-hydroxy-methotrexate is slower than that of 
methotrexate in both serum and pleural effusion. The variability in serum concentrations 
of both compounds, however, is small compared to the high variability of pleural effusion 
values. In total, pleural effusion was present in 12 patients during 35 courses (Table 1). In 
patients (8 patients) without a pleural drain, the pleural effusion was evacuated prior to the 
Figure 4. Methotrexate (A) and 7-hydroxy-methotrexate (B) concentrations in serum in 4 patients (during 7 courses) with pleural 
effusion after the administration of a fi xed dose of 3000 mg
Figure 3. Methotrexate (A) and 7-hydroxy-methotrexate concentration (B) in pleural effusion in 4 patients (during 7 courses) after 
the administration of a fi xed dose of 3000 mg. The course number of each patient is depicted between parentheses
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methotrexate administration. Ascitic fl uid was present in 3 patients during 3 courses and was 
also evacuated prior to the methotrexate administration.
The use of concomitant medication during the methotrexate administration was as follows: 
13 patients used gastric hydrogen pump inhibitors during 35 courses (dose of omeprazole 
ranged from 1*20 to 2*40 mg/day po and lansoprazole 60 mg/day po), 3 patients used 
salicylates during 7 courses (ascal 80-100 mg day po), 3 patients used NSAIDs during 6 
courses (diclofenac 75-100 mg/day po), 2 patients used penicillin derivates (penicillin 6*106 
E/day and amoxicillin 3*625 mg/day iv), 1 patient used co-trimoxazole (2*960 mg/day po), 
1 patient used phenytoin (3*150 mg/day po), 1 patient used triamterene (1*25 mg/day 
po). The gastric hydrogen pump inhibitors, salicylates and the NSAIDs were studied in 
the population analysis for their possible infl uence on the pharmacokinetic parameters of 
methotrexate and 7-hydroxy-methotrexate. 
Population pharmacokinetic analysis
Basic population pharmacokinetic model
Several pharmacokinetic models were applied to the data. The fi rst model tested consisted 
of 2 compartments for methotrexate and 1 compartment for 7-hydroxy-methotrexate 
(OFV = 987). The same model with an additional compartment for patients with pleural 
effusion or ascites showed a marked decrease in the OFV (∆OFV = -16.0, p < 0.001) but 
the model predicted concentrations for both compounds were underestimated. Therefore, 1 
compartment was added for 7-hydroxy-methotrexate which resulted again in a statistically 
signifi cant decrease in OFV (∆OFV = -39.3, p < 0.001) but the model predicted concentrations 
were still underestimated at high concentrations of both compounds. The model was further 
optimised by the addition of a third compartment for methotrexate in all patients. This 
resulted in an additional statistically signifi cant decrease in OFV (∆OFV = -177, p < 0.001). 
The model predicted concentrations improved and were only slightly underestimated at the 
maximal concentrations of methotrexate and 7-hydroxy-methotrexate. 
It was assumed that the underestimation could be caused by the relatively high number of 
concentration-time points obtained at 24 hours and later after the methotrexate administration 
(625 and 635 for methotrexate and 7-hydroxy-methotrexate, respectively). The dataset 
comprised only 46 concentration-time points obtained between the start of the administration 
and before 24 hours after the start of the methotrexate administration. A model was fi tted 
to the same population model with different residual errors for the 2 subpopulations. This 
resulted in a non-signifi cant difference in OFV (∆OFV = 0.35, p > 0.25), therefore the linear 
5-compartment model was considered as the fi nal basic model (Figure 1).
The population pharmacokinetic parameter estimates including the standard errors, 
the interindividual variability and the residual errors are summarised in Table 2. The 
pharmacokinetic parameters were estimated accurately, except for V
7-OH-MTX 
. The relative 
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standard error of this parameter was 72%. Interindividual variability was determined for 
CL
MTX
 (39%), V2
MTX 
(65%), Q2
MTX 
(34%), CL
7-OH-MTX
 (37%) and QF
7-OH-MTX 
(9.3%). Interoccasion 
variability was determined for CL
MTX
 (18%) and CL
7-OH-MTX 
(17%). For methotrexate, the 
residual variability of the logarithmically transformed concentrations consisted of an 
additional error of 0.0432 and a proportional error of 0.49. For 7-hydroxy-methotrexate, 
the residual variability of the logarithmically transformed concentrations consisted of an 
additional error of 0.0515 and a proportional error of 0.68. Inclusion of interindividual 
or interoccasion variability on the other pharmacokinetic parameters did not result in 
a signifi cant decrease in OFV value. This should not be interpreted as an absence of 
interindividual variability in these pharmacokinetic parameters. It indicates that the data 
did not contain suffi cient information to estimate the interindividual and interoccasion 
variability of these parameters.
Finally, the correlations between the interindividual variability of CL
MTX
, V2
MTX
, Q2
MTX
, CL
7-
OH-MTX
 and Q
7-OHMTX
 were graphically evaluated. The matrix plots showed a possible positive 
correlation between the ηV2
MTX
 and ηQ2
MTX
 and between ηCL
MTX
 en ηQ2
MTX 
(data not shown). 
The inclusion of these correlations in the population model did not result in an improved fi t 
of the model according to the standard error values and the goodness of fi t plots. 
Table 2. Population pharmacokinetic parameters of the final population model of methotrexate and  
7-hydroxy-methotrexate 
 Estimate RSE  
(%) 
Interindividual  
variability (%) 
Interoccasion  
variability (%) 
Pharmacokinetic parameters 
   V1MTX (L) 
   CLMTX (L/h) 
   Q1MTX (L/h) 
   V2MTX (L) 
   Q2MTX (L/h) 
   V3MTX (L) 
   CL7-OH-MTX (L/h)
   V17-OH-MTX (L)
   Q7-OH-MTX (L/h) 
   V27-OH-MTX (L)
21.3
9.08
1.39
9.03
0.936
513
21.4
197
4.87
180
15
13
45
44
28
34
9.2
8.2
15
72
39
65
34
37
9.3
18
17
Residual variability 
   Proportional errorMTX 
   Additional errorMTX
   Proportional error7-OH-MTX 
   Additional error7-OH-MTX
0.493
0.0432
0.677
0.0515
27
36
14
35
V1MTX = Volume of the central compartment of methotrexate; CLMTX = Clearance of methotrexate from the central 
compartment; V2MTX = Volume of the first peripheral compartment of methotrexate; Q1MTX = Clearance between 
the central and the first peripheral compartment of methotrexate; V3MTX = Volume of the second peripheral 
compartment; Q2MTX  = Clearance between the central and the second peripheral compartment of methotrexate; 
CL7-OH-MTX = Clearance of 7-hydroxy-methotrexate from the first metabolite compartment; V17-OH-MTX = Volume of 
the second metabolite compartment; V27-OH-MTX = Volume of the second metabolite compartment; Q7-OH-MTX = 
Clearance between the first and the second metabolite compartment.  
Desirée van den Bongard 14-10   112 15-10-2002, 10:39:46
Population pharmacokinetics of methotrexate and its major metabolite 7-hydroxy-methotrexate
113
Intermediate model
The graphical analysis of the plots of covariates versus individual pharmacokinetic 
parameters indicated a possible relationship between concomitant use of gastric hydrogen 
pump inhibitors, serum total bilirubin (decreased clearance at higher total bilirubin levels), 
BSA (decreased clearance at higher BSA), pleural effusion/ascites and CL
MTX
, between gastric 
hydrogen pump inhibitors and CL
7-OH-MTX
 and between gender and V2
MTX
. Forward inclusion 
(p < 0.005) of these covariates in the basic model, however, revealed that these covariates 
were not signifi cantly correlated with the pharmacokinetic parameters of methotrexate and 
7-hydroxy-methotrexate.
Final population pharmacokinetic model
Since no signifi cant infl uence of covariates on the pharmacokinetic parameters could be 
detected, the fi nal model was equal to the basic model. 
In Figure 5, the model predicted concentrations (5A and 5C) and the Bayesian individual 
predicted concentrations (Figure 5B and 5D) are depicted for methotrexate and 7-hydroxy-
methotrexate, respectively. Model (Figure 5A and 5C) and Bayesian (Figure 5B and 5D) 
predicted concentrations for methotrexate and 7-hydroxy-methotrexate were symmetrically 
distributed around the line of unity. The model predicted concentrations are based on 
the population pharmacokinetic parameter estimates, whereas the individual Bayesian 
predicted concentrations are based on the population pharmacokinetic parameter estimates 
and the individual observed concentrations. 
Discussion
The pharmacokinetics of methotrexate and 7-hydroxy-methotrexate vary considerably 
among patients.[2,6,7] Since both compounds can cause life-threatening toxicity it is important 
to study which covariates can cause the variability in their pharmacokinetic behaviour. The 
aim of this study was to perform a simultaneous modelling of methotrexate and its primary 
metabolite 7-hydroxy-methotrexate to asses their pharmacokinetic parameters, the intra- 
and interindividual variability, and to determine the infl uence of covariates and concomitant 
use of medication on the pharmacokinetic parameters of both compounds. The dataset 
consisted of 2 subpopulations, 1 selected cohort with complete concentration-time curves 
(n=21, 33 courses) and 1 unselected cohort with routinely measured concentration-time data 
(n=55, 275 courses). 
According to the OFV, the standard error values of the parameter estimates, and the 
goodness of fi t plots, it appeared that the data were best fi tted by an integrated 3-
compartment model with linear elimination of methotrexate from the central compartment 
and a 2-compartment model with linear elimination of 7-hydroxy-methotrexate (Figure 1). 
All parameters were estimated accurately, except for V
7-OH-MTX
 (relative standard error was 
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72%) and the residual error of the population model was relatively high. We assume that 
this can be attributed to the relative low number of concentration-time data obtained shortly 
after the infusion of methotrexate compared to the high number of routinely measured 
methotrexate concentrations (24- and 48-hour concentrations). In previous population 
pharmacokinetic models of methotrexate after high-dose administration intravenously, the 
drug was modelled to linear 2- or 3-compartment models.[8-11] The population values of 
the pharmacokinetic parameters in our study were in the same range. The total volume 
of distribution of methotrexate in our study (543 L) was substantially higher compared to 
the other population analyses. Since the volume of distribution of the central (21.3 L) and 
the fi rst peripheral compartment (9.03 L) of methotrexate is in accordance with previous 
reported values, we assume that the volume of the third compartment in our study is 
high due to the relative high number of patients with pleural effusion or ascites (20%) in 
Figure 5. Goodness of fi t plots of the observed concentrations versus the model and Bayesian predicted concentrations. Observed 
versus model predicted methotrexate concentrations (A), observed versus Bayesian predicted methotrexate concentrations (B), 
observed versus model predicted 7-hydroxy-methotrexate concentrations (C), observed versus Bayesian predicted 7-hydroxy-me-
thotrexate concentrations (D). Solid line is the line of identity
C.
-5.00
-3.00
-1.00
1.00
3.00
5.00
7.00
-5.00 -3.00 -1.00 1.00 3.00 5.00 7.00
ln (Observed concentration (µmol/L))
ln
 
(M
o
de
l p
re
di
ct
e
d 
co
n
ce
n
tr
a
tio
n
 
(µm
o
l/L
))
-5.00
-3.00
-1.00
1.00
3.00
5.00
7.00
-5.00 -3.00 -1.00 1.00 3.00 5.00 7.00
ln (Observed concentration (µmol/L))
ln
 
(B
a
ye
si
an
 
pr
e
di
ct
ed
 
co
n
ce
n
tr
a
tio
n
 
(µm
o
l/L
))
A.
B.
-5.00
-3.00
-1.00
1.00
3.00
5.00
7.00
9.00
-5.00 -3.00 -1.00 1.00 3.00 5.00 7.00 9.00
ln (Observed concentration (µmol/L))
ln
 (
B
a
y
e
si
a
n
 p
re
d
ic
te
d
 c
o
n
c
e
n
tr
a
ti
o
n
 
(µ
m
o
l/
L
))
-5.00
-3.00
-1.00
1.00
3.00
5.00
7.00
9.00
-5.00 -3.00 -1.00 1.00 3.00 5.00 7.00 9.00
ln (Observed concentration (µmol/L))
ln
 (
M
o
d
e
l 
p
re
d
ic
te
d
 c
o
n
c
e
n
tr
a
ti
o
n
 
(µ
m
o
l/
L
))
Desirée van den Bongard 14-10   114 15-10-2002, 10:39:48
D.
Population pharmacokinetics of methotrexate and its major metabolite 7-hydroxy-methotrexate
115
combination with the inclusions of time-points long after the administration in patients with 
pleural effusion or ascites. 
In one previous reported population analysis the methotrexate and 7-hydroxy-methotrexate 
data were simultaneously modelled.[12] The pharmacokinetic parameter estimates were in 
the same range as in our study. However, this model was based on concentration-time 
data obtained in only 8 patients compared to 76 patients in our study. Furthermore, the 
infl uence of covariates on pharmacokinetic parameters was not studied. In our population 
analysis, some covariates, BSA, gender, concomitant use of proton pump inhibitors and 
salicylates, serum total bilirubin and presence of ascites and pleural effusion (with and 
without a pleural drain), showed an infl uence on the volume of distribution or clearance of 
methotrexate, or the 7-hydroxymethotrexate clearance. However, the intermediate analysis 
showed that these infl uences were not signifi cant. In two population analyses (n=34 
and n=23), signifi cant relationships between patient weight and age, and the volume of 
distribution of methotrexate, methotrexate clearance and renal function as determined by 
the glomerular fi ltration rate, were observed.[8,9] Our patient population consisted of more 
patients (n=76) but no signifi cant infl uence of covariates on the pharmacokinetic parameters 
could be detected. This may be attributed to the low percentage of full concentration-time 
data (11%) in the dataset. Moreover, no patients with abnormal renal function were included 
in the dataset (serum creatinine ≤ 129 µmol/L). 
Concomitant use of drugs that can interact with methotrexate had no signifi cant infl uence 
on the pharmacokinetic parameters of methotrexate and 7-hydroxy-methotrexate. It is 
well known that some of these covariates, e.g. concomitant use of NSAIDs and salicylates, 
ascites and pleural effusion, can cause delayed methotrexate elimination that can result in 
life-threatening toxicity.[3,12,19-26] We assume that the non-signifi cant relationships are caused 
by the high diversity of our patient population and the small number of patients that used 
concomitantly other medication. Moreover, the non-signifi cant infl uence of the presence of 
pleural effusion and ascites on the pharmacokinetic parameters demonstrates the correct 
clinical management of the pleural drain, and the ascitic fl uid and pleural effusion drainage 
prior to methotrexate administration. The concentration-time data in pleural effusion as 
obtained in four patients with a pleural drain, showed that only a low fraction of the 
administered methotrexate dose diffused into pleural effusion (range: 0.00019% to 0.13%). 
Moreover, therapeutic serum drug levels were achieved in these patients despite the pleural 
drain. This is confi rmed by the serum concentration-time curves obtained in 2 patients 
who developed pleural effusion and ascites after the methotrexate administration. The 
elimination of both methotrexate and 7-hydroxy-methotrexate is substantially prolonged in 
both patients (Figure 2).
After iv administration of methotrexate, drug- drug interactions have been reported to occur 
due to protein binding replacement and decreased renal clearance of the drug.[19-26] Since 
the plasma protein binding of methotrexate is about 50%, it seems unlikely that interactions 
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caused by displacement of methotrexate from binding sites can have clinical relevance.[29,33] 
Since 7-hydroxy-methotrexate is 91-93% protein-bound in plasma, this metabolite can 
contribute to drug-drug interactions with highly albumin-bound compounds.[29,33] Only a 
few drug-drug interactions have been reported for 7-hydroxy-methotrexate.[27-29] Naproxen 
can increase the unbound fraction of 7-hydroxy-methotrexate.[28,29] Pantoprazole has 
been reported to inhibit the metabolite elimination of the hydroxylated metabolite in 1 
patient.[27] Future studies should focus on the relationship between 7-hydroxy-methotrexate, 
concomitant medication and observed toxicity after the administration of high-dose 
methotrexate.
In conclusion, we showed that the pharmacokinetics of methotrexate and 7-hydroxy-
methotrexate can be best described by an integrated linear 3- and 2- compartment model. 
This population model can be used to explore the relationships between the 7-hydroxy 
metabolite and its toxicity. Moreover, this population model may aid further research 
to elucidate the relationship between the pharmacokinetics of methotrexate, 7-hydroxy-
methotrexate, and toxicity and possible drug-drug interactions.
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Chapter 4.1
A population analysis of the pharmacokinetics of Cremophor EL using 
nonlinear mixed-effect modelling
HJG Desirée van den Bongard, Ron AA Mathôt, Olaf van Tellingen, Jan HM Schellens 
and Jos H Beijnen
Summary
The purpose of this study was to develop a population pharmacokinetic model for 
Cremophor EL used as a formulation vehicle for paclitaxel. Plasma concentration-time data 
of 70 patients (85 courses, 3- and 96-hour iv infusions) treated with paclitaxel dissolved in 
Cremophor EL were used. The non-linear mixed effect modelling (NONMEM) program was 
used for the population pharmacokinetic analysis. The infl uence of patient characteristics 
and biochemical parameters on the pharmacokinetics of Cremophor EL was determined. 
The stability of the fi nal model was evaluated using the bootstrap resampling method.
The data were most optimally described by a 3-compartment model with Michaelis-Menten 
elimination from the central compartment. The following pharmacokinetic parameters were 
estimated: volume of the central compartment (V1=2.59 L), volumes of two peripheral 
compartments (V2=1.81 L, V3=1.61 L), intercompartmental clearance between central 
and peripheral compartments (Q12=1.44 L/h, Q13=0.155 L/h), maximal elimination rate 
(Vmax=0.193 ml/h), and concentration at half Vmax (Km=0.122 ml/L). Interindividual 
variability of the pharmacokinetic parameters was quantifi ed for V1 (25%), V2
 
(36%), and 
Vmax (31%). Residual variability consisted of a combined additional (0.095 ml/L) and 
proportional error (7%). Gender, body surface area and performance status according to the 
World Health Organisation were signifi cantly correlated with V1, V2, Vmax, respectively (p 
< 0.0001). The median parameter estimates of 1000 bootstrap samples were in accordance 
with those obtained with the original data set indicating the validity of the population model. 
In conclusion, the population model was able to adequately describe the pharmacokinetic 
parameters and infl uence of covariates on pharmacokinetics of Cremophor EL. This model 
can be used when studying the relationship between the pharmacokinetics and toxicity of 
Cremophor EL, and the drug’s infl uence on the pharmacokinetics of paclitaxel.
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Introduction
Cremophor EL is a polyethoxylated castor oil that is used for the formulation of vitamin 
preparations and a variety of poorly water-soluble drugs including teniposide, cyclosporin 
A, and paclitaxel.[1-3] Taxol® is the pharmaceutical product in which paclitaxel is dissolved (6 
mg/mL) in a mixture of Cremophor EL and ethanol (1:1, v/v).[4] 
Cremophor EL can cause hypersensitivity reactions by complement activation.[5-7]  Cremophor 
EL can cause neurotoxicity probably caused by the ethoxylated derivatives of castor oil.[7] 
Despite the extensive use of Cremophor EL as a solubilising agent in clinical formulations 
and its reported toxicity, the pharmacokinetics in humans have not been extensively 
studied.[1,8-11] There is, however, substantial evidence that Cremophor EL can alter the 
pharmacokinetics of certain cytotoxic drugs with clinical implications, e.g. paclitaxel.[7,11-14] 
In several studies the pharmacokinetics of Cremophor EL in mice and cancer patients have 
been studied in relation to its use as pharmaceutical solubilizer of paclitaxel.[11-14] Dose 
increments of paclitaxel dissolved in Cremophor EL result in disproportional increases in the 
systemic exposure to paclitaxel, as represented by the area under the plasma concentration-
time curve (AUC). In the absence of Cremophor EL, a linear pharmacokinetic behaviour 
of paclitaxel was observed.[12] Several mechanisms of the nonlinear pharmacokinetics 
of paclitaxel induced by Cremophor EL have been reported.[11,13-20] Cremophor EL might 
inhibit the elimination of paclitaxel by preventing access of the drug to the elimination 
sites.[15] Furthermore, it has been suggested that Cremophor EL induces a serum lipoprotein 
dissociation product with a high affi nity for paclitaxel.[18,20] 
More recently, it has been demonstrated that Cremophor EL can form micelles in blood in 
vitro, acting as a high-affi nity drug-transporting site for paclitaxel that results in a decreased 
free paclitaxel fraction in plasma.[13,14,16,17,19] Cremophor EL can decrease the blood:plasma 
ratio of paclitaxel at higher dose-levels by reducing the uptake in red blood cells.[2]
The pharmacokinetic behaviour of paclitaxel can thus be infl uenced by the pharmacokinetics 
of Cremophor EL. Consequently, Cremophor EL can modify the toxicity profi le of 
paclitaxel.[21] Assessment of the clinical pharmacokinetics of Cremophor EL during paclitaxel 
administration may be of major importance. The purpose of this study was to develop a 
population pharmacokinetic model of Cremophor EL when administered in combination 
with paclitaxel. In this population analysis, the pharmacokinetic parameters and the patient 
characteristics that correlate with the pharmacokinetics of Cremophor EL were determined.
Materials and Methods
Patient population 
Plasma concentration-time data (85 courses) of Cremophor EL concentrations were collected 
during safety and pharmacokinetic multicentre studies of paclitaxel performed in 70 cancer 
patients (21 patients with hepatic dysfunction). The results of these studies have been 
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published recently.[22-25] In these studies paclitaxel was infused intravenously (iv) with or 
without co-infusion of carboplatin in patients with primarily metastatic breast-, ovarian- and 
non-small cell lung cancer. The patient characteristics are summarised in Table 1. Every 
course was included separately in the data set that resulted in 85 identifi cation numbers 
(ID) in this population pharmacokinetic analysis. Paclitaxel (Taxol®, Bristol Myers Squibb, 
Syracuse, NY) was provided as a sterile 6 mg/ml solution and dissolved in Cremophor EL:
Ethanol 1:1, v/v. Prior to administration this solution was diluted with 500-1000 ml 0.9% 
Table 1. Patient characteristics (n=70) and serum parameter values during 85 courses 
 Number Median Range 
Patient characteristics 
     Female  
     Male 
44
26
Number of courses with pharmacokinetic data 
     First course 
     Second course 
70
15
Dose range Paclitaxel (in mg/m2)
     3-hour infusion  
     24-hour infusion  
     96-hour infusion  
78
3
4
100-250
135-175
105-135
Dose range Cremophor EL (in ml/m2)
     3-hour infusion  
     24-hour infusion  
     96-hour infusion  
78
3
4
8.3-20.8
11.2-14.5 
8.7-11.6
Dose range Carboplatin (in mg/m2)
   3- hour infusion  32 300-400
Age (in years)  52 24-75 
Primary site of disease 
     Lung 
     Ovarian 
     Breast 
     Colon 
     Pancreas 
     Sarcoma 
     Endometrium 
     Granulosa theca cell 
32
17
16
1
1
1
1
1
WHO Performance status 
     0 
     1 
     2 
21
48
16
BSA (in m2)  1.82 1.50-2.30 
Biochemical parameters 
   Creatinine (in µmol/L) 78 37-120 
   AST (in U/L)  19 7-260 
   ALT (in U/L)  21 3-343 
   Alkaline Phosphatase (in U/L)  112 52-1269 
   GGT (in U/L)  116 7-1527 
   Albumin (in g/L)  36 23-52 
   Total bilirubin (in µmol/L)  7 3-50 
   LDH (in U/L)  306 190-5942 
BSA = body surface area; AST = aspartate aminotransferase; ALT = alanine-amino transferase; GGT = gamma-
glutamyl-transpeptidase; LDH = lactate dehydrogenase; WHO = World Health Organisation.
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sodium chloride solution to a fi nal paclitaxel concentration between 0.3 and 1.2 mg/ml. As 
Cremophor EL may leach plasticiser from the infusion lines, adapted PVC-free administration 
equipment was used. Paclitaxel was iv infused in 3-, 24-, and 96-hour infusions at doses 
ranging from 100 to 250 mg/m2. The corresponding Cremophor EL doses ranged from 8.3-
20.8 ml/m2 in the 3-hour infusion schedule (78 courses), from 11.2 to 14.5 ml/m2 in the 
24-hour infusion schedule (3 courses), and from 8.7 to 11.6 ml/m2 in the 96-hour infusion 
schedule (4 courses). Written informed consent was obtained from all patients. Standard 
premedication with dexamethasone (20 mg orally at 12 and 6 hours prior to paclitaxel 
administration), clemastine (2 mg iv. 30 minutes prior to paclitaxel administration) and 
cimetidine (300 mg iv. shortly prior to paclitaxel administration) was administered to prevent 
hypersensitivity reactions. If indicated, 5-HT
3
-receptor antagonists were administered iv as 
standard antiemetic agent. The Medical Ethics Committees of the participating hospitals 
approved the studies.
Pharmacokinetic sampling and bio-analysis
Plasma concentration-time data were obtained by pharmacokinetic sampling during the 
fi rst course (n=70) and the second course (n=15). The samples for Cremophor EL analysis 
were collected into heparinised tubes prior to the start of the infusion, at 1 and 2 hours 
after the start, at the end of the infusion and at 5, 30, 60 minutes, and 1.5, 2, 4, 8, 10, 12, 30, 
and 48 hours after the end of the infusion in the 3-hour infusion schedules. In the 24-hour 
infusion schedules, blood samples were taken prior to the start of the infusion, at 3, 10 and 
20 hours after the start of the infusion, at the end of the infusion, and at 5, 15, 30, and 60 
minutes, and 2, 4, 8, 12, 24, 30 hours after the end of the infusion. In the 96-hour infusion 
schedule, blood samples were taken prior to the start of the infusion, at 8, 48 and 72 hours 
after the start of the infusion, at the end of the infusion, and at 4, 9 and 19 hours after the 
end of the infusion. Whole blood was centrifuged immediately after withdrawal for 5 min 
at 3000 rpm, and the plasma fraction was stored at –20°C until analysis. The Cremophor EL 
concentrations in plasma were determined by a validated reversed-phase high-performance 
liquid chromatographic method based on the determination of ricinoleic acid after 
saponifi cation of Cremophor EL, followed by precolumn derivatization and reversed-phase 
high-performance liquid chromatography as has been described in detail elsewhere.[11,26] 
Population pharmacokinetic analysis
The program NONMEM (non-linear mixed effect modelling (NONMEM, version V 1.1, 
double precision) and PREDPP package were used throughout the analysis.[27] Since the 
patients were sampled extensively, fi rst-order conditional estimation was applied with 
interaction. The NONMEM analysis consisted of the following three-step approach.[28]
Desirée van den Bongard 14-10   124 15-10-2002, 10:39:53
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling
125
Basic population pharmacokinetic model
The fi rst step consisted of the development of a basic population pharmacokinetic model. 
The data were described by a three-compartment model with Michaelis-Menten elimination 
(Figure 1). The following pharmacokinetic parameters were estimated: volume of the central 
compartment (V1 in L), volume of the fi rst peripheral compartment (V2 in L), volume of the 
second peripheral compartment (V3 in L), intercompartmental clearance from the central 
compartment to the fi rst peripheral compartment (Q12 in L/h), and to the second peripheral 
compartment (Q13 in L/h), maximal elimination rate (Vmax in ml/h), and the concentration 
at half of the Vmax (Km in ml/L). Standard errors for all parameters were calculated using 
the COVARIANCE option in the NONMEM program. Interindividual variability in V1, V2, and 
Vmax was estimated using a lognormal error model. For V1 the interindividual variability 
was defi ned as in equation 1:
V1
i 
= V1
pop
 * (1+ η
i
V1)      equation 1
where V1
i 
represents the V1 of the ith individual, and V1
pop
 is the population value, and η
i
V1 is the 
interindividual random effect that is normally distributed with mean zero and variance ω2. 
The residual variability was estimated using a combined additive and proportional model:
C
obs,ij
 = C
pred,ij 
(1+ε
2
)+ε
1      
equation 2
Figure 1. Schematic overview of the basic population pharmacokinetic model: a three-compartment model with Michaelis-Men-
ten elimination from the central compartment (V1). V2 and V3 indicate the two peripheral compartments. k12, k21, k13 and k31 
indicate the intercompartmental rate constants. Vmax is the maximal elimination rate, and Km is the plasma-concentration of 
Cremophor EL at half of the Vmax
        Infusion 
             k31                  k12   
 V3            V1             V2      
            k13                     k21 
Km
      Vmax         
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where C
obs,ij
 is the jth observed concentration in the ith patient (C
obs,ij
) and its respective 
prediction (C
pred,ij
), and ε is an independent random variable with mean 0 and standard 
deviation σ that is assumed to be constant in this population analysis. 
The stability of the basic pharmacokinetic model was evaluated by the bootstrap resampling 
technique as implemented in the program Wings for NONMEM (WFN version 3).
designed by Dr. N.H. Holford and available via the internet (http://wfn.sourceforge.net).[29] The 
median parameter estimates obtained from the 1000 bootstrap replications were compared 
with those obtained from the original data set.
Intermediate model
The second step consisted of the individual Bayesian regression analysis. For each subject, 
individual pharmacokinetic parameters were calculated using the individual Cremophor EL 
plasma concentration-time data and the population pharmacokinetic parameter estimates 
obtained in the fi rst step. The individual Bayesian estimates were plotted against the 
demographic factors and blood chemistry parameters (as covariates). The relations between 
the covariates and the Bayesian parameter estimates of each individual patient were 
investigated graphically in the program Xpose (Xpose, version 2.0, Uppsala University, 
Sweden) as implemented in the S-PLUS statistical package (version 2000, Mathsoft, 
Cambridge, Mass.).[30] The following 13 covariates were investigated for their correlation 
with the pharmacokinetics of Cremophor EL: age, gender, weight, body surface area (BSA), 
performance status according to the World Health Organisation (PS), serum creatinine, serum 
alanine-aminotransferase (ALT), serum aspartate-aminotransferase (AST), serum alkaline 
phosphatase, serum gamma-glutamyl-transpeptidase (GGT), serum albumin, serum bilirubin 
and serum lactate dehydrogenase (LDH). The selected covariates that showed a graphical 
relationship with a pharmacokinetic parameter were tested by univariate analysis. These 
covariates were entered individually into the basic population pharmacokinetic model by 
forward inclusion. Continuous covariates, e.g. BSA, were centred to their median values.[31] 
For instance, the relationship between V2 and BSA was described as in equation 3:
V2 = θ
3
 * (1 + θ
4
 * (BSA – 1.82))     equation 3
where V2 represents the value of V2 in L, θ
3
 the V2 value of a (median) patient with a BSA 
of 1.82 m2, and θ
4
 is the increase or decrease in V2 per m2 BSA difference.
Dichotomous covariates were modelled as described in equation 4:
V1 = θ
1
 * θ
10
 FLAG1       equation 4
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where V1 represents the value of V1 in L, θ
1
 the V1 value in females (FLAG1 =0), and θ
10
 the 
change in V1 in males (FLAG1=1).
Several criteria were taken into account when comparing the models. The difference in 
the NONMEM objective function value that is equal to minus twice the log likelihood of 
the data, after the introduction of a covariate in the model, approximates to a chi-squared-
distribution with one degree of freedom. During the forward inclusion of the covariates 
in the basic model, the signifi cance level was set at p < 0.005 that is associated with a 
decrease in the NONMEM objective function value of > 7.88. All signifi cant covariates were 
incorporated into an intermediate multivariate model.
Final population pharmacokinetic model
The development of the intermediate model was followed by multivariate analysis that 
consisted of a stepwise backward elimination procedure. Covariates retained in the 
intermediate model when elimination of the covariate caused an increase in the NONMEM 
objective function value of > 10.83 that is associated with a signifi cance level of p < 0.001. 
The stability and performance of the fi nal model was evaluated using the bootstrap method 
by fi tting the fi nal model to 1000 bootstrap samples. The parameter estimates and the 95% 
confi dence intervals obtained from the original data set were compared with the median 
parameters estimates including the 2.5%-97.5% percentile range obtained from the 1000 
bootstrap replicates.
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Figure 2. Plasma concentration versus time curves of Cremophor EL in three representative patients treated with a 3-hour (z), 
24-hour ( ) and a 96-hour () iv infusion of paclitaxel, dissolved in Cremophor EL, at doses of  30, 24.6, and 19.4 ml, respectively 
(corresponding paclitaxel doses of 360, 295, and 235 mg, respectively)
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Results
The plasma concentrations versus time curves of Cremophor EL after the start of the infusion 
were analysed. Individual plots of plasma concentration versus time curves after a 3-, 24- 
and 96-hour iv infusion are shown in Figure 2.
Population pharmacokinetic analysis
Basic population pharmacokinetic model 
Two- and three-compartment models with fi rst order elimination and Michaelis-Menten 
elimination, and with linear distribution and saturable distribution were fi tted to the 
Cremophor EL concentration-time data. According to the objective function values (OFV), 
the standard error values, and the goodness of fi t plots, it appeared that the data were best 
described by a three-compartment model with Michaelis-Menten elimination (Figure 1). The 
population pharmacokinetic parameters (without taking covariates into account) including 
the standard errors, the interindividual variability and the residual errors are summarised in 
Table 2. All pharmacokinetic parameters were estimated accurately, except for the Km. The 
relative standard error of this parameter was 71%. Interindividual variability was determined 
for V1, V2, and Vmax. Inclusion of interindividual variability for V3, Q12, Q13 and Km 
did not improve the fi t. This should not be interpreted as an absence of interindividual 
variability in these pharmacokinetic parameters. It indicates that the data did not contain 
suffi cient information to estimate the interindividual variability of these parameters. The 
residual variability consisted of an additional error of 0.099 ml/L, and a proportional error 
of 6.8%. 
The stability of the basic pharmacokinetic model was tested by the bootstrap method. From 
the original concentration-time data, 1000 bootstrap resamples were generated. The median 
values of the parameter estimates obtained by 1000 bootstrap resamples were in accordance 
with the parameters of the model (data not shown). Parameter estimates of the basic model 
were all within 5.6% of the median bootstrap value. We concluded that the stability of the 
basic population pharmacokinetic model was adequate. The basic model was used in the 
development of the fi nal population pharmacokinetic model.
Intermediate model 
The graphical analysis of the plots of the covariates versus individual pharmacokinetic 
parameters indicated a possible relationship between BSA, age, weight, gender, PS, bilirubin, 
AST, ALT and V1, between BSA, age, weight, gender, PS, creatinine, alkaline phosphatase, 
GGT, AST, ALT and V2, and between BSA, creatinine, age, weight, gender, PS, creatinine, 
AST, ALT  and Vmax. Forward inclusion (p < 0.005) of these covariates in the basic model 
resulted in an intermediate multivariate model with the following signifi cant covariates: V1: 
gender, weight, PS, BSA, V2: gender, BSA, weight, and Vmax: PS, BSA, weight. 
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Table 3. Differences in the objective function value between the final population pharmacokinetic model and the final model
with one significant covariate eliminated
NONMEM Objective function value:
Basic population PK model  -857.9 
Final population PK model   -909.5
Eliminated covariate Objective function Difference in objective function p value
Gender on V1 -891.7 17.7 < 0.0001
BSA on V2 -894.0 15.4 < 0.0001
PS 2 on Vmax -893.9 15.6 < 0.0001
BSA = body surface area; PS = performance status according to the World Health Organisation; V1 = volume of the central compartment;
V2 = volume of the first peripheral compartment; V3 = volume of the second peripheral compartment; Vmax = maximal elimination rate.
Figure 3. Signifi cant relationships between individual pharmacokinetic parameters (Bayesian estimates) and covariates 
(p < 0.0001); between V1 and gender (A), between V2 and BSA (B), and between Vmax and PS (C)
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Final population pharmacokinetic model
Stepwise backward elimination (p < 0.001) was used to obtain the fi nal population 
pharmacokinetic model. Gender was signifi cantly correlated with V1, BSA with V2, and a 
PS of 2 with Vmax. Figure 3 shows the relationships between the Bayesian estimates of V1, 
V2 and Vmax, and gender, BSA and PS calculated from the fi nal model. Inclusion of these 
three covariates in the fi nal population pharmacokinetic model resulted in a decrease in the 
objective function value of 51.6 when compared to the value of the basic model (Table 3). The 
fi nal population pharmacokinetic model of Cremophor EL is defi ned in the equations 5-7:
V1 = (2.59 * (1.30FLAG1))      equation 5
where FLAG1 = 1 in males, FLAG1 = 0 in females
V2 = 1.81 – (1 + 1.13 * (BSA – 1.82))    equation 6
Vmax = (0.193 * (1.48FLAG2))     equation 7
where FLAG2 = 1 when PS = 2, FLAG2 = 0 when PS = 0 or 1.
In the fi nal model, V1 was 30% higher in males, Vmax was 48% higher in patients with a PS 
of 2 compared to patients with a PS of 0 or 1, and V2 was higher in patients with a higher 
BSA. 
The correlation between the interindividual variability of V1, V2 and Vmax was evaluated. 
The matrix plots showed no correlation between η
i
V1 , η
i
V2 , and η
i
Vmax (plots not shown). The 
inclusion of the covariance between interindividual variability of V1 and V2, V2 and Vmax, 
V1 and Vmax (∆OFV = -4.7) produced no signifi cant decrease in the objective function in 
NONMEM. We concluded that there was no signifi cant correlation, and therefore, it was 
not included in the fi nal model. The population pharmacokinetic parameters of the fi nal 
model including the standard errors, interindividual variability, and the residual errors are 
summarised in Table 2. The interindividual variabilities decreased to 24.7% (V1), 36.5% (V2), 
and 30.7% (Vmax). The residual error was almost unchanged (additional error 0.095 ml/L, 
proportional error 6.94%). The relative standard error of the Km was decreased to 61% in 
the fi nal model compared to 71% in the basic model. 
The Cremophor EL concentrations obtained after the 3- or 24- h infusions were higher than 
the Km value during the whole observation period, whereas the concentrations obtained 
after the 96-hour infusion were in the Km range. In order to explore the impact of the four 
patients receiving 96-hour infusion on the Km value, we repeated the fi nal analysis with 
these four patients excluded. This resulted in an increase of the Km value to 1.15 ml/L with 
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a relative standard error of 71%. Consequently, the concentration-time data of the 96-hour 
infusions substantially infl uence the estimation of the Km value. 
Plots indicating the goodness of fi t of the fi nal model are depicted in Figure 4. Model- and 
Bayesian-predicted concentrations were symmetrically distributed around the line of unity 
(Figures 4A and 4B). No trend was seen in the plot of individual weighted residuals (i.e. the 
weighted difference between the observed and the individually predicted concentrations) 
versus individually predicted concentrations (Figure 4C).  Moreover, no time-dependent 
trend was observed in the plot of the weighted residuals (the weighted difference between 
Figure 4. Goodness of fi t plots of the observed concentrations versus the model predicted concentrations (A) and Bayesian predic-
ted concentrations (B) as estimated by the fi nal population pharmacokinetic model. Figure 4C is a plot of the individual weighted 
residuals (i.e. the weighted difference between the observated and the Bayesian predicted concentrations) versus the Bayesian 
predicted concentrations. Figure 4D is a plot of the weighted residuals (i.e. the weighted difference between observed and model 
predicted concentrations) versus time. In Figures 4A and 4B the solid line is the line of identity 
A.
0.00
2.00
4.00
6.00
8.00
10.00
12.00
0.00 2.00 4.00 6.00 8.00 10.00 12.00
Observed CrEL concentration (ml/L)
Pr
e
di
ct
e
d 
Cr
EL
 
co
n
ce
n
tr
a
tio
n
 
(m
l/L
)
C.
-4
-3
-2
-1
0
1
2
3
4
0 1 2 3 4 5 6 7 8 9 10
Individual predicted CrEL concentration 
(ml/L)
In
d
iv
id
u
a
l 
w
e
ig
h
te
d
 r
e
si
d
u
a
ls
-4
-3
-2
-1
0
1
2
3
4
0 20 40 60 80 100 120 140
Time (h)
W
e
ig
h
te
d
 r
e
si
d
u
a
ls
B.
Observed CrEL concentration (ml/L)
0.00
2.00
4.00
6.00
8.00
10.00
12.00
0.00 2.00 4.00 6.00 8.00 10.00 12.00
Ba
ye
si
a
n
 
pr
e
di
ct
e
d 
Cr
EL
co
n
ce
n
tr
a
tio
n
 (m
l/L
)
Desirée van den Bongard 14-10   132 15-10-2002, 10:40:03
D.
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling
133
the observed and the predicted concentrations based on the parameter estimates for the 
typical individual versus time (Figure 4D). 
The fi nal model was fi tted to the 1000 bootstrapped samples to evaluate its stability 
and performance. The values of all parameter estimates obtained by bootstrapping are 
summarised in Table 2. The median parameter estimates were all within 2.7% of the 
parameter estimates of the fi nal model, indicating that the performance and stability of 
the fi nal population pharmacokinetic model of Cremophor EL was adequate. However, 
the 97.5% percentile of the Km value (0.87) produced by the bootstrap procedure was 
considerably higher than the boundary of the 95% confi dence interval produced by the fi nal 
model (0.27). This difference was probably caused by bootstrap datasets that did not contain 
patients receiving the 96-hour infusions resulting in higher estimated Km values.
Discussion
Despite the extensive clinical use of Cremophor EL as a formulation vehicle for various 
hydrophobic drugs, reports of its pharmacokinetics are sparse.[1,8-11] It has recently been 
reported that Cremophor EL can infl uence the pharmacokinetic and toxicity profi le of 
the drugs dissolved in it, e.g. paclitaxel.[7,11-14] The amount of Cremophor EL used in the 
formulation of hydrophobic drug varies from 5.5 ml/m2 (propofol, diazepam, and aplidine) 
to 12 ml/m2 (paclitaxel).[7] 
The purpose of this study was to develop a population pharmacokinetic model of 
Cremophor EL, as the solvent for paclitaxel, and to elucidate relationships between the 
pharmacokinetic parameters and patient characteristics, i.e. demographic factors and blood 
chemical variables. 
Previous reports with respect to the pharmacokinetics of Cremophor EL are confl icting. 
Noncompartmental pharmacokinetic analyses have shown that the elimination of 
Cremophor EL can be linear as well as non-linear with a disproportional increase of the 
exposure at higher Cremophor EL doses.[1,8,10,11] In these studies various assays for the 
determination of Cremophor EL in plasma were used that could have contributed to the 
differences in Cremophor EL concentrations. In one study the bioassay was based on the 
determination of the modulation of the multidrug resistance (mdr) in vitro by inhibition 
of P-glycoprotein inhibition.[1] In this study, the Cremophor EL concentrations in plasma 
were lower compared to the plasma concentrations determined by two other assays that 
are based on the measurement of ricinoleic acid and the binding of Cremophor EL to 
Coomassie brilliant blue G-250.[1,2,4,26] Moreover, the bio-assay based on mdr modulation has 
some disadvantages including the relatively large sample volume and its relatively poor 
sensitivity and precision.[26]
Our fi nal population pharmacokinetic model revealed that the plasma concentration-
time data of Cremophor EL could be best described by a three-compartment model with 
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Michaelis-Menten elimination after iv infusion as a solvent of paclitaxel in cancer patients. 
The saturated elimination could be due to capacity-limited Cremophor EL metabolism 
of the carboxylesterases within the systemic circulation.[7,9] The estimated population 
value of the total volume of distribution (=V1+V2+V3) was low (6.0 L) implying that the 
volume of distribution in humans is not much larger than the volume of the central blood 
compartment. This is in accordance with the low volume of distribution found in studies in 
which a noncompartmental pharmacokinetic analysis of Cremophor EL was performed.[8,10] 
This also implies that the distribution of Cremophor EL is limited to the peripheral tissues. 
Moreover, it can be hypothesised that V1 refers to the plasma compartment, and that V2 and 
V3 refer to the blood cells and micelles, respectively.
In our fi nal population model, the interindividual variability in V1, V2 and Vmax could 
partially be explained by gender, BSA and PS, respectively. The volume of the central 
compartment was 31% higher in males than in females. The volume of the fi rst peripheral 
compartment increased with BSA, and the Vmax was 48% higher in patients with a PS of 2 
compared to patients with a PS of 0 or 1. The renal and hepatic elimination of Cremophor 
EL has been demonstrated to be very low. In one patient, 0.08% of the administered dose 
was excreted in urine after a 3-hour iv infusion.[32] It has been reported that Cremophor 
EL is eliminated by serum carboxylesterases as ricinoleic acid.[7,33] In a study of 27 patients 
performed at our institute, a higher Cremophor EL clearance was observed in patients with 
hepatic dysfunction than in patients with normal hepatic function after noncompartmental 
pharmacokinetic analysis.[9] In this population analysis, 21 of these patients were included. 
The relationships between the biochemical parameters, that indicate hepatic dysfunction, 
and the Vmax were not signifi cant. We hypothesized that the higher Vmax in patients 
with a PS of 2 in our population analysis could be attributable to a higher serum esterase 
concentration in these patients. Higher serum esterase levels can be caused by hepatic 
dysfunction that results from liver metastasis that is more often present in patients with a PS 
of 2 compared to patients with a PS of 0 or 1.
The bootstrapping resampling method, that is considered to be a powerful internal validation 
technique, showed that the fi nal population pharmacokinetic model was stable.[34] The median 
values of the parameter estimates obtained by bootstrapping were in accordance with the 
parameter estimates of the fi nal model. The distribution of all parameter estimates showed a 
narrow range (Table 2) except for the Km. This observation is in accordance with the high 
relative standard error (61%) of the Km value in the fi nal population pharmacokinetic model 
implying that the population parameter estimate is not very accurate. 
The 95% confi dence interval of Km obtained by the bootstrap resampling was large 
compared to the confi dence interval obtained with the fi nal model. As indicated before 
this may result from the small number of patients receiving Cremophor EL in the 96-hour 
infusion. This indicates that bootstrapping is of limited use when a small subset of patients 
has a large impact on the estimation of a pharmacokinetic parameter.
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It is known that the pharmacokinetic behaviour of Cremophor EL can infl uence the 
pharmacokinetic and toxicity profi le of paclitaxel and other dissolved drugs.[11-14] Several 
suggested mechanisms for the non-linear pharmacokinetics of paclitaxel have been rejected 
by van Zuylen et al.[14] They reported that the observed decrease in hepatobiliary elimination 
of paclitaxel in the presence of Cremophor EL in rats is not caused by alterations in 
paclitaxel elimination by Cremophor EL but by micelle formation in plasma. Consequently, 
paclitaxel cannot reach the elimination sites.[14] They also excluded altered protein binding 
due to the formation of high-density lipoproteins induced by Cremophor EL because an in 
vitro study showed that the paclitaxel accumulation in erythrocytes induced by Cremophor 
EL is also observed in the absence of any plasma proteins.[13] It has been reported that the 
micellar formation of Cremophor EL most likely affects the paclitaxel pharmacokinetics in 
plasma.[11,13,14,17,19] Consequently, the free paclitaxel fractions in plasma are lower at higher 
Cremophor EL concentrations in plasma.[11.13,14,17,19]
In conclusion, we have showed that the non-linear pharmacokinetics of Cremophor EL 
after iv infusion can accurately be described by the developed population pharmacokinetic 
model. This population model of Cremophor EL could be used in the development 
of a pharmacokinetic/pharmacodynamic population model to further explore the 
relationships between the pharmacokinetics of Cremophor EL and its toxicity. Moreover, 
this population pharmacokinetic model could be used to further develop a detailed 
population pharmacokinetic model of paclitaxel after iv administration when it is dissolved 
in Cremophor EL. 
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Chapter 4.2.1
Development and validation of a population pharmacokinetic model of 
paclitaxel in cancer patients
HJG Desirée van den Bongard, Ron AA Mathôt, Jan HM Schellens and Jos H Beijnen
Summary
Paclitaxel is an anticancer agent with non-linear pharmacokinetic behaviour. The purpose of 
this study was to develop and to validate a population pharmacokinetic model for paclitaxel 
in cancer patients. A population pharmacokinetic model was developed using 100 total 
plasma concentration-time profi les of paclitaxel after 3- and 24-hour intravenous infusion 
in 61 patients (dose range 100-250 mg/m2). Population pharmacokinetic parameters were 
estimated by non-linear mixed effects modelling (NONMEM). The relationships between 13 
covariates and the pharmacokinetic parameters of paclitaxel were tested. The validity of the 
fi nal model was evaluated by the bootstrap resampling method of the data and performing 
a predictive check.
The data were best described by a 3-compartment model with saturable transport to one 
peripheral compartment and Michaelis-Menten elimination from the central compartment. 
The following population pharmacokinetic parameter estimates were obtained: volume of 
the central compartment (V=12.1 L), maximal transport rate from the central compartment to 
peripheral compartment 1 (Tmax=216 µmol/h), plasma concentration at half Tmax (Tm=2.59 
µmol/L), intercompartmental rate constants (k21=0.916 h-1, k13=1.63 h-1, k31=0.0722 h-1), 
maximal elimination rate (Vmax=47.0 µmol/h), and plasma concentration at half Vmax 
(Km=0.656 µmol/L). Inter-individual variability for V, Tmax and Vmax was 20%, 26% and 
22%, respectively. Inter-occasion variability could be quantifi ed for k21 (15%), k13 (26%), 
k31 (39%), and Vmax (18%). Body surface area (BSA) was signifi cantly correlated with V 
and Tmax (p < 0.005). The fi ts of 1000 bootstrap replicates to the data and the predictive 
check confi rmed the robustness of the model.
This developed population model adequately describes the pharmacokinetic parameters of 
paclitaxel in cancer patients. Furthermore, it has been demonstrated that BSA guided dosing 
for paclitaxel is important. This population model forms the basis of future studies with 
pharmacokinetically guided dosing of paclitaxel.
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Introduction
Paclitaxel (Taxol®) is a taxane derivative that acts on microtu bu lar structures by binding 
directly to tubulin, causing microtubuli stabilisation that arrests cell division in the G2/M 
phase of the cell cycle. The drug has a profound antitumour activity against a variety of solid 
tumours, especially against lung, breast, ovarian, and head and neck tumours.[1,2] 
For paclitaxel, non-linear pharmacokinetics in plasma have been described in several studies.[3-
10] In recently published reports the non-linearity has been attributed to its formulation 
vehicle Cremophor EL that forms micelles in plasma in which paclitaxel is entrapped.[11-15] 
Relationships between plasma pharmacokinetics and pharmacodynamics of paclitaxel were 
reported in ovarian cancer patients. Myelotoxicity was related to the duration of the paclitaxel 
concentration in plasma above the threshold levels of 0.05 or 0.1 µmol/L.[3,4] Furthermore, 
paclitaxel doses higher than 175 mg/m2 have been reported to result in higher response 
rates and more neutropenia in patients with non-small cell lung cancer (NSCLC).[16,17] In a 
retrospective analysis of a phase I study of paclitaxel plus carboplatin in 55 NSCLC patients, 
a longer survival was observed in patients with a plasma paclitaxel concentration above 0.1 
µmol/L equal to or longer than 15 hours compared to the survival in patients with a duration 
time above the threshold concentration shorter than 15 hours.[5] Based on these established 
pharmacokinetic-pharmacodynamic relationships, pharmacokinetically guided dosing may 
be used to attain paclitaxel plasma concentrations above 0.1 µmol/L during 15 hours or 
longer. In the present study, a population pharmacokinetic model was developed based on 
concentration-time data of patients treated at various paclitaxel doses. A covariate analysis was 
performed and the fi nal population model was validated, in contrast to other pharmacokinetic 
studies of paclitaxel. The population model was developed in order to evaluate the feasibility 
of pharmacokineticcally guided dosing of paclitaxel in a future study. 
Methods
Patient population 
Plasma concentration-time data (100 courses) of paclitaxel were collected during safety and 
pharmacokinetic studies of paclitaxel that were performed in 61 cancer patients in multi-
center studies. The results of these studies have been published in detail elsewhere.[5,18] 
In these studies paclitaxel was infused intravenously with co-infusion of carboplatin in 
chemonaive patients with NSCLC IIIB and IV (n=55, 3-h iv infusion), and paclitaxel as a 
single agent in with platinum pre-treated advanced ovarian cancer patients (n=6, 24-h iv 
infusion). Patient characteristics are summarised in Table 1. 
Paclitaxel (Taxol®, Bristol Myers Squibb, Syracuse, NY) was provided as a sterile 6 mg/
ml solution and dissolved in Cremophor EL:Ethanol 1:1, v/v. Prior to administration this 
solution was diluted with 500-1000 ml 0.9% sodium chloride solution to a fi nal paclitaxel 
concentration between 0.3 and 1.2 mg/ml. As Cremophor EL may leach plasticiser from the 
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infusion lines, an adapted PVC-free administration equipment was used. Written informed 
consent was obtained from all patients. Standard pre-medication with dexamethasone (20 
mg orally at 12 and 6 hours prior to paclitaxel administration), clemastine (2 mg iv 30 minutes 
prior to paclitaxel administration) and cimetidine (300 mg iv shortly prior to paclitaxel 
administration) was administered to prevent hypersensitivity reactions. If indicated, 5-HT
3
-
receptor antagonists were administered intravenously as standard anti-emetic agent. The 
studies were approved by the Medical Ethics Committees of the participating hospitals.
Pharmacokinetic sampling and bio-analysis
Plasma concentration-time data were obtained by pharmacokinetic sampling during the fi rst 
(n=59) and the second course (n=41). The samples for paclitaxel analysis were collected in 
heparinised tubes. In the 3-hour infusion schedules, blood samples were taken prior to the 
start of the infusion, at 1 and 2 hours after the start, at the end of the infusion, at 5, 10, 15, 
30, 45, and 60 minutes, and at 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 30, and 48 hours after the end of 
the infusion. In the 24-hour infusion schedules, blood samples were taken prior to the start of 
Table 1. Patient characteristics (n=61) and serum parameter values 
 Number Median Range 
Patient characteristics 
   Female
   Male 
20
41
   Number of courses with pharmacokinetic data 
      First course 
      Second course 
59
41
   Dose range paclitaxel (in mg/m2)
      3-hour infusion  
      24-hour infusion  
55
6
100-250
135-175
   Dose range carboplatin (in mg/m2)
      3- hour infusion  55 300-400
   Primary site of disease 
      Lung 
      Ovarian 
55
6
   Age (in years)  55 38-75 
   WHO Performance status 
      0 
      1 
      2 
18
29
14
   BSA (in m2)  1.81 1.50-2.22 
Biochemical parameters 
   Creatinine (in µmol/L) 77 37-144 
   AST (in U/L)  13 3-62 
   ALT (in U/L)  13 1-150 
   Alkaline Phosphatase (in U/L)  82 50-539 
   GGT (in U/L)  34 10-384 
   Albumin (in g/L)  35 18-52 
   Total bilirubin (in µmol/L)  6 3-14 
BSA = Body surface area; AST = aspartate aminotransferase; ALT = alanine-amino transferase; GGT = gamma-
glutamyl-transpeptidase; LDH = lactate dehydrogenase; WHO = World Health Organisation. 
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the infusion, at 3, 10, 20 hours after the start of the infusion, at the end of the infusion, 5, 15, 
30, and 60 minutes, and 2, 4, 8, 12, 24, 30 hours after the end of the infusion. Whole blood 
was centrifuged immediately after withdrawal during 5 minutes at 3000 rpm, and the plasma 
fraction was stored at –20°C until analysis. The paclitaxel concentrations in plasma were 
determined by a validated isocratic high-performance liquid chromatographic (HPLC) method 
with solid-phase extraction as the sample pre-treatment procedure, as has been described in 
detail elsewhere.[19,20] The quantitaion range of the HPLC method was 10-10,000 ng/ml.
Population pharmacokinetic analysis
The program NONMEM (nonlinear mixed effect modelling (NONMEM, version V 1.1, 
double precision) using the NMTRAN pre-processor and the PREDPP package (ADVAN 
6), operating on an MS-DOS computer.[21] The POSTHOC option in NONMEM was used to 
obtain Bayesian estimates of the pharmacokinetic parameters. All concentration-time data 
were logarithmically transformed, and the fi rst order method was used in all of the analysis 
processes. The fi rst order conditional estimate method was not used in this population 
analysis due to its high computational intensity. The model building procedure consisted of 
the following three-step approach.[22]
Basic population pharmacokinetic model
The fi rst step consisted of the development of a basic population pharmacokinetic model. 
The data were best described by a 3-compartment model with Michaelis-Menten elimination 
from the central compartment, saturable transport to the fi rst peripheral compartment 
and linear distribution to the second peripheral compartment (Figure 1). The following 
Figure 1.  Three-compartment model with Michaelis-Menten elimination from the central compartment V. Tmax is the maximal 
transport rate to the fi rst peripheral compartment, and Tm is the plasma concentration of paclitaxel at half Tmax. k21, k13 and 
k31 indicate the intercompartmental rate constants. Vmax is the maximal elimination rate, and Km is the plasma concentration of 
paclitaxel at half of the Vmax
    Infusion 
            
                Tm  
      second peripheral              k13            central           Tmax                  first peripheral 
      compartment      compartment (V)            compartment 
     
 k31                                      k21 
Km
      Vmax  
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pharmacokinetic parameters were estimated: volume of the central compartment (V in L), 
the maximal transport rate to the fi rst peripheral compartment (Tmax in µmol/h), the total 
plasma concentration of paclitaxel at half of the Tmax (Tm in µmol/L), intercompartmental 
rate constants from the peripheral compartments to the central compartment (k21 and k31 
in h-1) and from the central compartment to the second peripheral compartment (k13 in h-1), 
the maximal elimination rate (Vmax in µmol/h), and the plasma concentration of paclitaxel 
at half of the Vmax (Km in µmol/L). Standard errors for all parameters were calculated using 
the COVARIANCE option in the NONMEM program. Inter-individual variability in V and 
Tmax was estimated using a proportional error model. For V the inter-individual variability 
was defi ned as in equation 1:
V
i 
= V
pop
 * (1 + η
i
V)      equation 1
where V
i 
represents the V of the ith individual in L, V
pop
 is the typical population value, 
and η
i
V is the inter-individual random effect that is normally distributed with mean 0 and 
variance ω2.
 
Variability in the individual pharmacokinetics between the fi rst and second course (inter-
occasion variability) was estimated using a proportional model. For instance, inter-occasion 
variability in Vmax was defi ned as in equation 2:
Vmax
i
 = Vmax
pop
 * (1 + κ
i
Vmax)     equation 2
where Vmax
j 
represents the Vmax of the ith individual in µmol/h, Vmax
pop
 is the typical 
population value of Vmax and κ
i
Vmax is the inter-occasion random effect that is normally 
distributed with mean 0 and variance π2. 
Residual variance was modelled using an additive error model:
 
ln (C
obs,ij
) = ln (C
pred,ij
) + ε      equation 3
where C
obs,ij
 is the observed concentration and C
pred,ij
 is its respective prediction. ε is a 
random variable with mean 0 and variance σ2. 
The inter-individual variability in residual variance was accounted for by the assumption that 
the population was a mixture of 2 subpopulations (subpopulations 1 and 2) differing in σ2.
Several criteria were taken into account when comparing the basic models. The value of 
the objective function (OFV), that is equal to minus twice the log likelihood of the data, the 
reliability of parameters estimates (according to the standard error values of the parameter 
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estimates), and the fi t of the model to the data (goodness of fi t plots). The difference in 
the OFV of models approximates to a chi-squared-distribution with 1 degree of freedom. 
The signifi cance level was set at p < 0.001, which is associated with an OFV decrease of 
10.8. The goodness of fi t plots were studied in the program Xpose (Xpose, Version 2.0, 
Uppsala University, Sweden) as implemented in the S-Plus statistical package (version 2000, 
Mathsoft, Cambridge, Mass.).[23]
Intermediate model
For each subject, individual pharmacokinetic parameters were calculated using the individual 
paclitaxel plasma concentration-time data and the population pharmacokinetic parameter 
estimates obtained in the fi rst step. The individual Bayesian estimates were plotted against 
the demographic factors and blood chemistry parameters (=covariates). The relations 
between the covariates and the Bayesian parameter estimates of each individual patient 
were investigated graphically in the program Xpose. Thirteen covariates were investigated 
for their infl uence on the pharmacokinetics of paclitaxel (age, gender, weight, body surface 
area (BSA), performance status according to the World Health Organisation (PS), serum 
creatinine, serum alanine-aminotransferase (ALT), serum aspartate-aminotransferase (AST), 
serum alkaline phosphatase, serum gamma-glutamyl-transpeptidase (GGT), serum bilirubin, 
serum lactate dehydrogenase (LDH), and serum albumin). Since the number of patients 
treated with paclitaxel as a single agent was low (n=6) compared to the number of patients 
treated with paclitaxel in combination with carboplatin (n=55), we have not studied the 
infl uence of carboplatin on the pharmacokinetic behaviour of paclitaxel. 
The selected covariates that showed a graphical relation with a pharmacokinetic parameter 
were tested by univariate analysis. These covariates were entered individually into the basic 
population pharmacokinetic model by forward inclusion. Continuous covariates, e.g. BSA, 
were centred to their median values.[24]  For instance, the relationship between V and BSA 
was described as in equation 4:
V = θ
1
 * (BSA /1.81)θ12      equation 4
where V is expressed in L, θ
1
 represents the population value of V of a (median) patient with 
a BSA of 1.81 m2, and θ
12
 is an exponential factor.
Relationships with dichotomous covariates were investigated as described in equation 5:
Vmax = θ
8
 * θ
14
FLAG       equation 5
where Vmax is expressed in µmol/h, θ
8
 the Vmax value in patients with PS 0 or 1 (FLAG = 
0), and θ
14
 the change in Vmax in patients with PS 2 (FLAG = 1).
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During the forward inclusion of the covariates in the basic model, the signifi cance level was 
set at p < 0.01 that is associated with a decrease in the NONMEM objective function value of 
> 6.7. All signifi cant covariates were incorporated into an intermediate multivariate model.
Final population pharmacokinetic model
The development of the intermediate model was followed by multivariate analysis that 
consisted of a stepwise backward elimination procedure. Covariates were retained in the 
intermediate model when elimination of the covariate caused an increase in the NONMEM 
objective function value of > 7.9 that is associated with a signifi cance level of p < 0.005. 
The validity of the interindividual variability model was checked by evaluating correlations 
between the individual random effects (η) of the pharmacokinetic parameters that were 
included in the model.
The stability and performance of the fi nal model was evaluated by the bootstrap resampling 
technique as implemented in the computer program Wings for NONMEM (WFN version 3) 
designed by Dr. N.H. Holford and available via the internet (http://wfn.sourceforge.net).[25] 
The median parameter estimates and 95% confi dence intervals obtained from 1000 bootstrap 
replications were compared with those obtained from the original data set. 
A predictive check was performed for the fi nal population pharmacokinetic model.[26,27] 
One thousand data sets were simulated from the original concentration-time data of each 
administered dose (100, 125, 150, 175, 200, 225 and 250 mg/m2 in a 3-h iv infusion, 135 
and 175 mg/m2 in a 24-h iv infusion). For each dose-level the mean and corresponding 95% 
confi dence interval of the time above the plasma concentration 0.1 µmol/L of the simulated 
concentration-time data was calculated. The corresponding observed means of each dose-
level were compared with the 95% predicted intervals of the simulated means.
Results
Population pharmacokinetic analysis
Basic population pharmacokinetic model
Two- and three-compartment models with linear and saturable distribution, fi rst order 
elimination and Michaelis-Menten elimination were fi tted to the plasma concentrations 
versus time curves of paclitaxel. According to the objective function values (OFV), the 
standard error values, and the goodness of fi t plots, it appeared that the data were best 
described by a 3-compartment model with Michaelis-Menten elimination and saturable 
distribution to peripheral compartment 1 (Figure 1). All pharmacokinetic parameters were 
estimated accurately according to the relative standard error ≤ 29%. The patient population 
was divided in 2 subpopulations, the fraction of the patients belonging to subpopulation 
1 was 16.5%. Inter-individual variability was determined for V (23%) and Tmax (27%). 
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Inter-occasion variability was determined for V (12%), k21 (17%), k13 (22%), k31 (42%), 
and Vmax (26%). Inclusion of inter-individual variability for the other pharmacokinetic 
parameters did not improve the fi t. This should not be interpreted as an absence of 
inter-individual variability in these parameters. It indicates that the data do not contain 
suffi cient information to estimate the inter-individual and inter-occasion variability of these 
parameters. The residual variabilities of subpopulations 1 and 2 consisted of an additional 
error of 0.316 and 0.123, respectively.
Intermediate model
In the second step, the individual Bayesian estimates of the pharmacokinetic parameters 
were calculated using the individual paclitaxel plasma concentration-time data and 
the population pharmacokinetic parameter estimates obtained in the basic population 
model. The graphical analysis of the plots of covariates versus individual pharmacokinetic 
parameters indicated a possible relationship between BSA, weight, gender and V; between 
age, gender, BSA and Tmax; and between BSA, PS and Vmax. Forward inclusion (p < 0.01) 
of these covariates in the basic model resulted in an intermediate multivariate model with 
the following signifi cant relations between pharmacokinetic parameters and covariates: BSA 
and V, BSA and Tmax, BSA and Vmax, and PS and Vmax.
Final population pharmacokinetic model
The development of the intermediate model was followed by stepwise backward 
elimination (p < 0.005) of these covariates in the basic population pharmacokinetic model. 
BSA appeared to be signifi cantly related to V and Tmax, and PS with Vmax. Inclusion of 
these covariates resulted in a decrease in the objective function value of 65.1 compared to 
the basic population model. However, validation of the obtained population model with 
the bootstrap resampling method resulted in a non-signifi cant relation between PS of 2 
and Vmax due to the inclusion of 1 in the 2.5%-97.5% percentile range (0.88-1.65) of θ
14
 
(equation 5). Consequently, the correlation between PS and Vmax was deleted from the 
model. The objective function value of the obtained fi nal model was 122.6 points lower 
than the objective function of the basic model. The signifi cant relationship between the 
covariates and the pharmacokinetic parameters are given in equations 6 and 7:
V = 12.1 * (BSA/1.81)1.16      equation 6
Tmax = 216 * (BSA/1.81)1.05     equation 7
where V is expressed in L, BSA in m2 and Tmax in µmol/h.
Both equations indicate that V and Tmax increase with increasing BSA.
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The correlation between the inter-individual variability and the inter-occasion variability of 
the pharmacokinetic parameters was evaluated. The matrix plots showed no correlation 
(data not shown) and were not included in the fi nal model. The population pharmacokinetic 
parameters of the fi nal model including the standard errors, inter-individual variability, 
and the residual errors are summarised in Table 2. In the fi nal model, the inter-individual 
variability of V, Tmax and Vmax was 20%, 26% and 22% (versus an inter-individual 
variability of V and Tmax of 23% and 27% in the basic model, respectively. The goodness 
of fi t plots of the observed concentrations versus the predicted concentrations of the fi nal 
model are depicted in Figure 2A. In Figure 2B the observed concentrations versus the 
Table 2. Population parameters of the final population pharmacokinetic model of paclitaxel and 
corresponding parameter estimates obtained by 1000 bootstrap resamplings 
Final population model  1000 bootstrap replicates 
 Estimate  RSE (in %) Median 2.5-97.5%  
Pharmacokinetic parameter 
    
   V (L) 
       Influence of BSA (θ12)a
12.1
1.16
5.4
33
12.0
1.12
10.7-13.8 
0.231-1.86
   Tmax (µmol/h) 
       Influence of BSA (θ13)b
216
1.05
5.6
49
219
0.999
194-248
0.224-2.271
   Tm (µmol/L) 2.59 10 2.66 2.18-3.40 
   k21 (h
-1
) 0.916 7.0 0.914 0.779-1.080 
   k13 (h
-1
) 1.63 8.7 1.61 1.32-1.95 
   k31 (h
-1
) 0.0722 7.9 0.0713 0.061-0.0836 
   Km (µmol/L) 0.656 15 0.684 0.460-0.905 
   Vmax (µmol/h) 47.0 10 48.2 36.5-58.1 
   Population 1-2 0.380 27 0.366 0.119-0.574 
Inter-individual variability 
    
   IIV-V (%) 20 31 20 13-26 
   IIV-Tmax (%) 26 27 25 17-33 
   IIV-Vmax (%) 22 33 21 0-29 
Inter-occasion variability 
    
   IOV- k21 (%) 15 48 16 7-23 
   IOV- k13 (%) 26 25 25 18-31 
   IOV-k31 (%) 39 30 39 29-53 
   IOV-Vmax (%) 18 32 19 13-29 
Residual error 
    
   Additional error 1  0.202 11.0 0.203 0.167-0.301 
   Additional error 2  0.105 7.6 0.103 0.0919-0.129 
a
 V = θ1 * (BSA /1.81)θ12
b
 Tmax = θ2 * (BSA /1.81)θ13
where BSA is expressed in m
2
, θ1 and θ2 represent the population value of V and Tmax, respectively, of a patient 
with a (median) BSA of 1.81 m
2
, θ12 and θ13 are exponential factors.
Additional error = 1 residual variability of subpopulation 1; Additional error 2 = residual variability of subpopulation 
2; BSA = body surface area; IIV = inter-individual variability; IOV = inter-occasion variability; k21 = rate constant 
from the first peripheral compartment to the central compartment; k13 = rate constant from the central to the 
second peripheral compartment; k31 = rate constant from the second peripheral to the central compartment; Km 
= plasma concentration at half Vmax; Population 1-2 = fraction of the patient population (n = 61) belonging to 
subpopulation 1; RSE = Relative standard error; Tmax = maximal transport rate from the central to the first 
peripheral compartment; Tm = plasma concentration at half Tmax; V = volume of the central compartment; Vmax 
= maximal elimination rate.
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individual predicted concentrations based on the individual concentrations and the Bayesian 
parameter estimates are depicted.
The fi nal model was fi tted to 1000 bootstrapped samples of the data in order to evaluate 
its stability and performance. The values of the parameter estimates obtained by 1000 
bootstrap replicates are included in Table 2. Median values of the parameter estimates of 
Table 3A. Results of the predictive check performed for all dose-levels. After the intravenous infusion 
of paclitaxel in 3 hours 
Dose-level 
(mg/m2)
Observed mean duration of time 
concentration > 0.1 µmol/L (h) 
95% prediction interval 
(h)
100 (n=6) 6.7 6.0-10.7
125 (n=7) 8.8 7.4-13.4 
150 (n=6) 9.9 8.1-16.2 
175 (n=7) 17.1 11.5-22.7 
200 (n=8) 17.1 12.5-23.2 
225 (n=18) 20.9 17.5-25.7 
250 (n=3) 21.6 14.4-34.2 
Table 3B. Results of the predictive check performed for all dose-levels. After the intravenous infusion 
of paclitaxel in 24 hours 
Dose-level 
(mg/m2)
Observed mean duration of time 
concentration > 0.1 µmol/L (h) 
95% predicted CI 
(h)
135 (n=2) 26.7 ND
175 (n=4) 28.0 22.5-28.9 
ND = not determined. 
Figure 2. Goodness of fi t plots for the fi nal population pharmacokinetic model. Plot of the observed logarithmically transformed con-
centrations versus the model predictions of the paclitaxel concentrations (A). Plot of logarithmically transformed observed concentra-
tions versus the individual Bayesian predictions of the paclitaxel concentrations (B). The solid line is the line of identity
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the fi nal model were within 6.7% of the parameter value calculated in NONMEM. The 95% 
confi dence interval of the parameter estimates of the fi nal model calculated in NONMEM 
was in accordance with the 2.5-97.5 percentile range of the parameter obtained by 1000 
bootstrap replicates of the fi nal model. This indicates that the robustness of the fi nal model 
of paclitaxel was adequate. 
The results of the predictive check for all dose levels and infusion schedules are summarised 
in Table 3A and 3B. The observed mean durations of time that the total paclitaxel 
concentration in plasma was above 0.1 µmol/L were compared with values obtained after 
simulation of 1000 paclitaxel concentration-time curves. All observed means were in the 
95% predicted intervals of the simulated means at all dose-levels. Moreover, the simulation 
revealed that after the fi rst intravenous infusion of the standard dose of 175 mg/m2 in 3 
hours, the duration of time that the concentration was higher than 0.1 µmol/L during 15 
hours or longer in 52% of the patients.
 
Discussion
The purpose of this study was to develop a population pharmacokinetic model of paclitaxel 
in cancer patients. The pharmacokinetic behaviour of paclitaxel has been described 
based on 2- or 3-compartment models in combination with saturable distribution and 
Michaelis-Menten elimination.[4,9,10] In our study, the plasma concentration versus time 
data were best described by a three-compartment model with saturable transport to one 
peripheral compartment and Michaelis-Menten elimination from the central compartment 
after intravenous infusion in cancer patients. Inter-individual variability was determined 
for V, Tmax and Vmax, and inter-occasion variability for k21, k13, k31 and Vmax. Further 
inclusion of inter-individual or inter-occasion variability did not improve the fi t. BSA could 
partially explain the inter-individual variability in the volume of the central compartment 
and the maximal transport rate to one peripheral compartment; the two pharmacokinetic 
parameters increased with increasing BSA.
The non-linear pharmacokinetic behaviour of paclitaxel has also been described in various 
pharmacokinetic models as both saturable elimination and/or saturable distribution.[4,9,10] 
These pharmacokinetic models include a two-compartment model with saturable tissue 
distribution and saturable elimination based on total plasma concentration-time data of 
30 children with solid tumours, a four-compartment model with saturable distribution and 
saturable elimination based on total paclitaxel and 6α-hydroxypaclitaxel concentrations in 30 
patients after intravenous infusion, and a three-compartment model with saturable transport 
based on total plasma concentration-time data of 21 patients.[4,9,10] Our pharmacokinetic 
population model is also a pharmacokinetic 3-compartment model with saturable transport 
based on total plasma concentration-time data of 61 cancer patients. The parameter 
estimates do not have the same values in both population models except for the value of 
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the apparent volume of distribution. In addition, we performed a covariate analysis, and the 
stability of our fi nal model was demonstrated by the bootstrap resampling method, which is 
considered to be a powerful internal validation technique.[28] Furthermore, the validity was 
confi rmed by the predictive check. Predictions of time that the paclitaxel > 0.1 µmol/L were 
similar to the observed values for all studied dose-levels (Table 3).[28] 
Several investigators have studied the pharmacokinetic/pharmacodynamic relation of 
paclitaxel with the emphasis on myelotoxicity. Most studies revealed a threshold model in 
which the myelotoxicity is related to the duration of exposure above a certain threshold 
value (0.05 or 0.1 µmol/L).[3,4] Furthermore, an improved survival in non-small cell lung 
cancer patients (stage IIIB and IV) with a plasma concentration above 0.1 µmol/L during a 
period longer than 15 hours was observed compared to patients in which this threshold value 
was shorter than 15 hours above 0.1 µmol/L.[5] Therefore, we initiated a study to investigate 
whether it is feasible to attain a duration of 15 hours or longer above the threshold value 
in all patients by pharmacokinetically guided dosing. For this dose-individualisation study 
we developed and validated this population model of paclitaxel. The population model 
is an empirical model since it is well known that the non-linear behaviour of paclitaxel is 
caused by the formulation vehicle Cremophor EL due to the formation of micelles in blood 
in vitro.[11-14] These micelles act as high-affi nity drug-transporting sites for paclitaxel that 
result in a decreased free paclitaxel fraction in plasma and a reduced uptake of paclitaxel 
in red blood cells.[11-15] The fi rst peripheral compartment in our population model might 
represent the Cremophor EL micelles in plasma according to the saturated transport to this 
compartment. The second peripheral compartment may be represented by the peripheral 
tissues. 
Recently, a mechanism-based population model was developed based on free and total 
paclitaxel concentrations in plasma, total blood concentrations, and Cremophor EL 
concentrations obtained in 26 patients.[29] Nevertheless, although this is a more physiologic 
model, it has not been validated. Since no free plasma and total blood concentrations were 
present in our data-set, and our empirical model has been proven to be stable and has a good 
performance, it will be used for a future dose-adaptation study in NSCLC patients treated 
with paclitaxel and carboplatin. The results of the predictive check showed that in 52% of 
the patients that received 175 mg/m2 of paclitaxel, the plasma concentration was higher than 
0.1 µmol/L longer than 15 hours. According to these results, a dose adaptation should be 
performed in 48% of the patients after the infusion of the fi rst course of paclitaxel.
In conclusion, we have shown that the non-linear pharmacokinetics of paclitaxel after 
a 3- and 24-hour intravenous infusion can accurately be described by the validated 
fi nal population pharmacokinetic model. This robust population model can be used in 
pharmacokinetically guided dosing of paclitaxel.
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A feasibility study of Bayesian pharmacokinetically guided dosing of 
paclitaxel in patients with non-small cell lung cancer
HJG Desirée van den Bongard, Ron AA Mathôt, Alwin DR Huitema, Hilde Rosing, 
Ciska Koopman-Kroon, Paul Baas, Nico van Zandwijk, Marianne Keessen, Jos H Beijnen 
and Jan HM Schellens
Summary
Relationships between the time above a threshold concentration of paclitaxel in plasma and 
the drug’s effi cacy and toxicity were previously reported in cancer patients. The purpose 
of this study was to evaluate the feasibility of Bayesian dose individualisation to attain 
paclitaxel plasma concentrations above 0.1 µmol/L during 15 hours or longer. Patients with 
non-small cell lung cancer were treated with paclitaxel and carboplatin. During the fi rst 
course, the standard dose (175 mg/m2) of paclitaxel was administered intravenously (iv) in 3 
hours. Carboplatin was administered iv in a dose calculated according to the Calvert formula 
with a target area under the concentration-time curve of 6 mg/ml*min. The paclitaxel dose 
was individualised in subsequent courses based on a previously developed population 
pharmacokinetic model of paclitaxel and on the observed paclitaxel concentrations in 
plasma during the previous course(s). The paclitaxel dosage was individualised to achieve a 
plasma concentration of 0.1 µmol/L during 15 hours or longer in the subsequent course.
At interim analysis, 11 patients had been included who received 44 evaluable courses. 
Eleven of these courses (fi rst course) consisted of standard dosing (175 mg/m2), and 33 were 
individualised courses (175 mg/m2 or higher). During the fi rst course, the time above the 
threshold concentration ranged from 11.6 to 31.6 hours; for 7 patients (64%) the duration of 
time above the threshold concentration was longer than 15 hours (range 15.4-31.6 hours). 
During the second course, the time above the threshold concentration was longer than 15 
hours in 9 of the 11 patients (82%) ranging from 17.6-25.3 hours. During the third course 
and subsequent courses, the drug threshold concentration was longer than 15 hours in 15 
of the 22 courses (68%). Dose increments, ranging from 180 to 295 mg/m2, were performed 
in 14 of the 33 individualised courses (4 in the second course). 
Toxicity consisted mainly of haematologic toxicity (granulocytopenia grade 3/4 in 82% of 
the patients). In conclusion, the preliminary results indicate that pharmacokinetically guided 
dosing of paclitaxel in the second course resulted in a higher percentage of patients with 
a duration of time that the paclitaxel concentration of 0.1 µmol/L was achieved during 15 
hours or longer compared to the fi rst course that consisted of standard dosing of paclitaxel. 
More patients will be included to demonstrate the feasibility of individualised dosing in 
subsequent courses.
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Introduction
Paclitaxel (Taxol®) is a taxane derivative that acts on microtubular structures by binding 
directly to tubulin, causing microtubular stabilisation that arrests cell division in the G2/M 
phase of the cell cycle. The drug has a profound antitumour activity against a variety of 
solid tumours, especially against lung, breast, ovarian, and head and neck tumours.[1,2] 
The combination of paclitaxel with a platinum compound is one of the combination 
chemotherapy schedules used in the treatment of patients with advanced non-small cell 
lung cancer (NSCLC).[3] To offset cisplatin-related toxicity, cisplatin has been substituted by 
carboplatin. In a randomised study of paclitaxel in combination with cisplatin or carboplatin, 
the latter combination revealed no signifi cant difference in survival and response rates.[3,4] 
Relationships between plasma pharmacokinetics and pharmacodynamics of paclitaxel have 
been reported in ovarian cancer patients whereby myelotoxicity was related to the time 
period in which paclitaxel concentrations in plasma were above 0.05 or 0.1 µmol/L.[5,6] In a 
retrospective analysis of a phase I study of 55 NSCLC patients, a longer survival was observed 
in patients with a time above a threshold paclitaxel concentration of 0.1 µmol/L longer 
than 15 hours, compared to the survival in patients in which the time above the threshold 
concentration was shorter than 15 hours.[7] The purpose of this study was to evaluate whether 
pharmacokinetically guided dosing is feasible to attain paclitaxel concentrations above 0.1 
µmol/L during 15 hours or longer and to document preliminary activity and toxicity of this 
approach in fi rst line of treatment with chemotherapy for advanced NSCLC.
Materials and methods
Patients
Chemonaive patients with histologically proven NSCLC stage IIIB or stage IV were included 
in the study. Eligibility criteria included: a performance status ≤ 2 on the World Health 
Organisation (WHO) scale, life expectancy of ≥ 3 months to allow adequate follow-up of 
toxicity, adequate haematopoietic (absolute neutrophil count ≥ 1.5*109/L, platelet count 
≥ 100*109/L), hepatic (total bilirubin ≤ 25 µmol/L), aspartate aminotransferase (AST), 
and alanine aminotransferase (ALT) ≤ 2.5 times the normal upper limit (in case of liver 
metastasis AST/ALT ≤ 5 times the normal upper limit) and renal function (serum creatinine 
≤ 140 µmol/L and creatinine clearance ≥ 50 ml/min). Exclusion criteria consisted of active 
bacterial infections, clinical signs of active brain tumour involvement or leptomeningeal 
disease, known alcoholism, drug addiction and/or psychotic disorders leading to inadequate 
follow-up, pregnancy or breast-feeding. Written informed consent was obtained from all 
patients. The study was approved by the Medical Ethics Committee of the Institute.
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Trial treatment
All courses consisted of carboplatin infusion in 30 minutes followed by paclitaxel in a 3-hour 
infusion. Paclitaxel (Taxol®, Bristol Myers Squibb, Syracuse, NY) was provided as a sterile 6 mg/
ml solution and dissolved in a mixture of Cremophor EL and dehydrated alcohol (1:1, v/v). Prior 
to administration, this solution was diluted with 500-1000 ml 0.9% sodium chloride solution 
to a fi nal paclitaxel concentration between 0.3 and 1.2 mg/ml. As Cremophor EL may leach 
plasticizer from the infusion lines, a PVC-free administration equipment was used. Carboplatin 
(Paraplatin®, Bristol-Myers Squibb, Syracuse, NY) was supplied as a lyophilised product in a 
vial containing 150 mg carboplatin and 150 mg mannitol as bulking agent. Immediately before 
use the content of each vial was reconstituted with 15 ml of water for injection, and the total 
dose was added to 5% dextrose for intravenous infusion. The reconstituted and diluted product 
was protected from light and administered as soon as possible after reconstitution. 
In each course, the carboplatin dosage was calculated according to the Calvert formula with 
a target area under the concentration-time curve (AUC) of 6 mg/ml*min and GFR is the 
glomerular fi ltration rate based on the 51CrEDTA-clearance determination:[8] 
( )25GFRAUC target =Dose free +⋅       equation 1
where dose is expressed in mg, AUC in mg/ml*min and GFR is expressed in ml/min.
The GFR is approximated by the creatinine clearance (CL), which in turn was estimated by 
the Cockcroft-Gault formula (CL
CR-CG
):[9]
( ) ( )femaleif85.0
S
bodyweightage-1401.23
=CL
CR
CG-CR ⋅
⋅⋅
 
   equation 2
where CL
CR-CG
 is expressed in ml/min, age in years, S
CR
 in µmol/L and weight in kg.
A previous study revealed that replacement of the GFR by the creatinine clearance as 
determined by CL
CR-CG
 resulted in an overestimation of the AUC with 10.9% compared to the 
observed AUC based on the concentration-time data.[10] Therefore, the Calvert formula was 
modifi ed by multiplying the CL
CR-CG
 with 1.1 ((CL
CR-CG
 +25)*1.1).
Standard premedication with dexamethasone (20 mg orally at 12 and 6 hours prior to 
paclitaxel administration), clemastine (2 mg iv 30 minutes prior to paclitaxel administration) 
and cimetidine (300 mg iv at 30 minutes prior to paclitaxel administration) was administered 
to prevent potential hypersensitivity reactions. Furthermore, a 5-HT
3
-receptor antagonist (1 mg 
granisetron) was iv infused as standard anti-emetic agent. Treatment was discontinued in case 
of patient’s refusal, non-compliance of the patient with the protocol, and progressive disease. 
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Pharmacokinetics and bio-analysis
Pharmacokinetic sampling was performed during all courses. During the fi rst course, whole 
blood samples were collected in heparinised tubes prior to start of the carboplatin infusion, 
at the end of the carboplatin infusion (=prior to start of the paclitaxel infusion), 1.5 hours 
after the start of the paclitaxel infusion, at the end of the paclitaxel infusion, 30 and 60 
minutes after the end of the paclitaxel infusion, 2, 4, 6, 9, and 19 hours after the end of the 
paclitaxel infusion. Plasma was obtained by centrifugation at 3000 rpm for 5 minutes. Plasma 
was transferred to polypropylene tubes and stored at approximately –20°C until analysis. 
During subsequent courses of paclitaxel, whole blood samples were obtained prior to the 
start of the paclitaxel infusion, at the end of the paclitaxel infusion, 9 and 19 hours after 
the end of the paclitaxel infusion. Plasma was obtained by centrifugation at 3000 rpm for 
5 minutes, and transferred to polypropylene tubes and stored at approximately –20°C until 
analysis of the paclitaxel concentrations. 
Paclitaxel was determined in plasma using a validated isocratic high-performance liquid 
chromatographic method with solid phase extraction as sample pre-treatment as previously 
described.[5,7,11] The quantitation range of the method was 10-10,000 ng/ml. 
Pharmacokinetically guided dosing
In the fi rst course, the paclitaxel treatment consisted of the standard dose of 175 mg/m2 (3-
hour iv infusion). In the second course and subsequent courses the paclitaxel dosage was 
individualised to achieve a plasma concentration of 0.1 µmol/L during 15 hours or longer after 
the start of the infusion. The dosage adaptation was performed with a validated population 
pharmacokinetic model of paclitaxel that will be published elsewhere. Briefl y, this population 
model was developed based on 100 concentration-time curves from 61 chemonaive NSCLC 
stage IIIB and IV patients (n=55) treated with paclitaxel (3-hour iv infusion) in combination 
with carboplatin and from advanced ovarian cancer patients (n=6), pre-treated with platinum, 
treated with paclitaxel (24-hour iv infusion) as single agent. The population pharmacokinetic 
parameter estimates are summarised in Table 1. This population model consists of a 3-
compartment model with saturable distribution to one peripheral compartment and Michaelis-
Menten elimination from the central compartment using non-linear mixed effect modelling 
(NONMEM, version V 1.1, double precision) (Figure 1).[12] The concentration-time data were 
logarithmically transformed. Inter-individual variability (IIV) and inter-occasion variability 
(IOV) were estimated using a proportional error model. IIV was quantifi ed for the volume 
of the central compartment (V), maximal transport rate from the central compartment to 
peripheral compartment 1 (Tmax) and the maximal elimination rate (Vmax). IOV was 
quantifi ed for the intercompartmental rate constants (k21, k13, k31) and Vmax. The residual 
variance was modelled using an additive error model with the assumption that the population 
was a mixture of two subpopulations (subpopulations 1 and 2) with a different variance. Body 
surface area (BSA) was signifi cantly correlated with V and Tmax (p < 0.005). 
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    Infusion 
            
                Tm  
      second peripheral              k13            central           Tmax                  first peripheral 
      compartment      compartment (V)            compartment 
     
 k31                                      k21 
Km
      Vmax  
        
Table 1. Population pharmacokinetic parameter estimates used for the Bayesian predictions 
Estimate  RSE (in %) 
Pharmacokinetic parameter 
 V (L) 
       Influence of BSA (θ12)a
12.1
1.16
5.4
33
   Tmax (µmol/h) 
       Influence of BSA (θ13)b
216
1.05
5.6
49
   Tm (µmol/L) 2.59 10 
   k21 (h-1) 0.916 7.0 
   k13 (h-1) 1.63 8.7 
   k31 (h-1) 0.0722 7.9 
   Km (µmol/L) 0.656 15 
   Vmax (µmol/h) 47.0 10 
   Population 1-2 0.380 27 
Inter-individual variability 
   IIV-V (%) 20 31 
   IIV-Tmax (%) 26 27 
   IIV-Vmax (%) 22 33 
Inter-occasion variability 
   IOV- k21 (%) 15 48 
   IOV- k13 (%) 26 25 
   IOV-k31 (%) 39 30 
   IOV-Vmax (%) 18 32 
Residual error 
   Additional error 1  0.202 11.0 
   Additional error 2 0.105 7.6 
a
 V = θ1 * (BSA /1.81)θ12
b
 Tmax = θ2 * (BSA /1.81)θ13
where BSA is expressed in m2, θ1 and θ2 represent the population value of V and Tmax respectively, of a patient 
with a (median) BSA of 1.81 m2, θ12 and θ13 are exponential factors. 
Additional error 1 = residual variability of subpopulation 1; Additional error 2 = residual variability of subpopulation 
2; BSA = body surface area; IIV = inter-individual variability; IOV = inter-occasion variability; k21 = rate constant 
from the first peripheral compartment to the central compartment; k13 = rate constant from the central to the 
second peripheral compartment; k31 = rate constant from the second peripheral to the central compartment; Km 
= plasma concentration at half Vmax; Population 1-2 = fraction of the patient population (n = 61) belonging to 
subpopulation 1; RSE = Relative standard error, Tmax = maximal transport rate from the central to the first 
peripheral compartment; Tm = plasma concentration at half Tmax; V = volume of the central compartment; Vmax 
= maximal elimination rate.
Figure 1. Three-compartment model with Michaelis-Menten elimination from the central compartment. Tmax is the maximal 
transport rate to the fi rst peripheral compartment, and Tm is the plasma concentration of paclitaxel at half Tmax. k21, k13 and 
k31 indicate the intercompartmental rate constants. Vmax is the maximal elimination rate, and Km is the plasma concentration of 
paclitaxel at half of the Vmax
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Bayesian estimates of the pharmacokinetic parameters were obtained using the POSTHOC 
option based on the population pharmacokinetic parameter values and the individual 
paclitaxel concentration-time data in the previous course(s). The obtained individual 
pharmacokinetic parameter estimates were used to predict the concentration-time data 
during the subsequent course after the administration of 175 mg/m2. The duration of time that 
the paclitaxel concentration > 0.1 µmol/L was derived from these predicted concentration-
time data. If the predicted duration of time of the paclitaxel plasma concentration above 0.1 
µmol/L would be shorter than 15 hours in the subsequent course, the paclitaxel dosage was 
increased (in 5 mg steps) until the predicted duration of time was 15 hours or longer. The fi t 
of the population model to the observed individual concentration-time data in this feasibility 
study, was evaluated by goodness of fi t plots. The goodness of fi t plots were examined in 
the program Xpose (Xpose, version 2.0, Uppsala University, Sweden) as implemented in the 
S-PLUS statistical package (version 2000, Mathsoft, Cambridge, Mass.).[13]
In addition, the theoretical values of the duration of time above the threshold concentration 
after the administration of 175 mg/m2, were simulated based on the calculated 
pharmacokinetic parameter estimates in each individual during courses with dose increment. 
The theoretical value was compared to the observed duration of time.
Patient evaluation
Pre-treatment evaluation included a complete medical history and complete physical 
examination (including neurologic examination). Before each course, an interim history 
including concomitant medications was taken, toxicities and performance status were 
recorded and a physical examination was performed. Haematology was checked weekly 
during all courses. Blood chemistry including liver and renal function, liver enzymes, serum 
electrolytes, total protein, albumin and glucose levels were checked weekly during the fi rst 
course. During subsequent courses blood chemistry was checked prior to each course. The 
observed toxicity was graded according to the National Cancer Institute Common Toxicity 
Criteria (NCI CTC).[14] Tumour measurement were performed every other cycle. Responses 
were evaluated according to the WHO criteria.[15] Standard tumour measurement procedures 
included CT scan, MRI, ultra sound imaging and/or histopathology.
Results
Patients 
At interim analysis, 11 patients with NSCLC stage IIIB or IV were entered in this dose 
individualisation study. Patient characteristics and serum parameter values before the 
administration of the fi rst course are summarised in Table 2. Patients included 3 females and 
8 males and had a median age of 59 years (range 43 to 73). One patient was pre-treated with 
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surgery, and 3 patients with radiotherapy. A total of 46 courses of paclitaxel and carboplatin 
was administered.
Pharmacokinetics and bio-analysis 
In total, 247 paclitaxel concentration-time points were obtained. The paclitaxel concentrations 
in plasma as obtained during the fi rst course are presented in Figure 2 (n=11). The duration 
of time that the paclitaxel concentration was > 0.1 µmol/L was not evaluable during 2 of 
the 46 courses (courses 3 and 4) in 1 patient due to dose reductions of 25% and 50% after 
granulocytopenia grade 4 complicated with fever during the second (175 mg/m2) and third 
course (130 mg/m2), respectively. Paclitaxel pharmacokinetics were studied during the fi rst 
Table 2. Pre-treatment characteristics of the patients (n=11) 
 Number Median value Range 
Patient characteristics 
   Female
   Male
3
8
  Age  59 43-73 
   WHO Performance status 
      0 
      1 
      2    
3
6
2
   Tumour stage 
      IIIB 
      IV 
2
9
   Histologic type 
      Squamous cell carcinoma 
      Adenocarcinoma 
      Large cell carcinoma 
4
3
4
   Pre-treatment 
      None 
      Prior chemotherapy    
      Radiotherapy 
      Surgical therapy 
8
0
3
a
1
b
   
   Intertreatment interval 
      <3 months 
      3-6 months 
      >6 months 
2
1
0
Biochemical parameters 
   
   BSA (m
2
)  1.90 1.63-2.06 
   Creatinine (µmol/L)  74 63-115 
   Total bilirubin (µmol/L) 6 3-15 
   Albumin (g/L) 39
d
 36-44 
   Alkaline Phosphatase (U/L) 111
c
 60-305 
   AST (U/L)  18 12-34 
   ALT (U/L)  20 7.8-44 
   GGT (U/L) 45 12-224 
   LDH (U/L)  379 243-776 
a
Local radiotherapy in 1 patient, radiotherapy on the skull and right humerus in 2 other patients.  
b
 Surgical extirpation of a cerebral tumour (metastasis). 
c
 n=10. 
AST = aspartate aminotransferase; ALT = alanine-amino transferase; BSA = Body surface area; BUN = blood 
urea nitrogen; GGT = gamma-glutamyl-transpeptidase; LDH = lactate dehydrogenase; WHO = World Health 
Organisation.
Desirée van den Bongard 14-10   159 15-10-2002, 10:40:24
160
Chapter 4.2.2
cycle (n=11), second cycle (n=11), third cycle (n=6), fourth cycle (n=6), fi fth cycle (n=5), 
and sixth cycle (n=5).
Pharmacokinetically guided dosing
Drug monitoring was performed during all courses (44 evaluable courses). In the second 
course and subsequent courses (33 courses), the paclitaxel dosage was individualised 
based on the observed concentrations in the previous course(s). Bayesian predicted 
concentrations were obtained based on the population pharmacokinetic parameters and the 
individual observed concentrations. Subsequently, the predicted time above the paclitaxel 
concentration of 0.1 µmol/L was derived from these Bayesian predicted concentrations. 
The goodness of fi t plots of the observed concentrations versus the model predicted 
concentrations and the Bayesian predicted concentrations during all courses are depicted 
in Figure 3. The Bayesian predicted concentrations were symmetrically distributed around 
the line of unity (Figure 3B). The model predictions were lower than the observed 
concentrations especially at higher concentrations (Figure 3A).
The dose individualisation resulted in the administration of a standard dose (175 mg/m2) 
or an increased dose, to achieve a plasma concentration of 0.1 µmol/L during 15 hours or 
longer after the start of the infusion. Dose increments ranging from 180 to 205 mg/m2 were 
performed in 14 of the 33 courses (in 7 patients). The duration of time that the paclitaxel 
concentration in plasma > 0.1 µmol/L for each course is summarised in Table 3. 
During the fi rst course (standard dose of 175 mg/m2), the drug threshold time > 0.1 µmol/L 
ranged from 11.6 to 31.6 hours. In 7 of these patients (64%), the duration of time was longer 
than 15 hours ranging from 15.4 to 31.6 hours. During the second course (individualised 
dose of 175 to 205 mg/m2), the paclitaxel concentration was above threshold during 15 
hours or longer in 9 of the 11 patients (82%) ranging from 17.6 to 25.3 hours (Figure 4). In 
Figure 2. Paclitaxel concentrations in plasma after the iv infusion of 175 mg/m2 during the fi rst course (n=11). The dashed lines repre-
sent the plasma concentration in plasma > 0.1 µmol/L and the time point at 15 hours after the start of the paclitaxel infusion
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the other 2 patients the observed time above the threshold concentration was 14.3 and 14.7 
hours. In 3 of the 4 patients in whom the duration of time above the threshold concentration 
was shorter than 15 hours during the fi rst course, it was accomplished to obtain a duration 
of time longer than 15 hours during the second course. Dose individualisation in the second 
course resulted in a higher median duration of time above the threshold concentration of 
0.1 µmol/L. Moreover, the lower limit of the duration that the threshold concentration was 
achieved, was higher in the second course compared to the fi rst course. During the third 
course and subsequent courses, the observed time above the threshold concentration was 
achieved in 15 of the 22 courses (68%) ranging from 15.1 to 26.3 hours. In the other 7 
Table 3. Median duration of time that paclitaxel concentration in plasma was above 0.1 µmol/L in each course
Course number Number of patients Number of individualised doses 
(dose in mg/m
2
)
Median duration of time (h) 
(range)
1 11 0 (175) 17.5 (11.6-31.6)
2 11 7 (175)
2 (180)
1 (200)
1 (205)
18.8 (14.3-25.3)
3 6 3 (175)
2 (180)
1 (200)
15.5 (11.5-26.3)
4 6 3 (175)
2 (180)
1 (190)
15.8 (12.4-17.5)
5 5 4 (175)
1 (195)
15.2 (12.2-18.3)
6 5 2 (175)
2 (180)
1 (195)
17.7 (10.9-19.6)
Figure 3. Goodness of fi t plots for the observed paclitaxel concentrations versus the model predictions of the paclitaxel concen-
trations (A) and the individual Bayesian predictions of the paclitaxel concentrations (B) (n=11). The solid line represents the line 
of identity
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courses the duration of time ranged from 10.9 to 14.9 hours. The low duration of 10.9 hours 
was observed in 1 patient during the sixth course despite the dose individualisation (180 
mg/m2). In this patient no dose increment was indicated during courses 2 to 5 according to 
the Bayesian predictions of the paclitaxel concentrations in plasma. However, the duration 
of time that the paclitaxel concentration was higher than 0.1 µmol/L was below 15 hours in 
each course (course 2: 14.3 h, course 3: 11.5 h, course 4: 12.4 h, course 5: 12.2 h). 
Figure 4. The duration of time that the paclitaxel in plasma was higher than 0.1 µmol/L in patients during course 1 after the 
administration of the standard dose (175 mg/m2) and after the administration of the individualised doses (175 mg/m2 or higher) 
during subsequent courses (A). The time above the threshold concentration in the fi rst 11 patients during the fi rst and the second 
course (B)
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The duration of time that the paclitaxel concentration was above 0.1 µmol/L after the 
administration of the standard dose (175 mg/m2), was simulated in 6 patients who received 
individualised doses higher than 175 mg/m2 (during 14 courses). In Figure 5, the simulated 
values of the duration of time in patients treated with the standard dose of 175 mg/m2 are 
compared to the duration of time after the administration of the increased dose (180-205 mg/
m2). After standard dosing (175 mg/m2) the simulated duration of time above the threshold 
concentration was shorter than 15 hours during 6 courses. In contrast, the observed duration 
of time above the threshold was shorter than 15 hours in only 2 courses. However, these 
results also show that in 8 of the 14 courses no dose individualisation was needed.
Patient evaluation
Toxicity
In the fi rst 11 patients, haematologic toxicity consisted mainly of granulocytopenia (range 
CTC grade 1 to 4). Both leukocytopenia and thrombocytopenia ranged from CTC grade 1 
to 3 (Table 4). Neutropenic fever was observed in 1 patient with granulocytopenia grade 
4 during the third course (175 mg/m2), necessitating hospitalisation and iv antibiotics. The 
baseline levels of white blood cells (WBC) and granulocytes (ANC) decreased during later 
courses resulting in more pronounced leukocytopenia and neutropenia during later courses 
(data not shown). A positive correlation between the haematologic toxicity and the duration 
of time that the paclitaxel concentration in plasma is higher than 0.1 µmol/L cannot be 
observed yet. This will be evaluated after all patients (n=25) have been included in the 
study. 
Non-haematologic toxicity consisted of alopecia CTC grade 1 and 2 after the fi rst course, 
neurotoxicity CTC grade 1 and 2 after the fi rst and sixth course, respectively, skin erythema 
CTC grade 1 after the fi rst course, and cystitis CTC grade 1 after the third course. Furthermore, 
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Figure 5. The simulated time above the threshold concentration after the administration of 175 mg/m2 compared to the observed 
time after dose increment
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gastro-intestinal complaints CTC grade 1 to 3 were observed. Toxicity was not more severe 
in courses with dose increment compared to courses without dose increment. 
Response
The observed tumour responses in 11 patients were: a confi rmed partial response in 1 
patient, stable disease in 5 patients and progressive disease in 5 patients. Two patients with 
NSCLC stage IV died after the second administration (2 and 18 days after the administration) 
due to progressive disease. The other 9 patients are still alive (at 3 to 8 months after the start 
of the fi rst course).
Discussion
The main purpose of this study was to demonstrate the feasibility of Bayesian 
pharmacokinetically guided dosing strategy of paclitaxel to achieve a drug concentration 
in plasma above 0.1 µmol/L during 15 hours or longer. A previously validated population 
pharmacokinetic model of paclitaxel generated by applying data of two other studies, 
was used to generate Bayesian predictions of the paclitaxel concentrations in plasma. 
Subsequently, the duration of time that the paclitaxel concentration in plasma > 0.1 µmol/L 
was derived from these individual Bayesian predicted concentrations. In this study we used 
this population model to predict the individual paclitaxel concentrations in subsequent 
courses based on the individual observed concentrations in previous courses. During each 
course, we were able to determine the paclitaxel concentration in plasma and determine the 
dose individualisation before the start of the subsequent course.
Table 4. Haematologic toxicity during all courses (n=45) 
Toxicity Course #1 
(n=11)
Course #2 
(n=10)
a
Course #3 
(n=7) 
Course #4 
(n=7) 
Course #5 
(n=5) 
Course #6 
(n=5) 
Leukocytes 
   Grade 1 
   Grade 2 
   Grade 3 
   Grade 4 
3
2
2
0
3
1
3
0
1
4
2
0
0
4
3
0
0
3
2
0
1
2
2
0
Granulocytes 
   Grade 1 
   Grade 2 
   Grade 3 
   Grade 4 
2
1
3
1
0
0
4
2
0
1
3
3
0
1
4
2
1
0
0
4
0
2
1
2
Platelets
   Grade 1 
   Grade 2 
   Grade 3 
   Grade 4
2
0
0
0
2
0
1
0
3
0
0
0
4
1
0
0
1
1
1
0
2
3
0
0
a
Toxicity was evaluable in 10 patients during the second course since one patient died at two days after the 
administration of the second course. 
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In Figure 4, the preliminary results of the fi rst 11 patients show that the Bayesian estimated 
concentrations are well predicted but the model predictions show some bias at higher 
concentrations. This may be attributed to differences in demographic characteristics and 
blood chemistry parameters of the two populations, i.e. the population to develop the 
model and the current population, and the relatively small number of patients that has been 
evaluated in the feasibility study until now. Since the Bayesian predictions are used for the 
dose adjustment, the dose individualisation results are not infl uenced by the bias of the 
model predictions. 
The preliminary results of this feasibility study show that dose individualisation during the 
second course results in a higher median duration of time that the paclitaxel concentration is 
above 0.1 µmol/L in plasma compared to the fi rst dose without dose individualisation (Table 
3 and Figure 4). The duration of time above the threshold concentration was attained in 9 of 
11 patients in the second course compared to 7 of 11 patients in the fi rst course. Until now, 
no increase in the duration of the threshold concentration can be observed in the third and 
subsequent courses compared to the duration of time after the fi rst course. This is probably 
due to small patient cohorts (n=6 and n=5). 
In 9 of the 33 individualised courses (27%) the dose individualisation did not result in a 
time above threshold longer than 15 hours. This can be attributed to the relatively high 
interoccasion variability of the pharmacokinetic parameters (15%-39%) resulting in a 
relatively high variation in the pharmacokinetic parameters of individuals between the 
courses. Therefore, dose individualisation can not result in a duration time above the 
threshold concentration longer 15 hours since the interoccasion variability can result in an 
increase or a decrease in the pharmacokinetic parameter estimates in the subsequent course. 
However, more patients and courses are needed to decide whether it is feasible to achieve 
the threshold concentration during the defi ned threshold time by dose individualisation. 
Moreover, in one patient with the relatively high BSA (2.1 m2) dose individualisation did not 
result in a time above the threshold concentration of 15 hours. This may be attributed to the 
BSA since only a few patients with BSA value higher than 2 m2 were included in the original 
patient population that was used for the development of the population pharmacokinetic 
model of paclitaxel. 
The severity of the bone marrow toxicity, especially granulocytopenia, increased during 
subsequent courses, but no relationship between the dose increments and severity of toxicity 
could be reported (data not shown). The primary toxicity was granulocytopenia that was 
more pronounced during later courses. This cumulative effect has already been observed in 
an earlier study with NSCLC patients treated with the combination chemotherapy paclitaxel 
and carboplatin.[7] Thrombocytopenia was mild (grade 0 to 2). Several other investigators 
reported a reduced platelet toxicity for the paclitaxel-carboplatin combination that can be 
attributed to the reduced uptake of platinum agents in cells due to the formulation vehicle 
of paclitaxel, Cremophor EL.[16,17] 
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The pharmacokinetics of paclitaxel are non-linear caused by Cremophor EL due to its 
formation of micelles in plasma. Paclitaxel is entrapped in these micelles and this results in a 
decreased free paclitaxel concentration in plasma and a reduced uptake of paclitaxel in red 
blood cells.[18-22] Several studies showed that the exposure-effi cacy relationship for paclitaxel 
can be best described by a threshold model.[5,7,23] But the relationship between the unbound 
drug concentration and toxicity or response have not been elucidated yet.
In conclusion, the preliminary results of this study show that Bayesian pharmacokinetically 
guided dosing of paclitaxel is feasible. In the second course, in 82% of the patients the 
drug threshold time above 0.1 µmol/L during 15 hours or longer compared to only 64% 
the fi rst course. In the third course and subsequent courses this was accomplished in 68% 
of the patients. In total, in 27% of the individualised doses the target drug threshold time 
was not achieved. Another 14 patients will be included in this study to investigate whether 
dose individualisation to attain the threshold concentration during 15 hours or longer can 
be feasible. Future directions should also focus on the pharmacokinetic-pharmacodynamic 
relationships of the unbound paclitaxel concentration. 
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Development and validation of a method to determine the unbound 
paclitaxel fraction in human plasma 
HJG Desirée van den Bongard, E Marleen Kemper, Olaf van Tellingen, Hilde Rosing, 
Ron AA Mathôt, Jan HM Schellens and Jos H Beijnen
Summary
Paclitaxel is pharmaceutically formulated in a mixture of Cremophor EL and ethanol (1:
1, v/v). The unbound fraction of the anticancer drug paclitaxel in plasma is dependent 
on both plasma protein binding as well as by entrapment in Cremophor EL micelles. We 
have developed a simple and reproducible method for the quantifi cation of the unbound 
paclitaxel fraction in human plasma. After the addition of 3H-paclitaxel and 14C-glucose 
(unbound reference), human plasma was spiked with paclitaxel and Cremophor EL and 
incubated at 37°C for 30 minutes. Plasma ultrafi ltrate was obtained by a micro partition 
system (MPS-1). A small amount of plasma (100 µl) in the collection cup prevented loss 
of paclitaxel due to adsorption. The radionuclides were separated after combustion of the 
biological samples using a sample oxidiser and the radioactivity was determined by liquid 
scintillation counting. The unbound fraction of paclitaxel was calculated by dividing the ratios 
of 3H and 14C in plasma ultrafi ltrate and in plasma. The method was precise, with a within-
day precision ranging from 3.9% to 11.0%. The between-day precision ranged from 5.8% to 
13.1% at pharmacologically relevant Cremophor EL and paclitaxel concentrations (ranging 
from 0.25% to 2.0% (v/v) and 10 to 1000 ng/ml, respectively). In patient plasma (spiked with 
100 ng/ml paclitaxel) with low serum albumin values containing 1% of Cremophor EL, the 
unbound fraction appeared to be signifi cantly higher than in plasma with normal albumin 
values. The determination of the unbound fraction of paclitaxel proved to be stable during 
a 10-week storage at –20°C. Furthermore, the assay was applicable in patient samples.
This assay can satisfactorily be used to determine the unbound fraction of paclitaxel in 
plasma and its design can also be used to determine the unbound concentrations of other 
hydrophobic drugs.
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Introduction
Paclitaxel is a taxane derivative that acts on microtubular structures, causing microtubular 
stabilisation that arrests the tumor cells in the G
2
/M phase of the cell cycle. Paclitaxel 
has shown profound antitumour activity against a variety of solid tumours, especially 
against lung, breast, ovarian, and head and neck tumours.[1,2] Due to the formulation 
vehicle Cremophor EL, the pharmacokinetics of paclitaxel are non-linear, as manifested 
by disproportional increases in both the maximal plasma concentration (C
max
) and the 
area under the plasma concentration-time curve (AUC) at higher doses.[3-7] It has been 
demonstrated that Cremophor EL can form micelles in blood in vitro, acting as a high-
affi nity drug-carrier site of paclitaxel. Consequently, the unbound paclitaxel concentration 
in plasma is lower at higher Cremophor EL concentrations in plasma.[4-6,8] Since the unbound 
drug concentration in blood can be the active fraction, measurement of total paclitaxel levels 
can result in inaccurate assessment of pharmacokinetic-pharmacodynamic relationships of 
paclitaxel. Therefore, it is important to measure the total paclitaxel concentration in plasma 
(= the sum of protein-bound, micellar encapsulated and unbound paclitaxel in plasma) in 
combination with the unbound fraction of paclitaxel.[9,10] In earlier studies, the unbound 
fraction of paclitaxel has been determined by equilibrium dialysis, however, the time to 
reach equilibrium ranged from 5 to over 64 hours.[4,5,11-13] The binding of paclitaxel to human 
plasma is approximately 95% at pharmacologically relevant concentrations, especially to 
human serum albumin and α-acid glycoprotein.[12] The purpose of this study was to develop 
an accurate and more rapid assay to determine the unbound fraction of paclitaxel in human 
plasma.
Materials and Methods
Chemicals and reagents
Paclitaxel reference standard was obtained from Bristol Myers Squibb (Syracuse, NY). 
Determination of unbound fraction of paclitaxel
A stock solution of paclitaxel at a concentration of 1 mg/ml in methanol was used to spike 
control human plasma (Central Laboratory for the Blood Transfusion Services, Amsterdam, 
The Netherlands) to obtain a concentration of 10,000 ng/ml of the drug. This plasma sample 
was stored at –20°C. Cremophor EL was obtained from Sigma Chemical Co. (St. Louis, MO, 
USA). Tritriated paclitaxel (3H-paclitaxel) was manufactured by Moravek Biochemicals Inc 
(Brea, CA, USA), and carbon-14 (14C)-radiolabelled glucose was manufactured by Amersham 
International Ltd. of Little Chalfont (Buckinghamshire, United Kingdom). Before use, 3H-
paclitaxel was purifi ed by an HPLC method. 3H-paclitaxel (specifi c activities between 17.4 
and 24.4 MBq/ml) was diluted in blank human plasma to a target concentration of 6670 
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Bq/ml. 14C-glucose (specifi c activity of 9.25 MBq/ml) was diluted in blank human plasma to 
a target concentration of 333 Bq/ml. Both solutions were mixed in a ratio of 1:1, v/v.
Scintillation fl uids, for the determination of the radioactivity levels, consisted of Monophase 
S, Permafl uor E+ and Carbo-Sorb (Packard Bioscience B.V., Groningen, The Netherlands). 
Cellulose was purchased from Sigma Chemical Co., St. Louis, MO, USA.
Determination of total paclitaxel concentration in plasma
Ethanol, ammonium acetate, glacial acetic acid, n-hexane and triethylamine were obtained 
from Merck (Darmstadt, Germany). Acetonitrile (HPCL gradient grade) was obtained from 
Biosolve Ltd. (Barneveld, The Netherlands), methanol (ChromAR®) was obtained from 
Promochem (Wesel, Germany).
Determination of unbound fraction of paclitaxel in plasma
Sample preparation
Blank human plasma was thawed and spiked with Cremophor EL to fi nal concentrations of 
0, 0.25, 0.5, 1.0 and 2.0% in triplicate (v/v). Aliquots of the 10,000 ng/ml paclitaxel plasma 
standard were added to obtain concentrations of 10, 100 and 1000 ng/ml. Subsequently, 3H-
paclitaxel and 14C-glucose (solutions in blank human plasma) were both added (10 µl per 
ml spiked plasma). All plasma samples were then incubated in a water bath at 37°C for 30 
minutes. Blank human plasma was incubated (in triplicate) to determine any background 
radiation in plasma and plasma ultrafi ltrate in each run. After the incubations, 500 µl of each 
plasma sample was transferred to an ultrafi ltration device, Amicon micropartition systems 
(Amicon Corporation, Danvers MA, USA) with membrane discs with a cut off level of 30,000 
MW (Millipore Corporation, Amicon, Beverly MA, USA). Subsequently, the ultrafi ltration 
devices were centrifuged at approximately 1500 g at 37ºC for 20 minutes yielding about 120 
µl plasma ultrafi ltrate. 
Measurement of radioactivity levels
One hundred µl of each plasma and plasma ultrafi ltrate sample was transferred to Combusto 
conesTM (Packard Bioscience B.V., Groningen, The Netherlands) fi lled with cellulose. 
The radionuclide content in all plasma and plasma ultrafi ltrate samples was separated in 3H 
and 14C by combustion of the samples in a sample oxidiser model 307 (Packard, Meriden, 
CT, USA). Scintillation fl uid was added by the oxidizer in 2 glass vials: Monophase S in the 
3H-vial, Permafl uor E+ and Carbo-Sorb in the 14C-vial. After manual mixing for 20 seconds, 
the radioactivities in the vials were measured using a (Tri-carb 2300 TR) liquid scintillation 
counter (Packard, Meriden, CT, USA). The disintegrations per minute (dpm) levels in each 
sample were counted for 15 minutes with quench correction by external standardisation. 
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Calculation of the unbound fraction
The 3H dpm levels in plasma (3H plasma) and plasma ultrafi ltrate (3H plasma ultrafi ltrate) 
were divided by the 14C concentrations in these samples (14C plasma and 14C plasma 
ultrafi ltrate, respectively). Subsequently, the unbound fraction of paclitaxel was calculated 
by the ratio between the 3H/14C ratio in plasma ultrafi ltrate and 3H/14C ratio in plasma: 
  
100
plasmaCH/
ateultrafiltrplasmaCH/
=fractionUnbound
143
143
⋅      equation 1
where the unbound fraction is expressed in %.
All dpm levels were corrected for the measured background levels in the corresponding 
blanks.
Validation procedures
A three-run validation was completed for the determination of the unbound fraction of 
paclitaxel in plasma. The validation involved the following assay parameters: precision 
(reproducibility and repeatability) and stability. Furthermore, infl uence of paclitaxel and 
Cremophor EL concentrations on the unbound paclitaxel fraction in plasma, and the infl uence 
of the albumin and total bilirubin levels on the unbound fraction was determined.
Calibration standards were not required since the unbound fraction was calculated by using 
equation 1. According to this equation, the limit of detection (LOD) and the lower limit of 
quantifi cation (LLQ) are related to the LLQ of the method to determine the total paclitaxel 
concentration in plasma. Since there are no standard samples for protein binding, it was not 
possible to test the accuracy of the assay.
To determine the infl uence of the Cremophor EL and paclitaxel concentrations on the 
unbound fraction of paclitaxel, 3.5 ml plasma was spiked with 1% Cremophor EL and 3.5 
ml plasma without Cremophor EL as a control in polypropylene tubes (in triplicate) in 
three separate runs. Subsequently, all plasma was spiked with paclitaxel, 3H-paclitaxel and 
14C-glucose as previously described. Plasma was incubated followed by ultrafi ltration and 
determination of the radioactivity levels. After calculation of the unbound fractions in all 
samples, the infl uence of Cremophor EL on the unbound fraction of paclitaxel in plasma 
was determined by the student’s t test with a signifi cance level of 0.01. The infl uence of 
the paclitaxel concentrations of 10, 100 and 1000 ng/ml on the unbound fraction was 
determined by one-way analysis of variance (ANOVA).
To determine the precision, six replicates of plasma spiked with Cremophor EL to a fi nal 
concentration of 0.25%, 1.0% and 2.0% were prepared with paclitaxel to a fi nal concentration 
of 100 ng/ml. Samples were processed as previously described. All samples were analysed 
in 3 separate analytical runs. The between-day precision (reproducibility) and within-day 
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precision (repeatability) were calculated for each concentration by ANOVA using the 
following equations:[14]
100
meanOverall
)MS(
=(WDP)PrecisionDay-Within
2/1
WG
⋅
    equation 2
where MS
WG 
= Mean Square Within Groups.
100
meanOverall
)/nMS-MS(
=(BDP)PrecisionDay-Between
2/1
WGBG
⋅
   equation 3
where MS
BG 
= Mean Square Between Groups and n = number of replicates within each 
day.
Hence, the between-day precision was expressed as the variance additional to the within-
day variance, resulting from analysing the samples in different runs. 
The unbound fraction of paclitaxel was determined in plasma of cancer patients (who were 
not treated with paclitaxel) with low serum albumin and/or high serum total bilirubin levels. 
The unbound fraction values in plasma with abnormal albumin and/or total bilirubin levels 
were compared to the unbound fraction in blank plasma. Five of these patients had a low 
serum albumin level (range 22-29 g/L [normal values: 44-56 g/L]), 3 of these patients had a 
high serum total bilirubin level (range 21-129 µmol/L [normal values: <16 µmol/L]), and 4 
of these patients had both high serum total bilirubin and low serum albumin levels (ranges 
18-31 µmol/L and 16-24 g/L, respectively). Whole blood samples were centrifuged at 2000 
g followed by transfer of plasma to Falcon tubes. Heparinised venous blood was obtained 
from 2 healthy volunteers. Blank plasma was obtained by centrifugation and was used as 
a reference. Patient and reference plasma was stored at -20ºC until analysis. After thawing, 
half of the plasma samples were spiked with Cremophor EL to a fi nal concentration of 1%, 
and half of the plasma samples was processed without Cremophor EL. All plasma samples 
were spiked with paclitaxel to a fi nal concentration of 100 ng/ml. The samples were further 
processed as described in the ‘Materials and methods’ section. In total, 5 replicates of each 
sample were analysed in 2 separate runs. The unbound paclitaxel fraction in plasma as 
determined in patient plasma was compared with that in normal plasma by regression 
analysis with a signifi cance value of 0.01.
Finally, stability was tested by the determination of the unbound fraction in plasma spiked 
with 100 ng/ml paclitaxel without and with Cremophor EL to a fi nal concentration of 2%. 
Six replicates of each sample were prepared and analysed at time zero according to the 
procedure as described in the ‘materials and methods’ section. The rest of the spiked 
plasma was stored in polypropylene tubes during 10 weeks at -20°C. After storage, samples 
were pre-treated and analysed as described previously. The unbound fraction values as 
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determined at 10 weeks were compared with the values as determined at day 0, and was 
not allowed to deviate more than 15% from the baseline value.
Patient samples
The unbound fraction of paclitaxel in plasma was determined in plasma samples obtained 
from a 74-year-old male patient with non-small cell lung cancer stage IIIB. The treatment 
consisted of 336 mg (3–hour iv infusion of 175 mg/m2) paclitaxel (Taxol®, Bristol Myers 
Squibb) and 630 mg (30-min iv infusion with target AUC 6 mg/ml*min) carboplatin 
(Paraplatin®). The patient was not pre-treated with any chemotherapeutic agents.
Paclitaxel was provided as a sterile 6 mg/ml solution in a mixture of Cremophor EL 
and dehydrated alcohol (1:1, v/v). Prior to administration, this solution was diluted with 
500 ml 0.9% sodium chloride solution. As Cremophor EL may leach plasticiser from the 
infusion lines, a PVC-free administration equipment was used. Standard pre-medication 
with dexamethasone (20 mg orally at 12 and 6 hours prior to paclitaxel administration), 
clemastine (2 mg iv 30 minutes prior to paclitaxel administration) and cimetidine (300 mg iv 
at 30 minutes prior to the paclitaxel administration) was administered to prevent potential 
hypersensitivity reactions caused by Cremophor EL. Furthermore, 5-HT
3
-receptor antagonists 
(1 mg granisetron) was iv infused as standard anti-emetic agent. Before treatment, the 
Eastern Co-operative Oncology Group performance status was 0 on the World Health 
Organisation scale, and the haematopoietic (white blood cells 6.6*109/L, platelets 280*109/
L) renal (serum creatinine 79 µmol/L), hepatic function and hepatic enzymes (serum total 
bilirubin 6 µmol/L, alkaline phosphatase 58 U/L, aspartate aminotransferase (AST) 16 U/L, 
and alanine aminotransferase (ALT) 25 U/L) were normal. Written informed consent was 
obtained before start of the treatment. 
Ten blood samples were collected by intravenous sampling from the arm opposite to the 
arm used for the infusion, just before the start of the infusion (blank), 1.5 hours after the 
start of the infusion, at the end of the infusion, and 30 minutes, 1, 2, 4, 6, 9 and 18 hours 
after the end of the infusion. Whole blood samples were centrifuged at 2000 g and plasma 
was transferred to polypropylene tubes, and stored at -20°C until analysis. 3H-paclitaxel and 
14C-glucose was added to all samples followed by the determination of the unbound fraction 
as previously described. The total paclitaxel concentrations in plasma were determined by 
an HPLC assay as described below.
Determination of total paclitaxel concentrations in plasma
A validated isocratic high-performance liquid chromatographic method was used for the 
quantitative determination of paclitaxel that has been published elsewhere.[9,10] Briefl y, 
aliquots of a paclitaxel stock solution (10 mg of paclitaxel reference material in 2.0 ml of 
ethanol) were added to blank human plasma to obtain plasma concentration standards 
with fi nal concentrations ranging from 10 to 10,000 ng/ml. 2’-methyl paclitaxel was used as 
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internal standard and samples were extracted on Cyano Bond Elut columns (1.0 ml; 100 mg, 
Varian, Palo Alto, CA, USA). The columns were fi rst conditioned with 2.0 ml of methanol 
and 0.01 M ammonium acetate buffer, pH 5.0. A volume of 1.0 ml of plasma diluted with 0.2 
M ammonium acetate buffer pH 5.0 (1:1, v/v) was transferred to the column. The columns 
were washed consecutively with 2.0 ml of methanol-0.01 M ammonium acetate, pH 5.0 
(2:8, v/v) and 1.0 ml of n-hexane. The columns were dried under maximum vacuum (15 
mm Hg) for 1 minute. The analytes were eluted from the columns with 2.0 ml of a mixture 
of acetonitrile-triethylamine (1,000:1, v/v). The eluent was evaporated to dryness under 
a nitrogen stream at 40°C. Samples were reconstituted with in a mixture of acetonitrile, 
methanol and distilled water (4:5:1, v/v) by vortex mixing for 1 minute. Detection was 
performed by UV absorbance measurement at 227 nm. Runtimes were approximately 
20 minutes. The calibration curves were calculated by weighted (1/x) linear regression 
analysis. 
Calculations
The unbound paclitaxel concentration in plasma was calculated by multiplying the unbound 
fraction with the total paclitaxel concentration in plasma, as described in equation 4:
  
ionconcentrat totalfractionunbound=ionconcentratUnbound ⋅    equation 4
where the unbound and total concentrations are expressed in ng/ml and the unbound 
fraction in %.
All statistical analyses were performed in the program Statistical Product and Service 
solutions (SPSS) for Windows, version 11.0 (SPSS, Chicago, IL, USA) with a signifi cance 
level of 0.01.
Results and discussion
Determination of the unbound fraction of paclitaxel in plasma
The MPS-1 system is a generally accepted method to determine the protein binding of drugs 
such as platinum agents.[15] However, adsorption of paclitaxel occurred rapidly when this 
hydrophobic substance was present in a protein-free environment such as ultrafi ltrate. To 
prevent adsorption of paclitaxel, the collection cups of the Amicon ultrafi ltration device were 
fi lled with 100 µl of blank plasma before ultrafi ltration. Since the yield of ultrafi ltrate varied 
from sample to sample it was essential to include an unbound reference compound. The 
recovery of 14C-glucose in plasma ultrafi ltrate after ultrafi ltration ranged from 95% to 101% as 
determined (in triplicate) in plasma spiked with paclitaxel (10-1000 ng/ml). Consequently, 
all 14C-glucose passed the fi ltration membrane and could be used as unbound reference in 
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this ultrafi ltration method. We have previously shown that Cremophor EL in plasma does 
not pass the ultrafi ltration membrane, in spite of the fact that the molecular weight of 3000 
is far less than the membrane cut off value of 30 kD.[5] In the fi rst instance, the radioactivity 
concentrations were determined by direct liquid scintillation counting using 2 channels for 
3H and 14C. However, the substantial overlap in the energy spectra of these radionuclides 
reduced the precision of the method. Complete separation of the 3H- and 14C-radionuclides 
was achieved after combustion of the samples in the sample oxidiser. 
We tested the applicability of the method using blank human plasma spiked with known 
amounts of Cremophor EL and paclitaxel. The values of the unbound fractions as determined 
(0 to 2% Cremophor EL and 100 ng/ml paclitaxel) are depicted in Figure 1 and are in 
agreement with previous results.[4,5,13] It was observed that the unbound fraction decreased 
at higher Cremophor EL in plasma. 
Validation procedure
The results of the infl uence of Cremophor EL and paclitaxel concentrations on the unbound 
fraction in plasma, are summarised in Table 1. The unbound fraction was signifi cantly higher 
(p < 0.0001) in all plasma samples without Cremophor EL (mean value 9.0%) compared to 
plasma with a Cremophor EL concentration of 1% (mean value 3.0%). The unbound fraction 
was not signifi cantly infl uenced by the paclitaxel concentration in plasma (p > 0.01). The 
results of the test for precision are summarised in Table 2. The within-day precision and 
the between-day precision for all samples were less than 13.1%. Consequently, the method 
has a suffi cient repeatability and reproducibility for clinical studies. The mean values of 
the unbound fraction were 5.9%, 2.8% and 2.0% for plasma containing 0.25%, 1% and 2% 
Cremophor EL, respectively. 
In Table 3, the infl uences of low albumin and/or high total bilirubin levels on the unbound 
fraction are summarised. For plasma containing 1% of Cremophor EL, a low serum albumin 
level (with and without elevated serum total bilirubin levels) signifi cantly increased the 
Figure 1. Unbound fraction values in plasma spiked with 100 ng/ml paclitaxel containing 0.25% to 2.0% Cremophor EL, and in 
spiked plasma without Cremophor EL (in triplicate, mean ± SD)
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unbound fraction in plasma (p = 0.005). Interestingly, however, for plasma containing 
no Cremophor EL the low serum albumin level had no signifi cant effect on the unbound 
fraction (p = 0.840). Elevated serum bilirubin level had no infl uence on the unbound 
fraction of paclitaxel either with or without Cremophor EL in plasma. 
Finally, the stability test showed that the mean values of the unbound fraction at 10 weeks 
after the preparation of the spiked samples were still 97.2% and 98.5% (for the Cremophor 
EL concentrations 0% and 2%, respectively) of the values as determined at the day of 
preparation. 
Patient samples
To show the applicability of the method we have determined the unbound fraction in 
plasma samples obtained from a cancer patient receiving an iv infusion of paclitaxel (175 
mg/m2). The unbound fraction ranged between 3.4% and 4.8% (Table 4). As expected, the 
Table 4. Unbound paclitaxel fraction in plasma of a patient treated with a  
3-hour intravenous infusion of 175 mg/m2 paclitaxel 
Time after start of the infusion (h) Unbound fraction (%) 
0 0
1.53 4.7 
3.42 3.4 
3.72 3.7 
4.03 3.5 
5.12 3.6 
7.02 3.4 
8.98 3.9 
11.20 4.2 
21.05 4.8 
Figure 2. Total (■) and unbound (■) paclitaxel concentrations in plasma of a patient treated with a 3-hour intravenous infusion 
of paclitaxel (175 mg/m2)
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unbound fraction in plasma was lowest at the end of the infusion and shortly after infusion 
due to the relatively high Cremophor EL concentration in plasma at these time points. 
The total paclitaxel concentrations ranged from 42.1 ng/ml and 3554 ng/ml, whereas the 
unbound paclitaxel concentrations ranged from 2.0 ng/ml to 121 ng/ml (Figure 2). 
Conclusions
The presented method to determine the unbound fraction of paclitaxel in plasma proved 
to be a precise method at pharmacologically relevant paclitaxel and Cremophor EL 
concentrations. In agreement with the equilibrium dialysis method, the unbound fraction 
decreased at higher Cremophor EL concentrations in plasma.[4,5,11] Furthermore, it was shown 
that the unbound fraction was signifi cantly increased at lower plasma albumin levels, but 
only when the sample contained Cremophor EL. The method proved to be applicable for 
patient samples.
If suitable radiolabelled tracers are available, the design of this method may also be 
applicable to determine unbound levels of other hydrophobic substances.
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Summary and Conclusions
Chemotherapy represents one of the main treatment modalities of advanced cancer. Despite 
signifi cant improvement in the treatment of advanced cancer over the past decades, tumour 
response rates and survival still need to be improved in patients with advanced cancer. 
Therefore, it is important to fi nd new anticancer agents with a novel mechanism of action 
and to further optimise existing treatment.
Introduction 
Anticancer agents have a narrow therapeutic window, which limits optimal dosing. 
Moreover, the interpatient pharmacokinetic variability is generally high because of 
variable drug absorption, distribution and elimination processes. In cancer treatment, 
most anticancer agents are administered at the maximum dose tolerated by the patient 
with a dose calculation based on body surface area (BSA) of the patient. Therapeutic 
drug monitoring (TDM) and the assessment of pharmacokinetic parameters allow the 
characterisation of relationships between pharmacokinetic parameters of anticancer agents 
and pharmacodynamics (therapeutic effi cacy and toxicity). Due to the narrow therapeutic 
window of anticancer agents and the high interpatient pharmacokinetic variability, 
pharmacokinetically guided administration of anticancer agents has been studied. In Chapter 
1, the current insights into pharmacokinetically guided administration of anticancer agents 
are reviewed. Pharmacokinetically guided administration, using pharmacokinetic parameters 
including area under the plasma concentration-time curve (AUC), steady-state plasma drug 
concentration (C
ss
), maximal plasma drug concentration (C
max
) and drug exposure time 
above a threshold plasma concentration, has been studied for many anticancer agents. 
Lower interpatient variation in pharmacokinetic parameters has been reported by applying 
pharmacokinetically guided administration of anticancer agents. In particular, the AUC-
guided administration of carboplatin has been extensively studied. The drug’s total body 
clearance is predominantly determined by glomerular fi ltration. Consequently, the AUC 
of carboplatin is better correlated with creatinine clearance than the BSA with creatinine 
clearance. Several formulae, limited sampling models and Bayesian analyses have been 
derived to predict the AUC of carboplatin. The application of these formulae results in 
less variability in AUC of carboplatin than administration per unit of BSA. The relationship 
between AUC and pharmacodynamics has also been studied for other anticancer agents, 
e.g. for cyclophosphamide, etoposide, fl uorouracil, topotecan. However, AUC-guided 
administration has only found wide clinical application for carboplatin. In current practice, 
the Calvert and Cockcroft-Gault formulae are widely used to calculate the carboplatin dose 
(based on a target AUC) and the glomerular fi ltration rate, respectively. 
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Relationships between pharmacodynamics and other pharmacokinetic parameters than 
AUC (C
ss
, C
max
 and drug exposure time above a defi ned threshold concentration) have been 
reported as well for anticancer agents, for example cisplatin, doxorubicin, methotrexate and 
paclitaxel. TDM is routinely used in the clinic only for methotrexate, to guide supportive 
measures in patients at high risk for developing signifi cant toxicity after the administration 
of intermediate and high-doses of methotrexate. 
The relationships between the pharmacokinetic parameters and the therapeutic effi cacy 
and toxicity need to be investigated in prospective randomised studies to validate 
pharmacokinetic-pharmacodynamic relationships before implementation of adaptive 
control algorithms in clinical practice.
E7070
The second chapter describes pharmacokinetic studies of E7070, a novel sulphonamide 
anticancer agent that arrests tumour cells in the G
1
-S phase of the cell cycle. Pharmacokinetic 
studies during phase I trials of E7070 revealed non-linear pharmacokinetics of the drug, as 
manifested by disproportional increase in systemic exposure to the drug at higher dose 
levels. A mass balance study was conducted to evaluate the excretion and pharmacokinetics 
of E7070 and its metabolite 1,4 benzene-sulphonamide (M1) in cancer patients after 
intravenous infusion of E7070 (Chapter 2.1.1). One thousand mg of E7070 was radiolabelled 
by carbon-14 (14C) in the benzenedisulphonamide moiety, or in the indole moiety. E7070 
exposure was signifi cantly higher than M1, consequently, M1 is only a minor metabolite 
in humans. The excretion of the benzene-sulphonamide and the indole moieties of E7070 
followed the same pattern with a higher renal than gastro-intestinal excretion. A high 
proportion of the radioactivity in human plasma, urine and faeces was represented by 
compounds other than E7070 and M1. Consequently, E7070 is extensively converted into 
currently unidentifi ed metabolites. Glucuronidation is a major metabolic pathway. 
A population analysis of the plasma concentration-time data as obtained in phase I 
studies, revealed that a three compartment model with non-linear distribution was best 
fi tted to the data. Therefore, we studied the in vitro distribution of E7070 in whole blood 
at pharmacologically relevant concentrations (Chapter 2.1.2). This study indicated that 
E7070 is preferentially bound to red blood cells, after incubation of the drug in whole 
blood. This binding was a saturable process at higher concentrations in whole blood. The 
plasma protein binding of E7070 was high (98-99%) without any evidence of saturation of 
protein binding with E7070 at the concentrations tested. Moreover, an in vitro and in vivo 
pharmacokinetic study of E7070 and acenocoumarol was performed since three patients 
treated with prophylactic daily oral maintenance therapy with acenocoumarol developed 
a haemorrhagic tendency and/or a prolonged prothrombin time following the intravenous 
administration of E7070. The study revealed that E7070 can interact with acenocoumarol 
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by reducing its metabolic clearance, and to a minor extent, by reducing the plasma protein 
binding of acenocoumarol (Chapter 2.2). The pharmacological research of E7070 will be 
continued. The knowledge about the elimination pathways of E7070 in humans is pivotal 
for the further development of the drug. Currently, metabolism studies and phase II trials 
are ongoing to identify the chemical structures of the metabolites, and to evaluate the 
antitumour activity in patients with solid tumours, respectively.
Methotrexate
High-dose methotrexate is used in combination chemotherapy schemes in the treatment 
of osteosarcoma, certain non-Hodgkin lymphomas and acute lymphocytic leukaemia. 
Methotrexate, an antimetabolite, is primarily converted to 7-hydroxy-methotrexate. The 
pharmacokinetics of methotrexate and 7-hydroxy-methotrexate vary considerably among 
patients. Both compounds can cause renal and hepatic toxicity. Serum methotrexate levels 
above 0.1 µmol/L at 48 hours after iv drug administration are considered to be toxic and 
require intensifi cation of the rescue therapy. In Chapter 3.1, we presented a patient with 
methotrexate-induced renal failure. The methotrexate levels in serum were higher than 
0.1 µmol/L during a long period of 12 days (Chapter 3.1). Intensifi cation of the leucovorin 
rescue therapy and the initiation of thymidine rescue therapy proved to be successful, 
and further toxicity was prevented. An integrated population pharmacokinetic model of 
methotrexate and 7-hydroxy-methotrexate was developed to study the pharmacokinetics of 
both compounds (Chapter 3.2). An integrated three-compartment model for methotrexate 
and a two-compartment model for 7-hydroxy-methotrexate was applied with fi rst-order 
elimination of methotrexate from the central compartment and fi rst-order elimination of 7-
hydroxy-methotrexate from the central metabolite compartment. The infl uence of covariates 
(age, gender, BSA, performance status according to the World Health Organisation (PS), 
serum creatinine, serum alanine-aminotransferase (ALT), serum aspartate-aminotransferase 
(AST), serum alkaline phophatase, serum albumin, serum bilirubin and serum lactate 
dehydrogenase (LDH), concomitant use of gastric hydrogen pump inhibitors, salicylates 
and non-steroidal anti-infl ammatory drugs (NSAIDs), and presence of pleural effusion or 
ascites) on the pharmacokinetic parameters was tested using univariate and multivariate 
analyses. Although several covariates, e.g. the presence of pleural effusion or ascites, 
concomitant use of gastric hydrogen pump inhibitors and NSAIDs, are known to infl uence 
the pharmacokinetics of methotrexate, no signifi cant infl uence of any covariate on the 
pharmacokinetic parameters could be identifi ed. Furthermore, the methotrexate and 7-
hydroxy-methotrexate concentrations were determined in pleural effusion as obtained in 
patients with a pleural drain. The methotrexate fraction that diffused to the pleural effusion 
appeared to be very low. 
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This population model may aid further research to elucidate the relationship between the 
pharmacokinetics of both compounds and pharmacodynamics (therapeutic effi cacy and 
toxicity) and possible drug-drug interactions. 
Paclitaxel
Paclitaxel is a taxane derivative that acts on microtubular structures by binding directly 
to tubulin, causing microtubuli stabilisation that arrests tumour cells in the G
2
-M phase 
of the cell cycle. Taxol® is the pharmaceutical product in which paclitaxel is dissolved in 
a mixture of Cremophor EL and ethanol (1:1, v/v). The pharmacokinetics of paclitaxel 
are non-linear, as manifested by a disproportional increase in both the maximal plasma 
concentration and the area under the plasma concentration-time curve at higher doses. In 
vitro studies have demonstrated that Cremophor EL can form micelles in plasma, acting as 
a high-affi nity drug-transporting site for paclitaxel. Consequently, Cremophor EL causes 
a decreased unbound paclitaxel fraction in plasma and a reduced uptake of paclitaxel in 
red blood cells. A population pharmacokinetic model of Cremophor EL, was developed to 
study the pharmacokinetics of Cremophor EL in patients treated with paclitaxel dissolved in 
Cremophor EL (Chapter 4.1). The Cremophor EL plasma concentration-time data were most 
optimally described by a three-compartment model with linear distribution and Michaelis-
Menten elimination from the central compartment. The infl uence of the covariates (age, 
gender, weight, BSA, PS, serum creatinine, ALT, AST, AF, serum gamma-glutamyltransferase 
(GGT), serum albumin, serum bilirubin and LDH) on the pharmacokinetic parameters was 
studied using univariate and multivariate analyses. Gender, BSA and PS were signifi cantly 
correlated with the volume of the central compartment, the fi rst peripheral compartment 
and the maximal elimination rate of Cremophor EL, respectively. The stability of the 
fi nal population model was demonstrated using a bootstrap procedure. The developed 
population model of Cremophor EL can be used to further explore the relationships 
between the pharmacokinetics of Cremophor EL and its toxicity. 
A method for the quantifi cation of the unbound paclitaxel fraction in human plasma was 
developed and validated using pharmacologically relevant Cremophor EL and paclitaxel 
concentrations (Chapter 4.3). The method was precise: the within-day precision ranged from 
3.9% to 11%, the between-day precision ranged from 5.8% to 13%. The unbound fraction 
appeared to be signifi cantly higher in plasma with low serum albumin values compared 
to plasma with normal serum albumin values (containing 1% of Cremophor EL). The 
determination of the unbound fraction proved to be stable during a 10-week storage at –
20°C. The assay was found applicable to determine the unbound concentration of paclitaxel 
in samples of a cancer patient treated with paclitaxel. The design of this assay can also be 
used to determine the unbound concentrations of other hydrophobic drugs. 
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A population pharmacokinetic model for paclitaxel was developed to describe the 
pharmacokinetics in patients with advanced non-small cell lung cancer and ovarian cancer 
(Chapter 4.2.1). The plasma concentration-time data were best described by a three-
compartment model with saturable transport to one peripheral compartment and Michaelis-
Menten elimination from the central compartment. The relationships between covariates 
(age, gender, weight, BSA, PS, serum creatinine, ALT, AST, serum alkaline phosphatase, GGT, 
serum bilirubin, LDH and serum albumin) and the pharmacokinetic parameters of paclitaxel 
were tested using univariate and multivariate analyses. BSA of the patient was signifi cantly 
correlated with the volume of the central compartment and the maximal transport rate from 
the central compartment to the fi rst peripheral compartment. The robustness of the fi nal 
population model was demonstrated using a bootstrap procedure. This population model 
of paclitaxel was used to evaluate the feasibility of Bayesian dose individualisation to attain 
paclitaxel plasma concentrations above 0.1 µmol/L during 15 hours or longer in each course 
(Chapter 4.2.2). The fi rst course consisted of standard dosing of paclitaxel (175 mg/m2, 3-
hour iv inf). The paclitaxel dosage was individualised in subsequent courses based on a 
previously developed population pharmacokinetic model of paclitaxel and on the observed 
paclitaxel concentrations in plasma during the previous course(s). The preliminary results of 
the fi rst eleven patients indicate that pharmacokinetically guided dosing of paclitaxel results 
in a higher percentage of patients in whom the duration of exposure above the threshold 
concentration is 15 hours or longer in the second course (individualised dose), as compared 
to the fi rst course (standard dose). However, more patients will be included to demonstrate 
the feasibility of individualised dosing in the third course and subsequent courses. 
Final remarks
The analyses described in this thesis have provided detailed insight into the pharmacokinetics 
of the novel anticancer agent E7070 and the widely applied cytotoxic agents paclitaxel and 
methotrexate. The results may turn out to be of great help to optimise the clinical application 
of these anticancer agents.
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Samenvatting en conclusies
Cytostatica (antikanker middelen) zijn één van de belangrijkste behandelingsmethoden 
van kanker. Ondanks een aanzienlijke verbetering in de behandeling van gemetastaseerde 
(uitgezaaide) kanker in de afgelopen decennia, kunnen het tumorrespons percentage en 
de overleving nog steeds worden verbeterd in deze patiënten. Daarom is het belangrijk 
om cytostatica te ontdekken met een nieuw werkingsmechanisme en het gebruik van de 
bestaande cytostatica te optimaliseren.
 
Introductie
Cytostatica hebben een smalle therapeutische breedte, met andere woorden de optimale 
dosering wordt beperkt door het optreden van bijwerkingen. De farmacokinetiek kan 
grote variabiliteit vertonen tussen patiënten, dat wil zeggen dat de concentraties van het 
geneesmiddel (bijvoorbeeld de bloedspiegels van het geneesmiddel) uitgezet tegen de tijd, 
sterk kunnen verschillen door de onderlinge variatie in opname, distributie (verdeling) over 
het lichaam en eliminatie (uitscheiding en omzetting) van de middelen. De meeste cytostatica 
worden gedoseerd aan de hand van de maximaal getolereerde dosis door de patiënt, 
waarbij de dosisberekening plaatsvindt aan de hand van het lichaamsoppervlakte van de 
patiënt. Het bepalen van de plasma- of serumconcentraties na toediening van cytostatica en 
de berekening van de farmacokinetische parameters van cytostatica, maken het mogelijk 
om de relaties tussen de farmacokinetiek en de farmacodynamiek (therapeutisch effect en 
bijwerkingen) te onderzoeken. Vanwege de smalle therapeutische breedte van cytostatica 
en de hoge variabiliteit in farmacokinetiek tussen patiënten, is doseren op geleide van 
de farmacokinetiek onderzocht. In Hoofdstuk 1 wordt een overzicht gegeven van de 
huidige inzichten met betrekking tot doseren op geleide van de farmacokinetiek. Bij deze 
manier van doseren kan gebruik worden gemaakt van farmacokinetische parameters als 
oppervlakte onder de plasma concentratie-tijd curve (AUC), stabiele plasma concentratie 
(C
ss
), maximale plasma concentratie (C
max
) en de duur van de blootstelling boven een 
bepaalde plasma concentratie van het cytostaticum. Deze parameters zijn bestudeerd 
voor vele cytostatica. Door het doseren op geleide van de farmacokinetiek wordt de 
variabiliteit in farmacokinetische parameters tussen patiënten kleiner. De dosering op 
geleide van het oppervlakte onder de plasma concentratie-tijd curve van carboplatine 
is uitgebreid onderzocht. De klaring van carboplatine wordt met name bepaald door de 
glomerulusfi ltratie in de nieren. Hierdoor is het oppervlakte onder de plasma concentratie-
tijd curve van carboplatine beter gecorreleerd met de creatinineklaring dan met de dosis 
per eenheid lichaamsoppervlakte. Verscheidene formules, methoden waarbij slechts enkele 
bloedmonsters hoeven worden afgenomen (‘limited sampling’ technieken) en Bayesian 
analyses zijn ontwikkeld om de AUC van carboplatine te voorspellen. De toepassing van 
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deze formules resulteert in minder variabiliteit in de AUC van carboplatine in vergelijking met 
toediening per eenheid lichaamsoppervlakte. De relatie tussen de AUC en farmacodynamiek 
is ook onderzocht voor andere cytostatica, bijvoorbeeld voor cyclofosfamide, etoposide, 
fl uorouracil en topotecan, maar AUC-geleide dosering wordt tot nu toe in de kliniek alleen 
voor carboplatine gebruikt. In de huidige praktijk worden de Calvert en Cockcroft-Gault 
formules gebruikt om de carboplatine dosering (gebaseerd op een van tevoren vastgestelde 
AUC) respectievelijk de glomerulusfi ltratiesnelheid te berekenen. Relaties tussen de 
farmacodynamiek en andere farmacokinetische parameters dan AUC (C
ss
, C
max
 en de duur 
van de blootstelling boven een bepaalde plasma concentratie) zijn gebruikt voor cytostatica, 
bijvoorbeeld cisplatine, doxorubicine, methotrexaat en paclitaxel. Het bepalen van de 
cytostatica concentraties in serum wordt echter alleen toegepast na het toedienen van 
methotrexaat (intermediaire en hoge doseringen). De relaties tussen de farmacokinetische 
parameters en het therapeutisch effect en toxiciteit zullen verder onderzocht moeten worden 
in prospectieve, gerandomiseerde studies om de farmacokinetiek-farmacodynamiek relaties 
te valideren, voordat de algoritmen voor een dosisaanpassing kunnen worden toegepast in 
de klinische praktijk.
E7070
Het tweede hoofdstuk beschrijft farmacokinetische studies van E7070, een nieuw cytostaticum 
waarvan de chemische structuur is gebaseerd op een sulfonamide. E7070 remt tumorcellen 
in de overgang van de G1- naar de S-fase van de celcyclus. Uit farmacokinetische studies, 
gedurende preklinische studies en fase I studies van E7070, bleek dat de farmacokinetiek 
niet-lineair is, gezien de meer dan evenredige verhoging van de systemische blootstelling 
bij hogere doseringen. Om de excretie (uitscheiding) en farmacokinetiek van E7070 
en de metaboliet (omzetproduct) 1,4 benzeen-sulfonamide (M1) in kankerpatiënten te 
onderzoeken, werd een massabalans studie uitgevoerd na intraveneuze toediening van 
E7070 (Hoofdstuk 2.1.1). Duizend mg E7070 werd radioactief gelabeld met koolstof-14 (14C) 
in de benzeendisulfonamide ring of in de indool ring. De systemische blootstelling aan 
E7070 was hoger dan die aan M1, dus E7070 wordt slechts in beperkte mate omgezet in M1. 
De excretiepatronen van de benzeen-sulfonamide ring en de indool ring van E7070 waren 
hetzelfde, namelijk een hogere excretie via de nier dan via de darmen. Een groot gedeelte 
van de radioactiviteit in plasma, urine en faeces werd niet verklaard door E7070 en M1. 
Hieruit volgt dat E7070 in hoge mate wordt omgezet in tot nu toe nog niet geïdentifi ceerde 
metabolieten van E7070. Voor deze metabolieten blijkt glucuronidatie een belangrijke route 
te zijn.
Uit een populatieanalyse van de plasma concentratie-tijd data, zoals verkregen in de Fase I 
studies, bleek dat de data het beste werden beschreven door een drie-compartimentenmodel 
met niet-lineaire distributie. Gezien de verzadigbare distributie van E7070, hebben we 
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de in vitro distributie van E7070 in volbloed onderzocht bij farmacologisch relevante 
concentraties (Hoofdstuk 2.1.2). Uit deze studie bleek dat E7070, na incubatie in volbloed, 
met name wordt gebonden aan rode bloedcellen waarbij een verzadiging van de rode 
bloedcellen optrad bij hoger incubatieconcentraties. De plasma-eiwitbinding van E7070 
was hoog (98-99%) en lineair bij verschillende incubatieconcentraties. Tevens hebben we 
in vitro en in vivo farmacokinetische studies van E7070 en acenocoumarol uitgevoerd, 
omdat drie patiënten die dagelijks werden behandeld met acenocoumarol, een verhoogde 
bloedingsneiging vertoonden en/of een verlengde protrombinetijd (tijd die nodig is om 
bloed te laten stollen) hadden nadat E7070 was toegediend. Uit deze studie bleek dat E7070 
een geneesmiddeleninteractie kan vertonen met acenocoumarol door het verminderen van 
de metabole klaring van acenocoumarol en in mindere mate, door het verminderen van de 
plasma-eiwitbinding van acenocoumarol (Hoofdstuk 2.2).
Het farmacologisch onderzoek van E7070 zal worden voortgezet. De kennis omtrent 
de eliminatieroutes van E7070 na toediening aan mensen, is belangrijk voor de verdere 
ontwikkeling van het cytostaticum. Er worden nu studies uitgevoerd waarbij het metabolisme 
verder wordt opgehelderd en waarin de antitumor werking van E7070 in patiënten wordt 
onderzocht (fase II studies).
Methotrexaat
Toediening van hoge dosis methotrexaat, in combinatie met andere cytostatica, wordt gebruikt 
bij de behandeling van patiënten met onder andere osteosarcoom, non-Hodgkin lymfomen 
en acute lymfatische leukemie. Methotrexaat is een antimetaboliet en wordt met name 
omgezet in 7-hydroxy-methotrexaat. De farmacokinetiek van methotrexaat en 7-hydroxy-
methotrexaat varieert in sterke mate tussen patiënten. Beide stoffen kunnen toxiciteit aan 
de nieren en aan de lever veroorzaken. Methotrexaat concentraties in serum die hoger zijn 
dan 0,1 µmol/L 48 uur na de toediening van methotrexaat worden als toxisch beschouwd en 
hierbij wordt de anti-toxiciteitsbehandeling geïntensifeerd. In Hoofdstuk 3.1 is een patiënt 
met nierschade beschreven, hetgeen werd veroorzaakt door methotrexaat. De methotrexaat 
concentraties in serum waren hoger dan 0,1 µmol/L gedurende 12 dagen. Verhoging van 
de leukovorin behandeling en start van de thymidine behandeling bleek succesvol te 
zijn waardoor verdere toxiciteit werd voorkomen. Een geïntegreerd populatiemodel van 
methotrexaat en 7-hydroxy-methotrexaat werd ontwikkeld om de farmacokinetiek van 
beide stoffen te onderzoeken (Hoofdstuk 3.2). De serum concentratie-tijd data van beide 
stoffen werden het beste beschreven door een geïntegreerd drie-compartimentenmodel voor 
methotrexaat en een twee-compartimentenmodel voor 7-hydroxy-methotrexaat met eerste 
orde eliminatie van methotrexaat vanuit het centrale compartiment en eerste orde eliminatie 
van 7-hydroxy-methotrexaat vanuit het centrale metaboliet compartiment. De invloed 
van co-variabelen (leeftijd, geslacht, lichaamsoppervlakte, performance status volgens de 
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Wereld Gezondheids Organisatie (PS), serum creatinine, serum alanine-aminotransferase 
(ALAT), serum aspartaat-aminotransferase (ASAT), serum alkalische fosfatase (AF), serum 
albumine, serum bilirubine en serum lactaat dehydrogenase (LDH), gelijktijdig gebruik 
van protonpompremmers, salicylaten en NSAID’s en de aanwezigheid van pleuravocht of 
ascites) op de farmacokinetiek werd bestudeerd met behulp van univariaat en multivariaat 
analyses. Alhoewel van verscheidene co-variabelen, bijvoorbeeld de aanwezigheid van 
pleuravocht of ascites, gelijktijdig gebruik van protonpompremmers en NSAID’s, bekend is 
dat ze de farmacokinetiek van methotrexaat kunnen beïnvloeden, werd er geen signifi cante 
invloed van de co-variabelen op de farmacokinetische parameters van methotrexaat en 7-
hydroxy-methotrexaat gevonden. Tevens werden de concentraties van methotrexaat- en 7-
hydroxy-methotrexaat bepaald in pleuravocht van patiënten met een pleuradrain. De fractie 
methotrexaat die naar pleuravocht diffundeerde bleek erg laag te zijn.
Dit populatiemodel kan gebruikt worden om de relaties tussen de farmacokinetiek van 
methotrexaat en 7-hydroxy-methotrexaat en farmacodynamiek en mogelijke geneesmiddel
eninteracties verder op te helderen.
Paclitaxel
Paclitaxel behoort tot de groep taxanen. Taxol® is het farmaceutisch product waarin 
paclitaxel is opgelost in een mengsel van Cremophor EL en ethanol (1:1, v/v). De 
farmacokinetiek van paclitaxel is niet-lineair, hetgeen blijkt uit een meer dan evenredige 
verhoging van zowel de C
max
 als de AUC bij hogere doseringen. In vitro studies hebben laten 
zien dat Cremophor EL micellen kan vormen in plasma, waaraan paclitaxel kan binden. Dit 
heeft tot gevolg dat Cremophor EL een verlaagde ongebonden paclitaxel fractie in plasma 
veroorzaakt en een verlaagde opname van paclitaxel in rode bloedcellen. Een populatie 
farmacokinetisch model van Cremophor EL werd ontwikkeld om de farmacokinetiek van 
Cremophor EL te bestuderen in patiënten die werden behandeld met Taxol® (Hoofdstuk 
4.1). De Cremophor EL concentraties in plasma zoals gemeten voor, tijdens en na toediening 
van Taxol®, werden het beste beschreven door een drie-compartimentenmodel met 
lineaire distributie en Michaelis Menten eliminatie vanuit het centrale compartiment. De 
invloed van de co-variabelen (leeftijd, geslacht, gewicht, lichaamsoppervlakte, PS, serum 
creatinine, ALAT, ASAT, AF, gamma-glutamyltransferase (γ-GT), serum albumine, serum 
bilirubine en LDH) op de farmacokinetische parameters was onderzocht met behulp van 
univariaat en multivariaat analyses. Geslacht was signifi cant gecorreleerd aan het volume 
van het centrale compartiment, lichaamsoppervlakte aan het volume van eerste perifere 
compartiment en PS aan de maximale eliminatiesnelheid van Cremophor EL. De stabiliteit 
van het fi nale populatiemodel werd bewezen met behulp van een ‘bootstrap’ procedure. 
Dit populatiemodel van Cremophor EL kan worden gebruikte om de relaties tussen de 
farmacokinetiek en toxiciteit verder te onderzoeken.
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Een methode om de ongebonden fractie paclitaxel in humaan plasma te bepalen, werd 
ontwikkeld en gevalideerd met farmacologisch relevante Cremophor EL en paclitaxel 
concentraties (Hoofdstuk 4.3). De intra- en inter-dag precisie was kleiner dan 11% 
respectievelijk 13%. De ongebonden fractie bleek signifi cant hoger te zijn in plasma 
verkregen in patiënten met lage serum albumine waarden (waaraan 1% Cremophor EL was 
toegevoegd) in vergelijking met plasma met normale serum albumine waarden. De bepaling 
van de ongebonden fractie was stabiel gedurende 10 weken opslag bij -20°C. De methode 
kon worden toegepast om de ongebonden paclitaxel fractie te bepalen in plasmamonsters 
verkregen in een patiënt die werd behandeld met paclitaxel. De opzet van deze methode 
kan ook worden gebruikt bij het bepalen van de ongebonden fractie van andere hydrofobe 
middelen.
Een populatie farmacokinetisch model voor paclitaxel werd ontwikkeld om de 
farmacokinetiek in patiënten met gemetastaseerde longkanker en eierstokkanker te 
beschrijven (Hoofdstuk 4.2.1). De plasma concentratie-tijd data werden het beste 
beschreven met een drie-compartimentenmodel met verzadigbaar transport naar één van 
de perifere compartimenten en Michaelis-Menten eliminatie naar het centrale compartiment. 
De relaties tussen de co-variabelen (leeftijd, geslacht, gewicht, lichaamsoppervlakte, PS, 
serum creatinine, ALAT, ASAT, AF, γ-GT, serum bilirubine, LDH en serum albumine) en 
de farmacokinetische parameters van paclitaxel werden getest met behulp van univariaat 
en multivariaat analyses. Het lichaamsoppervlakte was signifi cant gecorreleerd met 
het volume van het centrale compartiment en de maximale transportsnelheid van het 
centrale compartiment naar het eerste perifere compartiment. De stabiliteit van het fi nale 
populatiemodel werd bewezen met een ‘bootstrap’ procedure. Dit populatiemodel van 
paclitaxel werd vervolgens gebruikt om de haalbaarheid van een dosisindividualisatie-
studie te testen. In deze studie werd de dosis geïndividualiseerd om in elke kuur een 
paclitaxel concentratie in plasma boven 0,1 µmol/L gedurende 15 uur of langer te kunnen 
bereiken (Hoofdstuk 4.2.2). De eerste kuur bestond uit een standaarddosis van paclitaxel 
(175 mg/m2, 3-uurs infuus). De paclitaxeldosering werd aangepast in volgende kuren op 
basis van het ontwikkelde populatiemodel van paclitaxel en op basis van de geobserveerde 
paclitaxelconcentraties in plasma gedurende de vorige ku(u)r(en). De voorlopige resultaten 
van de eerste 11 patiënten laten zien dat doseren op geleide van farmacokinetiek resulteert 
in een hoger percentage patiënten met een duur waarin de beoogde concentratie wordt 
bereikt gedurende 15 uur of langer, in vergelijking met patiënten gedurende de eerste kuur. 
Meer patiënten zullen geïncludeerd worden, om de haalbaarheid van de studie gedurende 
alle kuren te evalueren.
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Slotopmerkingen
De analyses die in dit proefschrift zijn beschreven, laten een gedetailleerd overzicht zien 
van de farmacokinetiek van het nieuwe cytostaticum E7070 en de veelgebruikte cytostatica 
paclitaxel en methotrexaat. De resultaten die zijn beschreven in dit proefschrift kunnen 
hopelijk gebruikt worden bij het verder optimaliseren van de klinische toepassing van deze 
cytostatica.
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